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Prostate cancer is a leading cause of cancer-related death in men, and while many men 
diagnosed with the disease will have an indolent clinical course, 20-25% of men will 
experience disease recurrence which is invariably lethal. There is an urgent need for 
prognostic biomarkers that will predict disease recurrence and risk-stratify patients upon 
diagnosis, allowing for personalised therapies. This thesis attempts to identify new 
prognostic biomarkers for prostate cancer and investigates their patterns of protein 
expression in human primary prostate tumour tissue. 
Cancer stem cells are cancer cells thought to be uniquely capable of self-renewal and 
tumorigenicity, and may have a role in tumour recurrence. Using a literature searching 
approach, potential biomarkers related to stem cells, cancer stem cells or recurrence in 
prostate cancer were identified, and ALDH7A1, BMI1, SDC1, MUC1-C, Nestin and 
ZSCAN4 were chosen for investigation. An in silico approach was also used for 
biomarker identification, with RS1 and SLC31A1 selected as their mRNA was found to 
be upregulated in recurrent tumours. The expression patterns of all 7 potential 
biomarkers were examined by immunohistochemistry on prostate tumour tissue and 
benign tissue from prostate biopsies and prostatectomies.   
BMI1, ALDH7A1, MUC1-C and Nestin showed no relationship to recurrence or other 
clinical features. RS1 protein levels increased in patients with recurrence within 5 years, 
negatively correlated with AR expression, and a meta-analysis showed that the RS1 
gene was amplified in up to 32% of castration-resistant prostate tumours. ZSCAN4 was 
heterogeneously expressed in a subset of 26% of prostate tumours with unclear 
characteristics and was not expressed in benign tissue, but was not associated with 
recurrence. Finally, SDC1 expression was lost in tumour epithelium, but a population of 
unidentified SDC1-expressing cells were found in the stroma of a third of tumours, and 
an increased burden of these cells was associated with primary Gleason pattern 5 
tumours. These cells do not overlap with common epithelial, mesenchymal or stromal 
lineages, but may be migratory. In summary, the data presented in this thesis identifies 3 
potential new biomarkers for prostate cancer, and provides the basis for future 
characterisation of their wider roles in the disease.
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1 INTRODUCTION 
Prostate cancer is a global healthcare burden, and a heterogeneous disease which 
presents with unique challenges to effective diagnosis and treatment. One of the largest 
challenges in the field is to identify features that will allow patients to be risk-stratified, 
tailoring their treatments to their individual needs. This thesis will attempt to address 
this challenge by identifying new biomarkers to predict recurrence and risk-stratify 
patients with prostate cancer. 
1.1 The Prostate 
The following section describes the prostate, its normal biological functions, anatomy 
and histology, and discusses the ongoing research with regards to understanding of the 
cell types and lineage hierarchies in the developing and adult prostate. This provides the 
basis for understanding the molecular processes involved in prostate cancer formation 
and progression which are discussed in later sections. 
1.1.1 Physiology and anatomy of the prostate 
1.1.1.1 Prostate physiology 
The prostate is a glandular organ located beneath the bladder and anterior to the rectum. 
Its main physiological function is the secretion of prostatic fluid, which contributes to 
approximately 30% by volume of the seminal fluid and promotes sperm motility and 
survival in the seminal plasma (Burden et al., 2006; Ousset et al., 2012). Chief 
components of the prostatic fluid include citrate and zinc, the levels of which are 
particularly high  and correlate with one another in benign prostate cells (Costello and 
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Franklin, 1998). Zinc is chelated by citrate and has antibacterial properties (Burden et 
al., 2006), while citrate serves as an energy source for spermatozoa (Medrano et al., 
2006). It is also the origin of the serine protease Prostate-Specific Antigen (PSA) which 
is responsible for cleaving seminal semenogelins and fibronectin in order to liquefy the 
seminal plasma clot and promote sperm motility in the female reproductive tract 
(Yousef and Diamandis, 2001; Lilja et al., 2008).  
The prostate is an androgen-dependent organ, being regulated by exposure to androgens 
synthesised in the testes and in the adrenal glands through expression of the Androgen 
Receptor (AR). Secretory functions of the prostate are regulated in an androgen-
responsive manner, a phenomenon demonstrated in early canine experiments by 
measuring secretion volumes following androgen and estrogen administration (Huggins 
and Sommer, 1953) and importantly many prostate epithelial cells require maintained 
levels of androgen and AR signalling to survive (Davis and Day, 2002; Kurita et al., 
2001). Early murine experiments showed that castration of adult rats results in apoptosis 
of prostate epithelial cells and subsequent involution of the gland (Kyprianou and 
Isaacs, 1988) – a finding replicated many times experimentally in mice and used as a 
model of adult prostate homeostasis and stem cell activity (Choi et al., 2012; Wang et 
al., 2009; Wang et al., 2013). Androgen-dependent epithelial cell survival is dependent 
on stromal androgen receptor activity, and appears to be a paracrine signalling effect of 
the stroma on epithelial cells, as even AR-negative prostate epithelium will undergo 
apoptosis if androgen is withdrawn in the context of an AR-expressing stromal 
microenvironment (Kurita et al., 2001). 
1.1.1.2 Prostate anatomy 
Anatomically, the prostate is a branched ductal structure which surrounds the urethra. 
Ducts are embedded in a fibromuscular stroma such that contractions empty the 
contents of the ductal lumens into the urethra (Fine and Reuter, 2012). According to 
publications by McNeal in the 1980s, who drew anatomical conclusions from dissecting 
autopsy specimens, this structure is divided into three glandular zones: the transition 
zone surrounding the urethra at the mid-gland region, the central zone surrounding the 
ejaculatory ducts, and the peripheral zone surrounding and encompassing these two 
regions to make up the outer portion of the prostate (McNeal, 1981) (Figure 1.1). The 
prostate also has an anterior fibromuscular zone sitting anteriorly to the urethra and 
transition zones (McNeal, 1981). Surrounding the prostate is a layer of fibromuscular 
Prostate Cancer Stem Cells: Potential New Biomarkers 
  Benjamin Peter Sharpe - November 2016 26 
tissue known as the prostatic capsule (Fine and Reuter, 2012). The peripheral zone is 
the largest of the glandular zones, accounting for approximately 65% of the prostate and 
is the most common site of occurrence for prostate carcinoma (Fine and Reuter, 2012). 
The central zone accounts for 30% of the prostate mass and the transition zone only 5% 
(Fine and Reuter, 2012; McNeal et al., 1988). The transition zone is the site at which a 
benign hyperplastic condition unrelated to carcinoma arises, known as benign prostatic 
hyperplasia (BPH), but the region varies considerably in size and positioning between 
individuals (Fine and Reuter, 2012). Carcinoma in this region is less common and 
usually assumes a distinct ‘clear cell’ histological appearance (McNeal et al., 1988; Fine 
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Figure 1.1: Diagram of prostate anatomy as described by McNeal. 
The prostate encircles the urethra consists of three glandular zones: the transition zone 
(TZ), central zone (CZ) and peripheral zone (PZ). A region of anterior fibromuscular 
stroma (AFS) is also present. Seminal vesicles (SV) also secrete their fluid into the 
urethra through the ejaculatory ducts, labelled. 
1.1.2 Prostate Histology 
The prostate gland consists of an array of branched ductal structures with a 
pseudostratified columnar epithelial lining surrounded by a fibromuscular stroma. The 
prostate epithelium has three main cell types: basal cells which line the basement 
membrane (De Marzo et al., 1999; McNeal, 1988); luminal cells, which are columnar 
cells that fulfil the secretory functions of the prostate and sit atop the basal layer 
(McNeal, 1988); and neuroendocrine cells – an “endocrine-paracrine” cell type which 
appears scattered infrequently through the prostate epithelium between basal and 
luminal cells (Taylor and Risbridger, 2008; McNeal, 1988), and secretes serotonin and 
regulatory peptide hormones (diSantAgnese and Cockett, 1996). Figure 1.2 shows a 
diagram of the histology of the normal prostate with all epithelial cell types labelled.  
1.1.2.1.1 Basal cells 
Basal cells are in contact with the basement membrane of the prostatic ducts, and in 
humans form a continuous layer with apparent cell-cell contacts (El-Alfy et al., 2000) 
whereas in other mammals the layer is discontinuous and form a basal-to-luminal ratio 
of approximately 1:7. Basal cells express high molecular weight cytokeratins identified 
by the antibody clone 34BE12 which includes cytokeratins 5 and 14 (De Marzo et al., 
1999), and the p53 homologue p63 that is essential for the development of basal cells 
(Kurita et al., 2004).  It is hypothesised that the basal cell compartment contains 
putative prostate stem cells, although in humans it has been shown that they also carry 
ultramicroscopic indicators of being terminally differentiated, such as glycogen particle 
accumulation and a large Golgi apparatus (El-Alfy et al., 2000). The function of basal 
cells is not fully understood, as they do not perform secretory roles and are AR- and 
PSA-negative (Taylor and Risbridger, 2008), but they do serve to completely separate 
the luminal cells from the stromal compartment which suggests a regulatory role for the 
cell type in humans (El-Alfy et al., 2000; Kurita et al., 2004), especially as basal cells 
communicate with luminal cells through gap junctions (El-Alfy et al., 2000). 
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Figure 1.2: Histology of the normal prostate epithelium. 
The normal prostate duct is an epithelial structure with a basement membrane, upon 
which a layer of flattened basal cells with minimal cytoplasm sit. Luminal cells sit upon 
the layer of basal cells at a 1:1 ratio and secrete substances such as zinc, citrate and PSA 
into the ductal lumen (labelled). In addition to these two main cell types, there is also a 
neuroendocrine cell type which secretes neuropeptides and is often found in the basal 
cell layer, histologically indistinguishable from the basal cells. 
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1.1.2.1.2 Luminal cells 
Luminal cells express nuclear AR, PSA, and Prostate Specific Acid Phosphatase 
(PSAP), as well as secretory cytokeratins 8 and 18 as identified by the Cam 5.2 
monoclonal antibody (De Marzo et al., 1999). These serve the secretory functions of the 
prostate as previously mentioned in Chapter 1.1.1.1. 
1.1.2.1.3 Neuroendocrine cells 
Neuroendocrine prostate cells are defined by dendritic processes and the secretion of 
serotonin and a number of neuropeptides: among them are chromogranins, calcitonin 
family peptides, parathyroid-like hormone, and somatostatin (diSantAgnese and 
Cockett, 1996; Hirano et al., 2004) as well as bombesin and vascular endothelial growth 
factors (Hirano et al., 2004; Ismail et al., 2002). They are commonly identified in situ 
by immunostaining for the markers chromogranin A (Mucci et al., 2000; Hirano et al., 
2004; Ahlgren et al., 2000) and synaptophysin (Mucci et al., 2000) or serotonin (Ismail 
et al., 2002). These neuropeptide secretory roles make them similar to neuroendocrine 
cells described in other organs, such as the intestine, lung, pancreas and thyroid (Ismail 
et al., 2002; diSantAgnese and Cockett, 1996). 
Neuroendocrine cells are innervated by efferent autonomic nerves and sensory afferent 
nerves (diSantAgnese and Cockett, 1996). Their presence is infrequent within the 
prostate epithelium and they are usually localised within the luminal cell layer, either 
exposed to the luminal space or surrounded by luminal cells instead (Ismail et al., 2002; 
diSantAgnese and Cockett, 1996). Unlike luminal cells, neuroendocrine cells do not 
express the androgen receptor whether in a benign or cancerous context, and do not 
respond to hormone deprivation (Krijnen et al., 1993). Interestingly, they seem to 
increase in frequency in human prostate cancer xenografts in mice when subjected to 
castration (Huss et al., 2004) and also in patients with castration-resistant prostate 
tumours (Hirano et al., 2004; Ahlgren et al., 2000), suggesting a relationship between 
prostatic androgen exposure and neuroendocrine differentiation.  
1.1.3 Adult prostate maintenance and prostate stem cells 
In tissues with rapid renewal and turnover, such as the skin and colon, there exists a 
long-lived adult stem cell population which are thought to both self-renew and gives 
rise to transit-amplifying cells: cells with a limited self-renewal potential but the ability 
to divide asymmetrically to give rise to differentiated cell types (Taylor and Risbridger, 
2008). A stem cell niche is thought to exist in the prostate, as it is capable of more than 
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fifteen rounds of serial androgen withdrawal and replacement, which causes most 
luminal and some basal epithelial cells to undergo apoptosis, before restoring normal 
glandular architecture and cell types upon androgen replacement (Wang et al., 2009). 
However, tissue renewal and cell turnover is much slower in the prostate than in the 
skin and colon, and heterogeneity in the system makes elucidation of a defined 
hierarchy difficult. In addition, any model of the prostate stem cell hierarchy must be 
able to take into account all three lineages of prostate cells: basal cells, luminal cells and 
neuroendocrine cells.  
Models have been hypothesised which include multipotent progenitors giving rise to 
multiple cell lineages, and/or unipotent progenitors that can only give maintain one cell 
type (Ousset et al., 2012). A study involving BrdU incorporation found that both basal 
and luminal cells were more slowly dividing in proximal than distal regions of murine 
prostate ducts, and these cells possessed the capacity to efficiently generate glandular 
structures in vitro (Tsujimura et al., 2002). In an attempt at ‘in situ lineage tracing’, 
mtDNA sequencing has been performed in cytochrome c oxidase-deficient and 
functioning areas of prostate epithelium, which accumulate mtDNA mutations over the 
course of years and decades, to predict the clonal origin of cells within each prostate 
acinus (Blackwood et al., 2011). The study identifies regions of shared clonal origin 
within individual acini, which suggests there may be a multipotent stem cell to give rise 
to basal, luminal and neuroendocrine cells in the human prostate (Blackwood et al., 
2011). However, it is currently unknown whether such a cell resides in the luminal or 
basal compartments of the epithelium. A knowledge of the hierarchy of prostate 
development and differentiation has the potential to inform future models of prostate 
cancer initiation and progression and so will be discussed here. 
In early experiments, proliferative markers such as Proliferative Cell Nuclear Antigen 
(PCNA) (McNeal et al., 1995; Bonkhoff et al., 1994) and Ki-67 (Feneley et al., 1996; 
Bonkhoff et al., 1994) were found to be present in a small proportion of basal cells in 
the benign human prostate epithelium. Mice carrying a homozygous deletion at the p63 
locus, which is expressed exclusively by the basal epithelial cells within the prostate, 
are unable to develop the organ proper (Signoretti et al., 2000). This suggests that the 
basal cell population contains a putative stem cell population responsible for prostate 
development and all the epithelial cell types found within. Van Leenders et al. 
demonstrated that a subset of basal prostate epithelial cells can express the canonical 
basal and luminal markers K5/K14/K18 simultaneously in human prostate tissue 
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sections and in culture (2000). They suggest that these correspond to stem cells whereas 
most basal cells, which are only K5/K14+, are a transit-amplifying or intermediate cell 
type that will lose K5/K14 expression and differentiate to become luminal cells with a 
K8/K18 expression profile. Although the group found cells with neurite-like processes 
suggestive of neuroendocrine differentiation in their explant culture system, they were 
unable to demonstrate neuroendocrine differentiation in the model (van Leenders et al., 
2000). Similarly, mice which bear a prostate tissue graft that is homozygous for a 
deletion at the p63 locus, which is expressed in prostate basal cells and necessary for 
murine basal cell development, develop synaptophysin-positive neuroendocrine cells at 
a similar frequency to wild-type tissue grafts, suggesting that neuroendocrine cells may 
not differentiate from a basal cell subtype in a developmental context (Kurita et al., 
2004). 
More recently, the subject has been studied using lineage tracing models in the mouse. 
The typical strategy for lineage tracing requires an inducible genetic recombination 
event that permanently marks specific cell types and all their progeny. Lineage-specific 
promoter-driven expression of a Cre recombinase enzyme is established in a transgenic 
organism and ‘floxed’ alleles containing a fluorescent reporter are designed to be made 
transcriptionally active following successful recombination (Wang et al., 2009; Wang et 
al., 2013). This allows the fates and identities of these cells and their progeny to be 
traced over time. Using this approach, Ousset et al demonstrated considerable 
heterogeneity during murine postnatal prostate development, with K5- and K14-
expressing basal cells able to give rise to both basal and luminal cells, although some 
traced cells formed clones of solely luminal cells (Ousset et al., 2012). In this setting, 
cells with an intermediate phenotype co-expressing luminal and basal markers were 
associated with bipotent clones that gave rise to luminal cells, suggesting that the 
intermediate phenotype is associated with luminal differentiation. The same group later 
used multi-colour lineage tracing to focus on postnatal prostate development and 
combined this with statistical modelling of the labelled cell populations, and found that 
lineage-marked basal cells gave rise to labelled luminal cells more than would be 
expected by chance (Wuidart et al., 2016). This further confirms that, during prostate 
development, basal cells are bipotent in nature. 
In the adult tissue homeostasis setting the situation may be less clear. It has been shown 
in one lineage-tracing study that in a model of castration and regeneration, at least a 
subpopulation of basal and luminal cells are unipotent and can generate more of their 
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own lineage, with no evidence of one lineage contributing to the other (Choi et al., 
2012). A later lineage-tracing study suggests that a switch from a bipotent to unipotent 
mode of cell differentiation occurs at approximately postnatal day 30, when the 
percentage of lineage-marked luminal cells remains relatively constant (Wuidart et al., 
2016). 
Other lineage-tracing studies show a less clear picture for the luminal cell lineage in the 
adult prostate. Another lineage-tracing study, which includes more rounds of castration 
and prostate regeneration, demonstrates that basal cells can give rise to luminal cells, 
although this is a rare phenomenon constituting 0.04% of lineage-marked basal cells 
(Wang et al., 2013). Tracking lineage-marked mice over a course of a year without 
castration confirmed that differentiation of bipotent basal cells occurs at a low 
frequency during normal prostate homeostasis (Wang et al., 2013). Similarly, a seminal 
study isolated a putative prostate stem cell population from mice which consisted of as 
few as 0.12% of prostate cells, and was identified by the marker panel Lin-
/Sca1+/CD133+/CD44+/CD117+, and was able to generate all three prostate lineages 
and the appropriate prostate duct architecture from a single cell (Leong et al., 2008). 
CD117 (c-kit)-expressing basal cells exist in human prostate tissue, but it has yet to be 
demonstrated that they have a similar stem-like potential (Leong et al., 2008).  
It has also been shown that a subset of NKX3-1 expressing luminal cells are resistant to 
castration and can regenerate all prostate epithelial cell types from a single cell, 
suggesting that there could be multipotent stem cells residing in the luminal 
compartment as well (Wang et al., 2009). NKX3-1 appears to be critical for prostatic 
differentiation: lentiviral expression of NKX3-1 in seminal vesicle tissue in a renal graft 
is sufficient to convert it to a prostate-like glandular structure with apparent basal and 
luminal cell layers (Dutta et al., 2016), and expression of NKX3-1 in the basal-like 
prostate cell line RWPE1 renders it similarly capable of generating secretory ductal 
prostate-like structures in renal grafts. 
In summary, lineage-tracing experiments demonstrate evidence for both multipotent and 
unipotent cells in the basal and luminal epithelial cell compartments, but due to the 
experimental models employed, which largely rely on murine prostate regeneration and 
grafting assays, the picture of what occurs during normal prostate homeostasis is far 
from clear. In addition, it is worth noting that most stem cell characterising experiments 
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have been conducted in murine prostate cells, and the murine prostate is anatomically 
and structurally distinct from the human prostate (Abate-Shen and Shen, 2000). 
1.2 Prostate cancer and other prostatic disease 
Prostate adenocarcinoma is the most common form of prostate cancer and is a 
malignant hyperplastic disease arising from the epithelial compartment of the prostate 
gland. It is one of the most common cancers in men and a leading cause of cancer-
related death, with the USA’s Surveillance, Epidemiology and End Results Program 
(SEER) predicting over 180,000 new diagnoses and over 26,000 deaths of prostate 
cancer in this year in the USA alone (Siegel et al., 2016). This accounts for 1 in 5 of all 
new cancer diagnoses in men, and an estimated 1 in 7 men will contract the disease at 
some point in their lives (Siegel et al., 2016). The following section examines the 
process of diagnosis and therapy for prostate carcinoma, the molecular pathology of the 
prostate carcinoma during its progression, and considers the utility of biomarkers for 
diagnosis and prognostication of the disease. 
1.2.1 The clinical course of prostate adenocarcinoma 
1.2.1.1 Diagnosis 
Patients with prostate carcinoma are normally identified through PSA screening (refer 
to Chapter 1.2.2) or presentation to primary care with lower urinary tract symptoms, 
such as a poor urinary stream, urinary urgency or hesitancy (Hamilton and Sharp, 
2004). However, these symptoms are common in other benign conditions such as 
benign prostatic hyperplasia, which is also a common hyperplastic disease in men 
(Hamilton and Sharp, 2004), and lower urinary tract symptoms do not confirm a 
diagnosis or add additional diagnostic power to an investigation. Therefore, care must 
be taken to distinguish patients with benign prostatic hyperplasia from patients with 
carcinoma. The histological methods for this will be covered in detail in Chapter 1.2.2. 
National Institute for Health and Care Excellence (NICE) guidelines currently state that 
patients with lower urinary tract symptoms should undergo a rectal examination and a 
PSA test (NICE, 2015). Rectal examination for a palpable prostate tumour is a more 
robust indicator of prostate cancer than an abnormal PSA reading (Hamilton and Sharp, 
2004; Thompson et al., 2004) and either an abnormal PSA test or an adverse finding on 
rectal examination warrants taking core needle biopsies of prostate tissue for 
histological evaluation (NICE, 2015). A PSA test revealing a serum PSA concentration 
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of greater 4ng/mL is usually considered abnormal, although this threshold is often 
disputed and men with lower levels can develop prostate cancer (Thompson et al., 
2004). Core needle biopsies are normally taken with 18 gauge needles and at least 10 
biopsy cores should be taken, guided by transrectal ultrasound (Heidenreich et al., 
2008). Histological evaluation will be discussed in more detail after considering 
treatment (see Chapter 1.2.2). 
1.2.1.2 Therapeutic intervention 
1.2.1.2.1 Primary therapies 
When patients are diagnosed with prostate cancer, the primary tumour is treated with 
one of several treatment modalities. The most common treatment modality for primary 
prostate carcinoma is radical prostatectomy (Whiting et al., 2016), where the prostate is 
removed surgically through well-defined methods dating back to 1947 (Mukouyama et 
al., 2001). The second most popular choices are external beam radiotherapy and 
brachytherapy (Whiting et al., 2016), where ionising radiation is delivered through 
either an external radiation source or surgically implanted radioisotope-containing 
materials, respectively. In either case, there are considerable impacts of primary therapy 
on patient quality of life, with commonly reported symptoms of treatment including 
erectile dysfunction, urinary and/or bowel incontinence and impotence as well as 
anxiety and depression (Whiting et al., 2016; Kundu et al., 2004). Treatment with 
hormone therapy is less commonly recommended as a primary therapy, but acts by 
lowering serum androgen levels and inhibiting the AR signalling axis in prostate cells, 
which is generally required for prostate epithelial cell survival (Kyprianou and Isaacs, 
1988). Common methods for hormone therapy include the administration of Luteinising 
Hormone Releasing Hormone agonists, which block testicular androgen synthesis, 
along with non-steroidal AR antagonists such as bicalutamide, flutamide or 
enzalutamide (Heidenreich et al., 2008). There may be a survival benefit for early 
administration of hormone therapy in patients with locally advanced prostate cancer 
(Smith et al., 2005), though this is still under debate and requires more randomised 
controlled trials to be conclusive (Heidenreich et al., 2008). 
In terms of outcomes for clinically localised disease, prostatectomy may have benefit 
over radiotherapy by reducing prostate cancer-specific mortality rates (Sooriakumaran 
et al., 2014; Lee et al., 2015a; D'Amico et al., 2002), although this benefit is most 
apparent in patients with lower risk disease (D'Amico et al., 2002) and outcomes may 
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be more equivalent in high risk disease (D'Amico et al., 2002; Boorjian et al., 2011). 
Reporting and standard classifications of recurrence differ under treatment with 
prostatectomy and radiotherapy, which precludes meaningful comparison between the 
two treatment groups, but there are indications that the less stringent reporting of serum 
PSA increases in radiotherapy could lead to a delay in reporting and thus increased risk 
to patients (Lee et al., 2015a). This is especially the case as the establishment of a PSA 
nadir, where serum PSA levels remain consistently at a minimum point, takes much 
longer to reach following radiotherapy than for prostatectomy (D'Amico et al., 2002), 
and this is part of the framework on which recurrence is assessed. 
Prostate carcinoma is biologically heterogeneous along with considerable heterogeneity 
in clinical outcome, and is one of the few forms of cancer for which 10-year recurrence-
free survival is a useful measure of outcomes due to the potentially long durations that 
can pass between treatment and recurrence (Bianco et al., 2003). Although primary 
therapy is usually of curative intent, approximately 20-25% of patients experience 
recurrence after primary therapy, either as assessed by rising serum PSA levels, local 
recurrence or presence of metastases (Epstein et al., 1993; Bianco et al., 2003). Due to 
the impacts of primary therapy and recurrence, it is important to classify patients based 
on estimated disease severity. 
1.2.1.2.2 Secondary therapies 
The choice of secondary therapy is much more variable and depends upon patient 
preferences as well as the site of recurrence. Salvage radiotherapy or prostatectomy may 
be recommended for patients who have experienced local failure following 
prostatectomy or radiotherapy respectively (Heidenreich et al., 2008). For patients with 
systemic failure, where the tumour has spread to distant locations including skeletal 
metastases, treatment with hormone therapy is recommended. As with primary 
hormonal therapy, secondary hormonal therapy usually consists of an LHRH agonist, 
although anti-androgens may be added when this treatment begins to fail (Sternberg et 
al., 2013). However, in patients with recurrent disease, hormone therapy invariably 
fails, usually within 19-24 months (Sternberg et al., 2013), and in this case Docetaxel 
chemotherapy is recommended as the last line of treatment, and patients generally 
respond for 12-29 months (Heidenreich et al., 2008). Castration-resistant disease, where 
cancer continues to progress clinically despite castrate levels of testosterone (Sternberg 
et al., 2013), is invariably lethal (Sung and Cheung, 2014), which means that predictors 
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of this progression and characterisation of the molecular pathways involved are vital for 
treatment of advanced prostate cancer. For more information on the pathways and 
alternations thought to be involved, see Chapter 1.2.3.9. 
1.2.2 Detection, diagnosis, and challenges 
1.2.2.1 Prostate-specific Antigen (PSA) and the PSA era 
Both benign prostate and prostate carcinoma express PSA as part of the normal 
secretory programme of luminal prostate epithelial cells (Catalona et al., 1991; De 
Marzo et al., 1999; Lilja et al., 2008). Serum PSA levels in healthy men are 
approximately 0.6ng/mL in normal prostate tissue, and rise in some cases of prostate 
cancer to 4ng/mL or greater (Catalona et al., 1991). This is suspected to be due to the 
structural damage and disorder inherent to prostate carcinoma, resulting in greater PSA 
release into the blood rather than overexpression of the protein in tumours proper (Lilja 
et al., 2008). This finding is used as a tool in both diagnostic and treatment monitoring 
settings for prostate cancer but has limitations, as outlined below. 
1.2.2.1.1 PSA testing for screening and diagnosis 
Routine screening of men for prostate cancer using a serum PSA test caused prostate 
cancer diagnoses to surge during the late 1980s and early 1990s (Siegel et al., 2016). 
Patients may suffer from prostate cancer but not have palpable disease on rectal 
examination, and a PSA test is invaluable for diagnosing these cases that would 
otherwise have been missed (Catalona et al., 1991). PSA screening has had the positive 
effect of shifting down the stages at which patients with prostate cancer present, 
meaning that most patients now present with small nodules of prostate cancer detected 
by screening or biopsy that would not be detectable by palpation or imaging, known as 
stage T1c (Bianco et al., 2003). Concomitantly, the frequency of patients presenting 
with advanced disease and high grade tumours has dropped dramatically in the PSA 
screening era (Penney et al., 2013).  
However, routine screening of men for prostate cancer using the PSA test is no longer 
advocated, as an estimated 23% to 42% of screen-detected tumours are over-diagnosed 
(Siegel et al., 2016), meaning that they present with clinically insignificant disease and 
are likely to expose the men to unnecessary risk in the forms of therapeutic intervention 
as well as the associated anxieties of cancer diagnosis. Because of this change in 
procedure in the USA, the number of diagnoses of prostate cancer in the USA are 
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beginning to fall (Siegel et al., 2016). While the general consensus in Europe is much 
the same with regards to screening of the general population, PSA screening has been 
found to be sufficiently sensitive, specific and cost-effective compared to other cancer 
screening programmes (Crawford and Abrahamsson, 2008). The benefits of early 
detection and reduced disease progression rates arguably outweigh the risks of over-
diagnosis. However, from its inception, PSA testing as a first line screening approach 
has had an additional flaw: half of all patients with an elevated PSA level, that would be 
considered suspect for carcinoma, have benign prostatic hyperplasia or prostatitis 
instead (Catalona et al., 1991). Additionally, some men may have prostate cancer even 
with normal serum PSA levels (Heidenreich et al., 2008). Thus, there is the potential for 
both false positive and false negative findings. As more men with prostate cancer die of 
other causes than due to the disease, and many more early-stage cancers are being 
detected, new biomarkers will be required to provide more specific cancer diagnosis and 
prognostication. 
1.2.2.1.2 PSA testing for monitoring treatment course 
Following therapy, the efficacy of a treatment can be monitored by routinely measuring 
the levels of PSA in the serum (Lilja et al., 2008). This manifests in different ways for 
different treatments. For prostatectomy, serum PSA levels are expected to fall rapidly 
after surgery, reducing to levels of less than 0.2ng/mL (Heidenreich et al., 2008). For 
radiotherapy, a serum PSA level of greater than 2ng/mL above the nadir PSA is 
considered to be recurrence, otherwise known as biochemical failure or biochemical 
recurrence (Roach et al., 2006). Unfortunately, there is no consensus definition of 
biochemical recurrence, although a standard has been suggested as serum PSA 
>0.4ng/mL followed by an increase at the next measurement (Stephenson et al., 2006).  
PSA kinetics such as the doubling time, or the time duration required for a doubling of 
serum PSA levels, are often used to monitor disease progression following therapy 
(Slovin et al., 2005). Another such measure is PSA velocity, which also measures the 
rate at which serum PSA levels increase over time. Both higher baseline PSA levels 
after treatment and higher PSA velocity are independent predictors of shorter survival 
and an increased risk of bone metastases in non-metastatic patients treated with 
hormone therapy (Smith et al., 2005). Many men in this study had an indolent clinical 
course despite having rising PSA, suggesting that the presence of a rising PSA level 
following therapy may not be as informative as the levels and kinetics. In this way, 
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biochemical recurrence does not always lead to clinical progression, and clinical 
endpoints are always the more certain measures of patient progression and survival. A 
shorter PSA doubling time was also significantly associated with shorter metastasis-free 
survival in a study of patients treated with prostatectomy (Antonarakis et al., 2012). 
However, in some patients metastatic progression of prostate carcinoma can occur 
without an accompanying rise in PSA levels, especially in patients with atypical 
histological variants of carcinoma such as small cell carcinoma (Leibovici et al., 2007).  
In summary, while testing serum PSA levels should not be used as the sole method of 
monitoring patient disease in a post-treatment setting, it remains a highly useful tool for 
routinely monitoring the response of patients to their therapies, and acts as a decision-
making tool guiding the timings of subsequent therapy selection. 
1.2.2.2 The Gleason grading system and tumour staging 
There are two systems in place in the clinic for categorising patients into risk categories. 
These are the Gleason grading system and tumour staging. 
The Gleason pattern was originally developed by Dr. Donald Gleason in 1974 as a 
means of classifying prostate tumour morphology and associating it with clinical 
outcome, based on the observation that there are distinct patterns of tumour growth and 
that there tend to be two or more major growth patterns within a tumour biopsy 
(Gleason and Mellinge.Gt, 1974). The grading system has been altered over the years, 
but is still largely descriptive and represents the degree of morphological differentiation 
of the tumour by H&E staining on a scale of 1 to 5. Pattern 1 is the most well 
differentiated and 5 is poorly differentiated, with higher Gleason patterns assigned to 
increasingly small, irregular or atypical glandular structures (Gordetsky and Epstein, 
2016; Humphrey, 2004). Gleason pattern 5 is assigned to cords and sheets of cells 
which have no discernible glandular structure and present comedonecrosis (glandular 
lumina filled entirely with necrotic cells). It represents the most invasive Gleason grade 
(Gleason and Mellinge.Gt, 1974). A descriptive summary, along with Dr. Gleason’s 
original staging diagram, is provided in Figure 1.3. 
The Gleason score, which is denoted as the combination or sum of the Gleason grades 
for the two largest areas of tumour foci in a specimen by order of size, technically 
ranges from 2 to 10, but rarely goes below 6 (Penney et al., 2013), as histological 
findings are rarely assigned a Gleason pattern 2 (Melia et al., 2006) and it is 
recommended that Gleason pattern 1 and 2 are never assigned to a prostate needle 
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biopsy (Gordetsky and Epstein, 2016). In addition, there are concerns regarding the 
poor inter-observer reproducibility of assigning a Gleason score of 2-4 (Allsbrook et al., 
2001), Gleason patterns 1, 2 and 3 are frequently mis-graded (Allsbrook et al., 2001; 
Gordetsky and Epstein, 2016) and thus Gleason scores of 5-6 are often under-graded 
(Allsbrook et al., 2001).  
Another system used to categorise patients is tumour staging, which reflects the extent 
of tumour progression in the prostate and the surrounding organs, as well as factoring in 
lymph node and distant metastases. The current system in use is the three-parameter 
Tumour, Nodes and Metastases (TNM) staging system, which is used to guide patient 
treatment options (Cheng et al., 2012). The T-stage denotes the extent of tumour 
involvement: T1 tumours are found incidentally upon transurethral resection of the 
prostate or are identified by needle biopsy but not palpable or visible by imaging 
techniques; T2 tumours are confined to the prostate but palpable or visible by imaging; 
T3 tumours have invaded locally and display extraprostatic extension, bladder neck 
invasion or seminal vesicle invasion; T4 tumours have more extensive local invasion 
into the rectum, pelvic wall or levator muscles (Cheng et al., 2012). The N-stage is used 
to categorise cancer for pelvic lymph node metastases, with N1, N2 and N3 cancers 
having lymph node metastases of varying sizes and frequencies. Extrapelvic lymph 
node metastases are considered as M1, which is the category assigned to distant 
metastases to bone and other sites. 
Evidence is unclear as to whether Gleason grade can change over time with increasing 
tumour stage. One study found that Gleason grade was not uniformly correlated with 
tumour stage (Penney et al., 2013). However, an increase in Gleason grading or staging 
can occur between biopsy and surgery, as shown by a Japanese cohort of patients 
treated with prostatectomy and adjuvant hormone therapy (Mukouyama et al., 2001). 
Gleason grading can also produce a higher grade for lymph node metastases than for the 
primary tumour in approximately 45% of cases, suggestive of dedifferentiation in a 
metastatic niche (Cheng et al., 2012). 
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Figure 1.3: A graphical depiction of the Gleason scoring system drawn by Gleason, 
along with some key descriptive criteria.  
Gleason grades are assigned with increasing degrees of glandular deformity from 1 to 5, 
with 1 being well-differentiated and 5 being poorly differentiated. Some of the key 
criteria for grading include: size, shape and uniformity of glands; presence or absence of 
glandular lumen; infiltration into the surrounding stroma and presence or absence of 
necrosis. This is not an exhaustive list and there are other factors for pathologists to take 
into account when Gleason scoring. Figure is adapted from Humphrey, 2004 and was 
originally presented in Gleason and Mellinger, 1974. 
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Despite the caveats of Gleason scoring, it remains one of the most robust diagnostic and 
prognostic variables in clinical use for prostate cancer (Gordetsky and Epstein, 2016). A 
high Gleason score is a positive predictor of metastasis following prostatectomy 
(Antonarakis et al., 2012). There have been several attempts to improve the Gleason 
system, both in terms of its quantification and its reliability. In intermediate Gleason 
score 7 (3+4 or 4+3) disease, recent data suggests that quantification of the amount of 
Gleason pattern 4 in a biopsy can be a useful prognostic tool (Deng et al., 2016; Cole et 
al., 2016) with patients bearing a higher burden of Gleason pattern 4 at greater risk of 
recurrence. Therefore, Gleason scores of 3+4 and 4+3 are not equal in terms of 
predicted outcome (Gordetsky and Epstein, 2016).  
A new grading system has very recently been adopted which combines information 
from the Gleason grading system into categories that better reflect the risk of recurrence 
for patients with prostate carcinoma (Epstein et al., 2016a; Epstein et al., 2016b). The 
new grading system creates 5 new Grade Groups: Grade Group 1 consists of any 
tumour with a Gleason grade of 6 or less; Grade Group 2 represents Gleason grade 3+4 
tumours; Grade Group 3 represents Gleason grade 4+3 tumours; Grade Group 4 
represents Gleason Grade 4+4 tumours; Grade Group 5 represents Gleason grades 9 and 
10 (Epstein et al., 2016b). The 5-year biochemical recurrence-free progression 
probabilities for the Grade Groups were 96%, 88%, 63%, 48% and 26% respectively, 
highlighting both the extraordinary clinical and morphological heterogeneity of prostate 
cancer, as well as the discriminatory power of this tool for prognostic use. However, 
there are only a limited number of other tools for diagnosis and prognostication in 
clinical use. Advances in immunohistochemistry, which was not originally part of the 
routine diagnosis of adenocarcinoma (Gordetsky and Epstein, 2016), form a large part 
of this technology and are discussed in the next section. 
1.2.2.3 The role of IHC in prostate pathology 
Histology is the workhorse of diagnostic pathology which aims to study the morphology 
of tissues and tissue components, using stains to bring out the contrast on molecules or 
cells of interest in the tissue to be viewed under a microscope. Recent advances in tissue 
fixation and specimen processing mean that special stain histology, IHC, fluorescent in-
situ hybridisation and other nucleic acid and protein-based techniques can be used in 
tandem to provide good quality data at multiple levels: DNA, RNA, protein and 
histological features may all be evaluated using clinical specimens (Braun et al., 2011). 
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These advances mean that there is the potential for incorporation of routine histological 
practice into an integrative approach, making use of the increasingly sophisticated 
molecular profiling techniques available at the transcriptomic and proteomic levels as 
these technologies become cheaper. 
The current use of histology in prostate pathology concerns elements of both diagnosis 
and prognosis. The chief role of H&E staining is to morphologically characterise core 
needle prostate biopsies and transurethral resections of the prostate (TURP) to 
determine the extent and Gleason score of any tumours found (Varma et al., 2002; 
Epstein, 2004), as well as to check surgical margins of an excised tumour for invasive 
cells. Diagnosis is often difficult with the small amount of material provided in a 
biopsy, as the wider glandular context is not evident and pathologists often have only a 
small focus of tumour on which to form a diagnosis (Varma et al., 2002; Paner et al., 
2008; Epstein, 2004). There are many benign mimics of prostate cancer, including 
adenosis and incidental sampling of the nearby Cowper’s glands or seminal vesicles 
(DeMarzo et al., 2003), making a differential diagnosis difficult . A key feature of 
prostate carcinoma is the absence of basal cells, a discovery first made in 1953 (Totten 
et al.). Basal cells are not always easy to identify on an H&E stained tissue section, as 
the tangential cutting of other cells, such as luminal cells or fibroblasts, can mimic basal 
cell morphology (Varma et al., 2002). Therefore, a differential diagnosis can be assisted 
by the use of IHC to identify these basal cells, or the absence thereof. 
1.2.2.4 Basal cell markers 
As mentioned in Chapter 1.1.2, basal cells express high molecular weight cytokeratins 
(HMWCK) such as CK5 and 14, which are routinely identified in IHC using an 
antibody against high molecular weight cytokeratins called 34BE12 (De Marzo et al., 
1999; Varma and Jasani, 2005). Additionally, basal cells express the p53 homologue 
p63 in the nuclear compartment (Signoretti et al., 2000; Paner et al., 2008). If desired, a 
stronger signal can be achieved by using an antibody cocktail with a mixture of 
antibodies identifying both p63 and HMWCK simultaneously (Paner et al., 2008). The 
presence or absence of basal cells in a prostate biopsy can confirm a suspect lesion, as 
absence of basal cells is a defining characteristic of prostate carcinoma (Paner et al., 
2008; Varma and Jasani, 2005). Potentially pre-malignant lesions, known as high-grade 
Prostatic Intraepithelial Neoplasia (PIN), are sometimes difficult to distinguish from 
prostate carcinoma with an H&E stain (Epstein, 2004). By staining for basal cell 
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markers, it is possible to distinguish PIN from carcinoma, as PIN lesions retain a basal 
cell layer despite a crowded glandular epithelium (Torabi-Nezhad et al., 2016), although 
the basal layer becomes increasingly discontinuous and disrupted with higher grades of 
PIN (Bostwick and Brawer, 1987; Liu et al., 2009; Brimo and Epstein, 2012). Given the 
loss of basal cell continuity in high-grade PIN foci, and the small amount of tissue being 
assessed, there is always the possibility of a false positive diagnosis of carcinoma from 
this information alone (Varma and Jasani, 2005). This means that additional sources of 
information are required for diagnosis. 
1.2.2.5 Tumour cell markers 
Markers of tumour cells may assist in the differential diagnosis of carcinoma from PIN 
lesions. The most promising prostate tumour cell marker in current pathology use is α-
methylacyl coenzyme A racemase (AMACR), or P504S. AMACR is an enzyme 
involved in the beta-oxidation of branched chain fatty acids, and is overexpressed at the 
mRNA (Luo et al., 2002; Petrovics et al., 2005; Ashida et al., 2004; Grasso et al., 2012) 
and protein level in prostate tumours compared to high grade PIN and benign prostate 
epithelium (Luo et al., 2002). AMACR is either negative or weakly positive in the 
cytoplasmic compartment of benign prostate epithelial cells, is expressed at an 
intermediate intensity variably in PIN, and stains intensely in most prostate carcinoma 
specimens (Luo et al., 2002). A 22-study meta-analysis of AMACR expression has 
shown that AMACR expression by PCR or by IHC is associated with increased risk of 
prostate cancer diagnosis (Jiang et al., 2013). AMACR is most useful in the 
identification of small lesions suspicious for carcinoma (Brimo and Epstein, 2012). 
The fact that AMACR is expressed in both PIN and carcinoma means that it is most 
commonly used as part of an antibody cocktail, sometimes known as the triple or PIN 
cocktail, which includes antibodies against AMACR, p63 and 34BE12 in a double-
chromogen system (Paner et al., 2008; Varma and Jasani, 2005; Tolonen et al., 2011). 
The use of a PIN cocktail increases the successful detection of carcinoma in small 
lesions as well as reducing pathologist workload (Tolonen et al., 2011). However, 
AMACR staining should only be considered in the context of concurrent basal cell 
marker staining, and the expected pattern for a carcinoma would be positive for 
AMACR and negative for basal cell markers in the focus, whereas PIN might be 
positive for both (Paner et al., 2008; Varma and Jasani, 2005). According to a study by 
Zhou et al. in 2004, a positive AMACR result on an atypical, basal cell-negative lesion 
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in a biopsy is likely to result in upgrading to a diagnosis of cancer in up to half of all 
cases (Zhou et al., 2004). However, the group also found 18% of cancer cases that did 
not stain with an anti-AMACR antibody, suggesting that there is a potential for false 
negative diagnoses (Zhou et al., 2004; Brimo and Epstein, 2012). This reinforces the 
conclusion that while AMACR possesses considerable diagnostic utility, there is no 
single marker specific to prostate carcinoma in prostate pathology. 
1.2.3 Progression and key molecular drivers of prostate cancer 
Despite prostate cancer being a disease of men predominantly over the age of 50 (Siegel 
et al., 2016), incidental findings of prostate cancer and high grade PIN, a precursor to 
carcinoma, on autopsy have been identified in men as young as 30 (Soos et al., 2005). 
This suggests that the natural history of prostate cancer and the initiation of pre-
neoplastic events begin early on in life. There are two potential precursor lesions to 
carcinoma: Proliferative Inflammatory Atrophy (PIA) and Prostatic Intraepithelial 
Neoplasia (PIN).  
PIA is a focal change in prostate architecture marked by increased presence of 
proliferation markers within prostatic epithelium (Feneley et al., 1996), and an 
increased burden of inflammatory cells in stromal and epithelial prostate compartments 
(De Marzo et al., 1999; De Marzo et al., 2003). It is accompanied by cytological 
alterations in luminal cells, namely a reduced, basophilic- to clear-staining cytoplasmic 
compartment. Basal cell layers remain intact. Meanwhile, PIN features benign glands 
with remaining basal cell architecture but with nuclear atypia and crowding (Epstein, 
2009). It is thought that the inflammatory nature of PIA drives progression to PIN, and 
PIN subsequently progresses to carcinoma, although this is controversial (De Marzo et 
al., 2003; Abate-Shen and Shen, 2000).  
The transition from benign prostate to PIN to carcinoma is marked by a number of key 
changes that support this hypothesis. Firstly, there is a progressive disruption and 
disappearance of the basal cell layer along with disruptions to the basement membrane 
underlying these cells: partial basal cell and basement membrane disruption is already 
apparent in PIN and is complete in carcinoma (Liu et al., 2009). This disruption of the 
basal cell layer is also apparent in several transgenic mouse models of PIN where the 
tumour suppressor PTEN is deleted, a constitutively active myristoylated form of AKT 
is expressed, or the oncogene c-myc is expressed (Majumder et al., 2008). Secondly, 
there is a progressive increase in copy number alterations in PIA, PIN and carcinoma, 
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an example being chromosome 8 gains in 8q24, which contains the oncogene c-myc 
(Yildiz-Sezer et al., 2006) and is often progressively overexpressed during these 
transitions (Tomlins et al., 2007). In addition, PIN and prostate carcinoma share similar 
patterns of global gene expression, as identified by shared expression signatures 
(Tomlins et al., 2007). A series of defined genetic alterations and signalling aberrations 
appear to underpin the transitions from PIA to PIN and then to carcinoma, which will be 
discussed in this section. Each molecular alteration or signalling pathway will be 
discussed individually, although where possible the order in which these processes 
contribute to initiation and progression is preserved. A summary of key driver events in 
prostate carcinogenesis is presented in Figure 1.4. 
Prostate Cancer Stem Cells: Potential New Biomarkers 
  Benjamin Peter Sharpe - November 2016 46 
 
  
Chapter 1: Introduction 
Benjamin Peter Sharpe - November 2016    47 
Figure 1.4: A summary of known key oncogenic events in prostate carcinogenesis. 
Key molecular events, including gene mutations, losses and rearrangements, are 
presented next to a visual representation of each stage of prostate carcinogenesis. The 
stages of prostate carcinogenesis in this model are: Proliferative Inflammatory Atrophy 
(PIA, green cells); Prostatic Intraepithelial Neoplasia (PIN, yellow cells); Prostate 
Carcinoma (PCa, brown cells); and Castration-Resistant Prostate Carcinoma (CRPC, 
red cells). 
1.2.3.1 GSTP1 expression is lost from PIN onwards 
The oxidative stress response protein glutathione S-transferase π (GSTP1), which is 
normally expressed in basal cells in normal prostate glands, is expressed more 
expansively in PIA, focally including luminal epithelial cells in addition to its normal 
basal staining pattern (De Marzo et al., 1999). This is accompanied by increased 
expression of the anti-apoptotic protein Bcl-2. Interestingly, CpG methylation at the 
GSTP1 promoter is also a frequent occurrence during tumorigenesis and occurs as early 
as PIN (Kang et al., 2004) and through to carcinoma (Kang et al., 2004; Abeshouse et 
al., 2015), resulting in downregulation of GSTP1 protein levels (Lin et al., 2001). 
Perhaps oxidative stress selects for new mutations in pre-neoplastic cells to facilitate 
progression. It would suggest that oxidative stress, apoptosis, inflammation and the 
appearance of potentially pre-neoplastic foci in the prostate may be linked together. 
However, the status of PIA as the precursor lesion to PIN is still controversial, since 
there are very few common genetic mutations between the two on a global level 
(Tomlins et al., 2007). 
1.2.3.2 NKX3-1 is downregulated in PIN and deleted in carcinoma 
Homeobox protein NKX3-1 is a transcription factor first expressed in the developing 
endodermal compartment known as the urogenital sinus, expressed at 15.5dpc before 
the prostate begins to form, and is therefore one of the first markers of the developing 
prostate (Abate-Shen et al., 2008). Its expression is dependent on androgen signalling, 
and it is required for secretory differentiation and branching morphology in the mouse 
prostate. Chromosomal alterations at 8p12-21 are thought to occur early in the process 
of prostate carcinogenesis (Abate-Shen and Shen, 2000) and include loss of the 
luminally-expressed tumour suppressor NKX3-1 at 8p21.2. Deletion of even a single 
NKX3-1 allele in mouse models generates PIN lesions which lack basal cells 
(Abdulkadir et al., 2002), and transgenic adenocarcinoma of the mouse prostate 
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(TRAMP) mice display progressive loss of NKX3-1 expression as they progress to 
invasive carcinoma (Bethel and Bieberich, 2007). NKX3-1 deficient lesions have 
progressive oxidative damage to DNA and protein along with concurrent decreases in 
expression of several antioxidant enzymes, suggesting that a key function of the protein 
in mice is to regulate the response to oxidative stress, which could have a role in the 
initiation of cancer (Ouyang et al., 2005).  
In the human prostate, modest reductions of NKX3-1 expression are observed in early 
pre-neoplastic events such as PIA, and the downregulation carries through to PIN and 
carcinoma (Bethel et al., 2006). However, losses of heterozygosity at the 8p locus are 
only found in a 12% of high-grade PIN lesions, while the deletion frequency increases 
to 33% and 74% of Gleason pattern 3 and Gleason pattern 4/5 tumours respectively 
(Bethel et al., 2006). In a separate study, 20% of high-grade PIN lesions were identified 
as having completely lost NKX3-1 expression, while in stage T1, T2 and T3/4 tumours 
this was 6%, 16% and 22% respectively (Bowen et al., 2000). Loss of NKX3-1 
expression was most prominent in castration-resistant and metastatic tumours with a 
frequency of 34% and 78% respectively. Mutations in NKX3-1, however, are rare 
(Abeshouse et al., 2015). Taken together, the evidence suggests that downregulation of 
NKX3-1 expression is an early event in prostate carcinogenesis, as it is detected as early 
as PIA and is observed through to carcinoma, although the mechanism for 
downregulation is still not understood (Abate-Shen et al., 2008). However, the more 
complete losses of NKX3-1 expression and losses of heterozygosity at the locus are 
more likely to be associated with progression to advanced or metastatic disease (Bowen 
et al., 2000).  
1.2.3.3 p27Kip1 is downregulated in the PIN-to-carcinoma transition 
As mentioned at the beginning, there are several mouse models for PIN: prostate-
specific PTEN deletion, myristoylated AKT expression, or c-myc expression will all 
generate PIN (Majumder et al., 2008). Oncogenic signalling in these models results in 
increased expression of the cyclin-dependent kinase inhibitor p27Kip1, which induces 
senescence and acts as a brake to proliferation in the epithelial compartment of PIN 
lesions. Thus, progression to carcinoma does not happen in these models unless p27Kip1 
expression is perturbed (Majumder et al., 2008; Wang et al., 2012a; Di Cristofano et al., 
2001) and this is thought to be due to changes in cell adhesion in the PIN environment 
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rather than from aberrant PI3K-Akt signalling induced by PTEN (Majumder et al., 
2008). This highlights the importance of tumour-stromal interactions in prostate cancer. 
In the context of human prostate tissue, p27Kip1 levels are suppressed in PIN lesions 
adjacent to tumours, whereas they are maintained in PIN lesions not associated with 
cancer (Majumder et al., 2008). Similarly, a reduction in staining for the cell cycle 
regulator p27Kip1 was observed in prostate tumour tissues when compared to benign 
controls and PIN in a separate cohort (Tsihlias et al., 1998). In contrast, other studies 
have found that p27Kip1 was weakly expressed in almost all studied PIN lesions (Fenic 
et al., 2004), and that p27Kip1 expression was just as low in PIN as in carcinoma 
(Doganavsargil et al., 2006). However, reduced expression of p27Kip1 correlates with 
recurrence in patients with primary prostate carcinoma and especially in those receiving 
neoadjuvant hormone therapy (Tsihlias et al., 1998), which could suggest an association 
between loss of p27Kip1 expression and castration resistance. While the resolving power 
of p27Kip1 expression for PIN and carcinoma is unclear, it is clear that in mice and in 
humans, the progression from PIN to invasive carcinoma requires the deregulation of 
cell cycle control and senescence programs, such as those regulated by p27Kip1 and p53 
(see Chapter 1.2.3.6), which appear to be initiated in the context of PIN and 
progression-induced changes of prostate epithelial organisation. 
1.2.3.4 C-myc amplification and overexpression occur throughout prostate 
carcinogenesis 
C-myc is a transcription factor oncogene located on chromosome 8q24.21 that is 
frequently amplified and overexpressed in many human tumours, including prostate 
cancer (Dang, 2012). It lies downstream of WNT signalling and many receptor tyrosine 
kinases, which positively regulate it at the transcriptional level (Dang, 2012). In 
combination with its co-activator max, c-myc activates gene expression and promotes 
cell growth and proliferation, while also being one of the Yamanaka factors necessary 
for reprogramming of differentiated cells to an embryonic stem cell-like state (Dang, 
2012). C-myc can also be regulated by microRNAs: miRNA-34a, a negative regulator 
of cancer stem cell phenotypes (see Chapter 1.3.6) and a transcriptional target of p53, 
directly represses c-myc at the translational level during oncogene-induced senescence 
(Christoffersen et al., 2010). 
Mechanistically, c-myc expression in prostate cancer is important in the control of cell 
growth and proliferation. A microarray study of myc overexpression in fibroblasts 
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revealed that c-myc both represses and promotes transcription of a diverse set of target 
genes: it represses cell cycle inhibitor p21 and promotes expression of Cyclin D2, 
suggesting that it promotes cell cycle progression (Coller et al., 2000) as well as the 
increased expression of translation initiation factors eIF4 γ and eIF5E, to name a few. 
Consistent with these roles, in the prostate cancer cell line LNCaP, c-myc 
overexpression upregulates biosynthetic pathways necessary for cell growth including 
ribosomal biogenesis and purine biosynthesis, and in castration-resistant prostate 
tumours it tightly correlates with expression of an enzyme involved in guanine 
nucleotide biosynthesis, IMPDH2 (Barfeld et al., 2015). Inhibition of IMPDH2 activity 
or downregulation with siRNA in LNCaP cells resulted in reduced cell proliferation 
which synergised with anti-androgens (Barfeld et al., 2015), suggesting that targeting 
the c-myc-driven regulation of biosynthesis could be therapeutically effective in 
castration-resistant prostate carcinoma. 
Mice that overexpress c-myc in a prostate-specific manner develop PIN followed by 
progression to carcinoma between 6 and 12 months of age, and are one of the few 
mouse models of prostate cancer that do not require ablation of a tumour suppressor 
gene to progress to carcinoma (Ellwood-Yen et al., 2003). Expression of NKX3-1 at the 
protein level is reduced in PIN and then lost in carcinoma, reminiscent of events in 
human prostate carcinogenesis (Ellwood-Yen et al., 2003). However, as with most 
mouse models of prostate cancer, they fail to be fully representative of the human 
disease: there were no genomic alterations underlying the transformation to PIN or the 
progression to carcinoma, which are pivotal in progression of the human disease 
(Ellwood-Yen et al., 2003). 
Evidence for a role of c-myc in human prostate cancer initiation and progression is 
strongest at the DNA level. In a FISH study, amplification of c-myc is observed in 
approximately 10% of metastatic tumours and in 5% of locally recurrent tumours 
(Bubendorf et al., 1999). Another FISH study found gains in 8q24 in 19% of PIA 
lesions, 21% of PIN lesions and in 27% of carcinoma lesions (Yildiz-Sezer et al., 2006). 
Interestingly, in this study even 10% of normal prostate tissue had amplification of c-
myc: this study either suggests that 8q24 amplifications occur very early on in prostate 
tumorigenesis, or there could be sources of false-positive amplification events being 
counted, such as overlapping nuclei in the sections. However, copy number gains of the 
whole of chromosome 8, which contains the c-myc locus, are strikingly common during 
prostate tumorigenesis (Jenkins et al., 1997; Sato et al., 2006): when factoring in these 
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events, c-myc amplifications occur in approximately 50% of PIN lesions, 44% of 
carcinoma lesions and 92% of metastases (Jenkins et al., 1997). In locally advanced 
stage (T3) prostate tumours treated with radical prostatectomy, copy number gain of c-
myc is associated with a higher Gleason score, and the presence of additional copy 
number gains relative to the copies of chromosome 8 is significantly associated with an 
earlier disease recurrence (Sato et al., 2006).  
Furthermore, c-myc mRNA expression in primary prostate tumours seems to be 
prognostically important, as it is an independent predictor of biochemical recurrence 
(Hawksworth et al., 2010). Using a qRT-PCR-based assay, Hawksworth et al. found 
that c-myc expression was positively correlated with expression of ETS family 
oncogene ERG (Hawksworth et al., 2010) (see Chapter 1.2.3.6). In addition, concurrent 
ERG and c-myc expression at the protein are associated with locally advanced prostate 
carcinoma (Udager et al., 2016), potentially indicating a tumour subtype-specific effect 
of c-myc on prostate cancer behaviour. 
Interestingly, c-myc mRNA levels were not observed to correlate with c-myc protein 
levels (Hawksworth et al., 2010), perhaps suggesting that c-myc is subject to additional 
regulation at the mRNA level as detailed previously. At the protein level, normal, PIA, 
PIN and carcinoma specimens are positive for c-myc in 23%, 21%, 76% and 82% of 
cases respectively (Gurel et al., 2008). Combined with evidence at the copy number 
level, this suggests that c-myc exerts its diverse effects on carcinogenesis throughout the 
spectrum from PIN to carcinoma and metastases. Although copy number changes and 
mouse models suggest that it could be a driver event for PIN-to-carcinoma transition, it 
is also implicated in tumour recurrence and heavily amplified in castration-resistant 
disease. C-myc-mediated signalling likely collaborates with other driver mutations in 
the maintenance of a castration-resistant phenotype, promoting cell cycle progression 
and cell growth. 
1.2.3.5 Other alterations during PIN-to-Carcinoma progression 
Other commonalities between PIN and prostate cancer include upregulation of AMACR 
and spermine synthase expression, and downregulation of complement components and 
serine protease inhibitors of the SERPIN family (Ashida et al., 2004). Synthesis of 
polyamines such as spermine are consistently elevated in prostate carcinoma (Rhodes et 
al., 2002), and their depletion results in a growth inhibitory effect in mouse prostate 
adenocarcinoma models and in vitro (Kee et al., 2004). Similarly, depletion of 
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complement components is observed in prostate carcinoma and BPH specimens 
compared to normal tissue (Hong et al., 2009), and complement factor C1q promotes 
apoptosis in prostate cancer cell lines in vitro, a process mediated by the tumour 
suppressors p53 and WOX1. This suggests that a key process in the transformation from 
PIN to carcinoma is the suppression of anti-proliferative and pro-apoptotic signals. 
With respect to SERPINs, a SERPIN family member known as maspin is frequently 
downregulated in prostate cancer, and has been associated with shorter recurrence-free 
survival in prostate cancer patients (Machtens et al., 2001). Additionally, expression of 
maspin in PC-3 and DU145 prostate cancer cell lines sensitises them to treatment with 
the chemotherapeutic gemcitabine (Huang et al., 2016), and in DU145 xenografts it also 
results in recruitment of B-cells and neutrophils accompanying an anti-tumour immune 
response (Dzinic et al., 2014). Interestingly, a cluster of SERPINs on 18q21 are 
frequently deleted in prostate cancer (Machtens et al., 2001; Yildiz-Sezer et al., 2006), 
which might explain the reduced expression of this protein family. This reflects an 
imbalance in proteolysis in favour of a more proteolytic prostatic environment 
(Machtens et al., 2001) and is another of the myriad copy number changes which are 
common on the route from precursors lesions to PIN and prostate carcinoma, albeit with 
progressively increasing frequency (Yildiz-Sezer et al., 2006).  
1.2.3.6 ETS gene family members fuse with TMPRSS2 in prostate carcinoma 
Gene expression signatures identify key changes in gene expression in the transition 
from PIN to carcinoma, and these include increased expression of E26 transformation-
specific (ETS) transcription factor family target genes, which is likely linked to 
increased protein biosynthesis (Tomlins et al., 2007). TMPRSS2-ERG gene fusion is 
the most common ETS family alteration in prostate cancer, where the ETS family 
oncogene ERG becomes expressed in an androgen-responsive manner due to fusion 
with the TMPRSS2 promoter. It is a common gene fusion event in prostate cancer, 
occurring in approximately 50% of cases (Wyatt et al., 2014; Abeshouse et al., 2015; 
Taylor et al., 2010). The TMPRSS2 and ERG loci, which are normally 3MB apart on 
chromosome 21q22.2, are brought into closer physical proximity with one another in 
androgen-dependent prostate cancer cells by ligand-bound AR (Mani et al., 2009), and 
TMPRSS2-ERG gene fusion events similar to those observed in human tumours can be 
brought about by the introduction of DNA double strand breaks. This suggests that a 
mutational environment, in the context of active androgen receptor signalling, 
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contributes to the extraordinarily high level of ETS translocation events in prostate 
cancer.  
Other ETS family members, ETV1 (Tomlins et al., 2005; Abeshouse et al., 2015), 
ETV4 and FLI1 (Abeshouse et al., 2015), are also subject to fusions with TMPRSS2, 
though less frequently. Collectively, overexpression of ETS family genes are found in  
50% to 70% of all primary tumours (Tomlins et al., 2007; Tomlins et al., 2005; 
Abeshouse et al., 2015) and are specific to prostate carcinoma, not being present in PIN 
lesions (Tomlins et al., 2005). Together they serve as useful biomarkers for molecular 
classification of prostate tumours: a recent study identified that 74% of primary prostate 
tumours could be separated into seven distinct molecular subtypes, four of which were 
based on ETS fusion events and comprised 59% of all tumours (Abeshouse et al., 
2015).  
Interestingly, despite high alteration frequency, the presence of ERG gene fusion is a 
predictor for poor outcome in patients with prostate carcinoma (Sboner et al., 2010). 
However, monoallelic TMPRSS2-ERG fusion has been associated with lower Gleason 
score tumours, whereas concurrent TMPRSS2-ERG and SLC45A3-ERG fusion was 
likely to increase ERG expression, co-occur with PTEN loss, and was associated with 
higher Gleason grade and stage tumours (Hernandez et al., 2016). This suggests that 
ERG gene fusion precedes other key molecular changes which lead to an aggressive 
phenotype, although further studies of SLC45A3-ERG fusion would be needed to 
confirm this. 
In mice, overexpression of transgenic ERG under the control of androgen responsive 
promoters is sufficient to induce PIN, but it is not sufficient for progressing to 
adenocarcinoma (Tomlins et al., 2008; Lawson et al., 2010; Chen et al., 2013). As with 
many molecular alterations in the mouse prostate, it is hypothesised that more 
oncogenic insults are necessary to drive oncogenic transformation. It is important to 
remember that ERG fusion events occur in the context of complex oncogenic stimuli 
during tumour development, rather than in isolation. ERG overexpression appears to 
have no effect on proliferation, but does drive an invasive programme even in benign 
prostate cell line RWPE and primary prostate epithelial cells, thought to be through 
plasminogen activator-dependent activation of matrix metalloproteinases (Tomlins et 
al., 2008). ERG expression in radical prostatectomies and metastases has also been 
associated with NF-kB activation and modulation of immune cell migration at the 
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transcriptome level by microarrays, and confirmed at the protein level by IHC (Roudier 
et al., 2016). ERG expression is correlated with the expression of a stem cell-related 
marker DLCK1 in both hormone-naïve and castration-resistant prostate carcinoma 
(Roudier et al., 2016). ERG expression in transgenic mice appears to positively regulate 
binding of AR to its transcriptional targets through a pioneer effect rather than through 
direct co-recruitment, and increases AR target gene transcription (Chen et al., 2013). 
Other ETS transcription factors such as ETV1 also have this effect (Chen et al., 2013). 
This suggests that ERG plays a role in upregulating AR signalling during the initial 
androgen-dependent phase of prostate carcinoma. In ERG mice and in human prostate 
tumours and cancer cell lines, deletion of PTEN causes a progression to invasive 
carcinoma and compensates for the reduction in androgen-mediated transcription that 
occurs as a result of PTEN loss (see Chapter 1.2.3.8) (Chen et al., 2013).  
Taken together, ETS fusion events probably occur early in prostate carcinoma 
development, after the transition from PIN to carcinoma. Such commonly mutated 
genes are clearly likely to serve a purpose in carcinoma development, and although the 
biological consequences of ETS fusion events remain to be completely understood, they 
appear to be important in priming the prostate for further oncogenic alterations.  
1.2.3.7 P53 mutations and deletions occur in the transition to advanced stage disease 
p53 is a key integrator of multiple signals including DNA damage, hypoxia and 
excessive oncogenic signalling, oversees multiple cell cycle checkpoints and also 
functions in the induction of apoptosis and senescence (Levine, 1997). This makes it a 
key tumour suppressor of prostate carcinoma. In mice, PIN lesions of PTEN-null 
transgenic models may progress to invasive carcinoma after the inactivation of p53, 
which otherwise induces senescence (Chen et al., 2005) suggesting that p53-mediated 
cell cycle regulation is important in the PIN-to carcinoma transition. This has yet to be 
proven in humans, where studies suggest that it is an important driver in the transition to 
advanced stage prostate carcinoma (Navone et al., 1993; McDonnell et al., 1997; 
Meyers et al., 1998; Qian et al., 2002; Ecke et al., 2010; Kuczyk et al., 1998; Machtens 
et al., 2001). 
p53 deletion occurs in approximately 30% of advanced-stage primary prostate tumours 
(Qian et al., 2002; Ecke et al., 2010), where it is associated with an increased risk of 
recurrence and a shorter time to recurrence (Ecke et al., 2010). In high Gleason grade 
androgen-independent prostate tumours (Navone et al., 1993) and in metastases 
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(McDonnell et al., 1997; Meyers et al., 1998), mutation of the locus results in nuclear 
accumulation of p53, and missense mutations of p53 are associated with increased p53 
stability (Navone et al., 1993). Such alterations are not found in benign prostate tissue 
or in PIN lesions, suggesting that the p53 alteration is an event occurring on transition 
to advanced disease and metastasis (Navone et al., 1993). This indicates that 
perturbation or alteration of p53 function is important for tumour progression to 
castration-resistant prostate cancer (CRPC) or metastasis.  
However, exon-sequencing and copy number alteration studies conducted by Taylor et 
al. suggest that missense mutation of p53 is a rare event, while deletion of the locus is 
much more common at 24% of tumours (Taylor et al., 2010), which agrees with 
previous studies on p53 deletion (Qian et al., 2002). Interestingly, while p53 is a tumour 
suppressor and is frequently mutated and deleted in prostate cancer, it is also 
overexpressed in some primary tumours (Kuczyk et al., 1998), and p53 overexpression 
is associated with increased risk of recurrence following prostatectomy (Kuczyk et al., 
1998; Machtens et al., 2001). While p53 clearly has roles to play in prostate cancer 
progression to advanced stages, it appears that they are context-dependent, and currently 
incompletely understood. 
1.2.3.8 Aberrations in PI3K-Akt signalling occur on the route to castration resistance 
The phosphatidylinositol 3 kinase (PI3K) pathway is a signalling pathway that begins at 
the cell membrane and serves to transduce RAS and growth factor receptor signalling 
(Keniry and Parsons, 2008). Activated RAS or growth factor receptors in turn activate 
PI3K, which acts to phosphorylate the lipid phosphatidylinositol bisphosphate (PIP2) to 
produce PIP3. PIP3 is recognised by some proteins containing the pleckstrin homology 
domain, and acts to recruit and activate these proteins at the plasma membrane. The 
most notable of these is the kinase AKT, which mediates proliferation and cell survival 
(Keniry and Parsons, 2008). Phosphatase and tensin homologue (PTEN) acts to inhibit 
this signalling pathway by dephosphorylating PIP3 to PIP2 and directly antagonising 
PI3K activity (Stambolic et al., 1998).  
Mice with mutant PTEN have increased cell proliferation and reduced sensitivity to 
apoptosis (Stambolic et al., 1998). PTEN deletion predisposes to PIN formation in mice 
(Majumder et al., 2008; Chen et al., 2006), and deletion of AKT1 is sufficient to inhibit 
this process, suggesting that the transformative event was brought about by aberrant 
AKT signalling (Chen et al., 2006). The PTEN protein interaction network is also 
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significantly mutated in human prostate cancer (Grasso et al., 2012; Abeshouse et al., 
2015). Alterations of PI3K signalling, either through over- and under-expression of 
signalling components or through somatic mutation, are found in approximately 42% of 
primary tumours and in 100% of metastases in a large-scale genomic and transcriptomic 
characterisation of prostate tumours (Taylor et al., 2010). The transition from PIN to 
carcinoma appears to be marked by loss of expression of PTEN (Torabi-Nezhad et al., 
2016; Lotan et al., 2013). Primary tumours not only have PTEN deletions in 
approximately 17% of cases (Abeshouse et al., 2015; Berger et al., 2011; Ahearn et al., 
2016), but also have a low frequency of activating mutations in downstream signalling 
components such as PIK3CA and PIK3CB (subunits of PI3-Kinase) and AKT1 
(Abeshouse et al., 2015).  
Interestingly, in mouse models which express a homozygous TMPRSS2-ERG fusion 
transgene, invasive carcinoma ensues only when homozygous deletions of PTEN are 
introduced (Chen et al., 2013). As mentioned before, upregulation of ETS gene 
expression in prostate epithelium in the context of PTEN loss restores some of the lost 
AR signalling frequently observed in PTEN-negative prostate tumours (Chen et al., 
2013). PI3K-AKT and AR signalling exhibit bidirectional cross-talk in the context of 
PTEN-negative prostate tumours: AKT inhibition restores AR signalling, whereas AR 
inhibition restores PI3K signalling (Carver et al., 2011). This is thought to be due to 
reciprocal negative feedback loops, where an androgen-dependent AKT phosphatase 
PHLPP is positively regulated by AR, and PI3K-AKT signalling negatively regulates 
levels of the receptor tyrosine kinases HER2/3, which stabilise AR and promote its 
transcriptional activity (Carver et al., 2011). This would help to explain why PI3K-AKT 
signalling persists after anti-androgens or castration, and why combined PI3K and AR 
inhibition is a more effective therapy than either alone (Zhang et al., 2009). Similarly, 
NKX3-1;PTEN mutant mice develop castration resistance early (Gao et al., 2006), 
suggesting that PTEN deletion could be an escape route for these cells to become 
castration resistant. This is consistent with a recent finding, in which PTEN loss is 
associated with lethal progression in patients with primary prostate carcinoma in the 
context of ERG-negative tumours (Ahearn et al., 2016), but not in ERG-positive 
tumours (where AR signalling is presumably sustained). Clearly, progression to an 
androgen-independent state is dependent on multiple factors, but the appearance of 
PI3K aberrations at both early and late stages of prostate tumour development 
underlines the importance of this signalling pathway in multiple stages of the disease. 
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1.2.3.9 AR signalling is key to castration resistance 
Prostate epithelial cells are androgen-dependent and the resulting tumours are normally 
treated with hormone therapy once primary interventions have failed (Heidenreich et 
al., 2008). When comparing gene expression signatures of PIN and carcinoma, 
increased androgen signalling is observed in carcinoma (Tomlins et al., 2007), 
suggesting an increased reliance on AR-mediated signalling outputs in the primary 
disease. In the absence of androgens, tumour cells are under selective pressure to 
survive and proliferate, resulting in numerous alterations to signalling and either the 
generation of, or selection for, a castration-resistant population of cancer cells (Grasso 
et al., 2012). Despite the low level of androgens in a castrate environment, most 
prostate tumours continue to rely on AR signalling (Groner et al., 2016). AR signalling 
has a diverse set of functions, including in cell cycle progression and in steroid, fatty 
acid and carbohydrate metabolism (Massie et al., 2011). Therefore, there are possibly 
many routes to castration resistance and metastasis, but AR signalling is nevertheless 
central to this process. This section will focus on the roles of AR signalling in the 
development of castration-resistant disease. 
Development of castration resistance may occur early on in prostate cancer progression, 
with androgen-independent cancer cells being identified in early primary tumours 
through tissue culture approaches (Finones et al., 2013) and it is hypothesised that this 
pre-existing ‘tumour-initiating’ cell/cancer stem cell (CSC) population could be selected 
for during androgen deprivation therapy to drive castration resistant disease (see 
Chapter 1.3 for more information on tumour-initiating cells). Consistent with this 
argument, in prostate cancer patients and in the prostate cancer cell line DuCaP the 
acquisition of castration resistance results in the upregulation of AR, steroidogenic 
enzymes and CSC markers such as CD44 (Pfeiffer et al., 2011). BCL-2 expression is 
also elevated in patients with castration resistant tumours as compared to hormone-
sensitive tumours, consistent with the concept that tumour cells are selected for their 
ability to resist androgen withdrawal-induced apoptosis (McDonnell et al., 1992). 
Similarly, castration resistance can manifest early in murine tumour development if the 
tumour suppressors NKX3-1 and PTEN are both deleted (Gao et al., 2006), suggesting 
that PI3K-AKT signalling and the background of tumour suppressor deletion is 
important in castration resistance, and is particularly important due to the cross-talk 
with AR signalling, as mentioned in Chapter 1.2.3.8. 
Prostate Cancer Stem Cells: Potential New Biomarkers 
  Benjamin Peter Sharpe - November 2016 58 
1.2.3.9.1 AR overexpression and mutation 
One common set of alterations that arises in response to hormone therapy is alteration to 
the AR locus itself. AR amplification is a frequent event in the development of 
castration-resistant prostate cancer (Grasso et al., 2012; Ulz et al., 2016), arising after 
hormone therapy (Visakorpi et al., 1995), presumably in order to sustain a level of AR 
signalling that will support survival and proliferation. Indeed, AR expression may be 
important for cell proliferation in both androgen-dependent and some apparently 
androgen-independent cells in vitro (Zou et al., 2006). AR mutations are also observed, 
many of which arise as a result of selective pressures brought about by specific anti-
androgen treatments (Steinkamp et al., 2009). Sequencing of AR cDNA in tumours 
reveals that there are many diverse mutations in AR throughout the coding sequence, 
including seven recurring unique mutations induced by bicalutamide and eight induced 
by flutamide (Steinkamp et al., 2009). Mutations in AR have many different effects that 
contribute towards treatment resistance: AR-V716M has promiscuous binding and is 
able to bind adrenal androgens and progesterone at higher affinity than wild type AR 
(Culig et al., 1993), whereas H875 and T878 activate AR signalling in the presence of 
flutamide, and AR-E255K has increased stability and nuclear localisation even in the 
absence of bound ligand (Steinkamp et al., 2009). Similarly, LNCaP prostate cancer 
cells that have been selected for resistance to bicalutamide develop a mutation in AR-
W741 that allows them to use bicalutamide as an agonist (Hara et al., 2003), although 
AR is still inhibited by other anti-androgens such as hydroxyflutamide. This suggests 
resistance involves sustaining AR activity in the presence of AR inhibitors and castrate 
hormone levels, but that there are multiple means to achieve this. Indeed, deep 
sequencing of AR in castration-resistant prostate cancer circulating plasma DNA reveals 
that there are often multiple, heterogeneous tumour clones which are dynamically 
regulated in both a spatial and temporal manner in response to treatment (Carreira et al., 
2014). For example, treatment with different hormone therapies results in emergence 
and regression of clones with different AR mutations, such as a glucocorticoid-activated 
AR-H875Y mutant which arose in a patient in response to prednisolone treatment, 
regressed upon addition of the anti-androgen abiraterone, only to re-emerge with an 
additional AR-T878A mutation upon treatment failure (Carreira et al., 2014). The 
dynamic acquisition and regression of different AR mutations in CRPC tumour clones 
due to selection explains why switching anti-androgens in a failing hormone therapy 
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regimen can sometimes prolong their effectiveness (Sternberg et al., 2013; Heidenreich 
et al., 2008). 
1.2.3.9.2 Mutations in coactivators and regulators of AR signalling 
Other routes to castration resistance involve sustaining AR signalling through mutations 
in other AR-interacting proteins. SPOP mutations, which result in increased AR target 
gene induction, have been recorded in primary prostate tumours (Abeshouse et al., 
2015). SPOP is a subunit of a cullin-type E3 ubiquitin ligase whose mutations are found 
in 10% to 13% of primary prostate tumours which are always ETS-fusion negative 
(Barbieri et al., 2012; Abeshouse et al., 2015) and appear to be located in the substrate-
binding pocket of the enzyme, suggesting altered substrate binding affinity or 
specificity. Prostate cancer cells expressing mutant SPOP or SPOP siRNA had 
increased invasive capabilities in vitro (Barbieri et al., 2012), similar to findings with 
ERG expression. Interestingly, SPOP mutation is mutually exclusive with ERG fusion, 
suggesting two distinct molecular subtypes of cancer with different routes to castration 
resistance (Abeshouse et al., 2015). SPOP has been shown to target SRC-3, a steroid 
receptor co-activator overexpressed in many cancer types, for proteasomal degradation 
(Li et al., 2011). SRC-3 is a co-activator for AR (Zou et al., 2006). SPOP also targets 
AR for degradation (An et al., 2014), while mutant SPOP is unable to bind to, or 
mediate the degradation of, either SRC-3 or AR (An et al., 2014; Geng et al., 2013). 
Both AR and SRC-3 are necessary for androgen-dependent and androgen-independent 
cell proliferation in prostate cancer cell lines in vitro and xenografts in vivo, and are 
recruited to the promoters of cell cycle genes such as Cyclin A to promote their 
expression (Zou et al., 2006). Another co-activator for AR, SRC-2 (alternatively known 
as NCOA2) is frequently amplified in prostate cancer, with up to 20% of primary 
tumours and 63% of metastases having amplifications of the chromosomal region of 8q 
which contains the gene (Taylor et al., 2010). A third example of AR coactivator 
alterations is TRIM24. SPOP mutations stabilise TRIM24, which also co-activates 
expression of cell cycle and AR target genes with AR, is associated with tumour 
recurrence and is progressively overexpressed in prostate tumours and metastases 
(Groner et al., 2016). While SPOP mutations have been found in high-grade PIN lesions 
suggesting that the event occurs early in tumorigenesis (Barbieri et al., 2012), it is likely 
that it plays a greater role in the acquisition of castration resistance in this subset of 
tumours. The high burden of mutational events in SPOP and SRC-2 suggest another 
way of sustaining AR signalling: through mutation of its coactivators and regulators. 
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Overall, the acquisition of a castration-resistant phenotype requires sustained androgen 
receptor signalling. It is clear that this may occur in many different ways, including 
through AR amplification and mutation, but also through mutations in the regulators of 
AR signalling and cross-talk with other key oncogenic signalling pathways such as 
PI3K-AKT. This is reflected in the accumulation of mutations in these pathways 
throughout prostate tumorigenesis. The fact that key drivers of the PIN to carcinoma 
transition also appear to play roles in castration resistance might help to explain why 
tumours treated with hormone therapy invariably become castration resistant. 
1.2.4 Summary 
PIA is one of the hypothetical origins of prostate carcinoma, through PIN as the 
intermediate state (Figure 1.4). From PIA to PIN, the following are observed: a 
progressive reduction in the expression of antioxidant genes such as GSTP1 and NKX3-
1; an increase in epithelial cell proliferation; expression of anti-apoptotic genes such as 
BCL2; and a progressive loss of basal cells and disruption of the glandular basement 
membrane. If PIA is the initial lesion, this would suggest that inflammation and the 
resulting oxidative stress are some of the first oncogenic insults in prostate cancer 
development, though this has yet to be proven and PIA’s status as a precursor lesion is 
still uncertain.  
The transition from PIN to carcinoma is marked by other key driver mutations including 
loss of PTEN and ETS gene fusion and SPOP mutation events which result in 
upregulation of PI3K-AKT and AR signalling respectively. PI3K and AR signalling are 
both key driver pathways of prostate cancer progression. Amplification of c-myc, 
upregulation of AMACR and loss of p27Kip1 are also observed during this phase of 
progression, probably reflecting changes in metabolism, cell cycle progression and the 
escape of apoptosis in the carcinoma environment. Progression to advanced carcinoma 
likely coincides with p53 mutation or loss for further downregulation of apoptosis. 
Transition from an advanced primary carcinoma to a castration resistant carcinoma is 
dependent upon selection induced by hormone therapy. In castration resistant prostate 
carcinoma, AR signalling persists in the absence of hormone and/or the presence of AR 
inhibitor. This event is mainly brought about by mutations or amplifications in the 
androgen receptor, and continued AR signalling is also sustained by aberrations in 
PI3K-AKT signalling and the pre-existing PTEN loss, ETS-fusions or SPOP mutations 
which alter these signalling pathways in the castrate environment. 
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1.3 Cancer Stem Cells (CSCs) in prostate cancer 
This section will introduce the cancer stem cell hypothesis, a relatively new research 
area in prostate cancer, and critically review the current evidence for the existence of 
prostate cancer stem cells. It will also cover the phenotypes that are associated with 
prostate cancer stem cells, including self-renewal, multipotency and resistance to 
multiple therapeutic strategies. Some of the content in this section has been published 
by the author in a previous review article on methodologies for isolating and 
characterising cancer stem cells in the prostate (Sharpe et al., 2013). 
1.3.1 The Cancer Stem Cell Hypothesis 
Stem cells are cell types that give rise to the terminally-differentiated, specialised cells 
of organs during development, and they continue to play a role in adult tissues in 
maintaining the homeostasis of their compartments by replenishing the differentiated 
cell populations found within (Blackwood et al., 2011). The cancer stem cell (CSC) 
hypothesis postulates that tumour masses may arise from a single cancer cell with stem-
like characteristics. These CSCs, sometimes known as “Tumour-Initiating Cells”, are 
thought capable of self-renewal and differentiation to regenerate the tumour mass and 
all tumour cell types within it. Such cancer cells were first identified in leukaemia in the 
1990s (Bonnet and Dick, 1997; Lapidot et al., 1994) followed by discoveries in breast 
cancer (Al-Hajj et al., 2003), and subsequently in other solid tumours (Visvader and 
Lindeman, 2008; Tirino et al., 2013) including prostate cancer (Collins et al., 2005). 
More recently, lineage-tracing evidence in the mouse suggests that putative prostate 
epithelial stem cells, such as the luminal castration-resistant NKX3-1-expressing cells 
known as CARNs, can act as a cell of origin for prostate carcinoma when given an 
oncogenic insult in the form of PTEN deletion (Wang et al., 2009). This lends more 
evidence to the argument that stem-like cancer cells may be important in tumour 
development, but it is currently unclear whether a stem cell acts as a cell of origin in the 
context of human prostate carcinogenesis. 
CSCs appear to be rare within tumours, as only a small proportion of all prostate cancer 
cells are able to reliably form large clones in vitro (Collins et al., 2005) and xenograft 
prostate tumours in mice in vivo (van den Hoogen et al., 2010; Hurt et al., 2008). 
Another feature attributable to cancer stem cells is their resistance to conventional 
treatment regimens, particularly chemotherapy (Abdullah and Chow, 2013) and the 
continued survival and self-renewal of CSCs is potentially an enticing explanation for 
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relapse, metastasis and therapy failure in prostate cancer. It is currently unclear whether 
CSCs are transformed stem cells or cancer cells that acquire stem-like phenotypes. A 
concerted effort is underway to isolate, characterise and target this critical cell 
population in order to produce more effective therapies. 
Cancer stem cells provide a compelling theory with which to explain the heterogeneity 
within tumours, particularly in prostate tumours which have marked heterogeneity even 
within the same patient. Patients tend to have multiple foci of carcinoma which are 
genetically and phenotypically distinct (Abate-Shen and Shen, 2000), apparently due to 
separate epithelial cells acquiring mutations independently of one another (Cheng et al., 
1998; Blackwood et al., 2011). Thus, it is possible to find benign tissue, PIN lesions and 
adenocarcinoma of multiple severities within the same biopsy and the same section 
(Abate-Shen and Shen, 2000), a heterogeneity already partly described and categorised 
by the Gleason scoring system. 
Prostate carcinoma is also notoriously heterogeneous between individual patients. 
Transcriptomic analysis of individual patient tumours suggests that each tumour may 
bear its own diverse and distinct set of mutations, genomic rearrangements and novel 
transcripts (Wyatt et al., 2014), and the molecular profiles are heterogeneous enough to 
confound attempts to construct a prognostic model that would provide extra predictive 
utility over standard clinical variables (Sboner et al., 2010). Successful attempts have 
been made at molecularly subtyping the disease, resulting in seven tumour subtypes 
based on gene mutations (Abeshouse et al., 2015), but even so over a quarter of all 
tumours remain unclassified. Thus, the disease presents a considerable challenge for the 
identification of reliable prognostic models that would help inform treatment decisions 
for patients with prostate cancer. Theoretically, identifying the cancer stem cells from 
which these heterogeneous populations emerge could provide useful insight into the 
tumour’s development and subsequent disease progression. Identifying CSC-related 
biomarkers for use in a pathology setting might allow for a more accurate prediction of 
disease course and tumour recurrence. 
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1.3.2 The identity of prostate CSCs 
The identity and the existence of prostate CSCs are both controversial, and there have 
been many attempts to isolate and characterise them, mainly from prostate cancer cell 
lines, but also from primary human tumour tissue. There are many potential biomarkers 
used to identify putative prostate CSCs, and this section will cover some of the 
frequently used protein biomarkers, such as CD44 and CD133, which are used to 
identify putative CSCs in several different tumour types including prostate, breast and 
gliomas (Visvader and Lindeman, 2008). Other CSC biomarkers will be reviewed in 
subsequent results chapters. These biomarkers are used either alone or in combination 
with other biomarkers to indicate the presence of putative cancer stem cells. 
1.3.2.1 CD44 as a prostate CSC biomarker 
CD44 is a hyaluronan-binding cell-surface glycoprotein that is often used to purify 
prostate cancer stem cells by fluorescence-activated cell sorting. CD44 has multiple 
splice isoforms and regulates many cellular processes including cell migration, 
proliferation and cell survival, which appear to be dependent on numerous binding 
partners such as Ezrin, Radixin and Moesin proteins and receptor tyrosine kinases such 
as c-Met (Ponta et al., 2003). Evidence from cell lines and xenograft experiments, 
detailed below, supports potential roles for CD44 in mediating CSC behaviour.  
SiRNA-mediated knockdown of splice variant CD44v6 has been found to reduce 
clonogenicity and sphere forming capacity in LNCaP, PC-3M and DU145 cells (Ni et 
al., 2014).  In vitro, orthotopic mouse xenografts of CD44+ subpopulations of prostate 
cancer cell lines DU145, PC-3 and LNCaP have greater proliferative, clonogenic and 
sphere-forming capacity than CD44- cells, as do immortalised normal human prostate 
epithelial NHP6 cells (Patrawala et al., 2006). Interestingly, even non-tumorigenic 
NHP6 cells had a subpopulation of 2% CD44+ cells, although minimally tumorigenic 
LNCaP cells had none and tumorigenic PC-3 cells had 100%, which suggests that CD44 
expression correlates with tumorigenic potential in vivo, as well as proliferation in vitro. 
When orthotopically xenografted into immunodeficient mice, these cell lines give rise 
to primary tumours and metastases more frequently, with as few as 100 implanted cells 
required for tumour formation (Patrawala et al., 2006), whereas CD44- and unsorted 
cells require several orders of magnitude more cells for successful tumour formation. 
Conversely, orthotopic xenografting of LAPC4, DU145 and PC-3 cells with silenced 
CD44 expression results in reduced tumour growth and metastasis (Liu et al., 2011a), 
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indicating that CD44+ tumour cells have a greater capacity for proliferation and 
invasion.  
CD44+ CSCs from prostate cancer cell lines display evidence of stem-like properties: 
BrdU label-retaining properties indicate a slower cycling time, and they also express 
increased levels of stem cell markers such as BMI1, SMO, OCT3/4 and beta-catenin 
(Patrawala et al., 2006). However, CD44- can give rise to CD44+ cells in prostate 
cancer cell lines, suggesting that this may be a dynamically regulated or fluctuating 
phenotype (Patrawala et al., 2006). 
However, the effect of CD44 expression on prostate tumours is far from clear: one study 
showed that CD44s and splice variant CD44v6 protein expression may be lost in 
metastases, and expression of CD44s inversely correlates with Gleason grade (De 
Marzo et al., 1998). Overexpression of CD44 in a rat prostate cancer cell line 
suppressed metastasis formation in subcutaneous murine xenografts (Gao et al., 1997). 
In summary, it is recognised that human prostate cancer cell lines are not homogeneous 
populations in terms of their proliferative and invasive capacities, but rather a stem-like 
CD44+ population has elevated tumorigenic potential, although this remains 
controversial. However, the putative CD44+ prostate CSC population is thought to be 
highly heterogeneous, and therefore when characterizing prostate cancer stem cells 
CD44 is often included in a panel of biomarkers of prostate CSCs (Table 1.1). 
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1.3.2.2 Other biomarkers for prostate CSCs 
Other cancer stem cell markers are frequently co-expressed in CD44+ prostate CSCs. 
CD44+/CD24- purified DU145 (Salvatori et al., 2012) and LNCaP (Hurt et al., 2008) 
prostate cancer cell lines form tumourspheres with the potential to differentiate. Stem-
like PSA-/low cells sorted for the antigenic profile ALDH+/CD44+/ α2β1+ had higher 
tumorigenicity than ALDH-/CD44-/ α2β1- cells and PSA- cells, with ten cells being 
sufficient to induce a xenograft tumour in NOD/SCID mice (Qin et al., 2012). 
Similarly, tumorigenic prostate cancer stem cells, comprising 0.1% of the total cells, 
have been isolated from primary human prostate tumours using the antigenic profile 
CD44+/α2β1high/CD133+ (Collins et al., 2005). CD133 is a 5-pass transmembrane 
glycoprotein expressed by some normal human stem cell populations, and was first 
identified in haematopoietic stem and progenitor cells (Yin et al., 1997). Interestingly, 
CD133 is also expressed in a small subset of quiescent, α2β1high prostate basal cells in 
benign human prostate tissue that have the capability of forming differentiated acinar 
structures, suggesting that populations of stem-like cells in the benign and malignant 
prostate epithelium may be related (Richardson et al., 2004). CD133+ subpopulations of 
prostate cancer cell lines CWR22RV1, C4-2, LNCaP have greater invasion and sphere-
forming capacity in vitro than the corresponding unsorted lines (Wen et al., 2016). 
Again, this suggests that prostate epithelial cells expressing stem cell markers have 
more invasive phenotypes, and that tumour cells may be remarkably heterogeneous, 
even in cell lines that were previously thought to be relatively homogeneous 
populations. If these findings translate into the human tumour, then they carry 
prognostic implications for the patients with higher burdens of cells with these stem-like 
and CSC-like expression patterns. 
Biomarker panels for prostate CSCs remain controversial. In CSCs isolated from cancer 
cell lines, such as DU145 tumoursphere cells (Rybak et al., 2011), the prostate CSC 
population was CD44+/CD24+/ α2β1+, in contrast to the CD44+/CD24- profile mentioned 
previously. Similarly in head and neck squamous cell carcinoma cell lines, CD44- cells 
had CSC-like properties despite its use as a marker for CSCs (Oh et al., 2013). In IHC 
experiments conducted on prostate tumours, high-grade PIN and normal prostate tissue, 
CD44 was found to be more frequently expressed in PIN and normal tissue than in 
carcinoma, but in CD44+ cases the expression is too widespread to represent a rare 
stem-like cell population (Ugolkov et al., 2011). This suggests that there may be more 
than one group of stem-like cells to be found in cancer cell populations, and a single 
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antigen - or panel of antigens - may be insufficient for isolating all CSCs of interest. 
Additionally, these CSCs may not necessarily be cells of origin for prostate cancer: in 
an in vivo murine renal capsule xenograft model of prostate cancer, only CD133- basal-
enriched human prostate epithelial cells derived from the benign prostatic hyperplasia 
cell line BPH1 were vulnerable to transformation, either by estrogen and androgen 
administration or by recombination with cancer-associated fibroblasts (Taylor et al., 
2012). Despite their stem cell marker expression and functional capacity for 
proliferation and invasion, it is still unclear whether these prostate CSCs, mostly from 
prostate cancer cell lines, represent the cells of origin of the tumour, or whether they are 
tumour cells that have activated stem-like programmes. The hypothesis is currently 
supported by evidence drawn from cancer cell lines and their xenografts, which are 
repeatedly passaged and not representative of the human tumour microenvironment. 
While CD44 and CD133 are commonly used biomarkers for prostate CSCs, no single 
marker or combination of markers is sufficient for identifying all putative prostate 
CSCs, and it remains to be seen whether such a biomarker exists. 
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1.3.3 Functional assays for prostate CSCs 
There have been many functional assays employed to identify and characterise prostate 
CSCs, each with a set of advantages and limitations. These will be referred to in the 
next section on CSC properties and subsequently in chapter 3, and so will be discussed 
here, separated by the CSC properties they characterise. 
1.3.3.1 Self-renewal 
A defining property of both stem cells and cancer stem cells is their self-renewal 
capacity. There are two main types of in vitro assays used to probe self-renewal in 
isolated cell populations: clonogenicity assays and sphere formation assays. Both assays 
involve the culture of isolated cells in conditions that preferentially maintain stem cells, 
thus selecting for those cancer cells with more stem-like properties in vitro. They may 
also be considered proliferation assays, as self-renewal and proliferation are not distinct 
in this context. As most cancer cells are expected to have some self-renewal capacity, 
these assays are comparative in nature, and rely on the isolated CSCs being significantly 
different from a control population of cells for a tested phenotype.  
1.3.3.1.1 Clonogenicity assay 
The clonogenicity assay involves seeding a single cell or a small number of cells onto 
culture plates, and monitoring colony formation after a defined time period. This assay 
is based on the assumption that small titres of cells will only form large colonies if they 
have the ability to self-renew (Hellsten et al., 2011). The number of colonies present is 
then treated as a correlate of self-renewal capacity. This assay can be done serially with 
a single cultured cell, making it possible to further demonstrate a clone’s self-renewal 
capacity over multiple passages in vitro (Collins et al., 2005). There are some 
disadvantages with this assay; one being that an arbitrary threshold must be assigned to 
determine which colonies are too small to count. More significantly the assay may not 
provide a complete representation of self-renewal capacity in vivo. However, they 
underline the important finding that subpopulations of stem-like prostate cancer cells 
have far greater proliferative capacity than the rest of the cell population. 
1.3.3.1.2 Sphere formation assay 
Another important tool is the sphere formation assay. The method was originally used 
to study adult neural stem cells in vitro (Reynolds and Weiss, 1992) and has now been 
applied to isolate prostate CSCs. Low adherence culture in defined serum-free medium 
produces clonal multicellular spheroid aggregates called tumourspheres, which are 
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enriched for cells displaying cancer stem cell phenotypes. Anchorage-independent 
growth is a malignant phenotype in itself, suggesting that isolated CSCs are selected by 
their innately malignant phenotypes. This method is now widely-used for the 
enrichment of cancer stem cells from many types of cancer, including prostate cancer. 
The assay is versatile, and may be used in prostate cancer cell lines (Zhang et al., 
2012a; Cho et al., 2012; Miki et al., 2007) and explanted human primary prostate 
tumour tissue (Rajasekhar et al., 2011; Miki et al., 2007; Castellon et al., 2012), or to 
further characterize cells isolated by other methods (Celia-Terrassa et al., 2012; Albino 
et al., 2012; Ma et al., 2011; Hellsten et al., 2011). CD44 was found to be highly 
expressed in tumourspheres derived from four different prostate cancer cell lines (Zhang 
et al., 2012a), suggesting that expression of this marker may be important for the 
anchorage-independent growth phenotype.  
Tumourspheres form at low efficiency, originating from a small fraction of the tumour 
cell population (Rajasekhar et al., 2011) and can be serially cultured (Doherty et al., 
2011; Duhagon et al., 2010; Rajasekhar et al., 2011; Kong et al., 2010), which further 
indicates that prostate cancer cells and their tumoursphere progeny both contain a 
subpopulation with extended proliferative capacity. Tumoursphere cells also tend to 
possess CSC-associated phenotypes, such as self-renewal in long-term culture and 
expression of putative cancer stem cell markers such as CD44 and integrin α2β1 (Rybak 
et al., 2011; Zhang et al., 2012b). However, sphere formation may not always select for 
cancer stem cells in vitro:  α2β1+ prostate cancer stem cells isolated from prostate 
xenograft tumours had high clonogenicity and sphere-forming capacity, but did not 
have the high tumorigenicity in xenografts expected of cancer stem cells (Patrawala et 
al., 2007). Similarly, when Matilainen et al. (2012) attempted to isolate breast cancer 
stem cells using this method, the result was an unexpected reduction in CSC-associated 
gene expression and a loss of metastatic phenotypes. Tumourspheres may not consist 
purely of CSCs, but contain some differentiated and dying cells (Salvatori et al., 2012), 
and there are concerns that sphere generation is not being sufficiently validated – for 
example, to ensure that sphere formation is a result of cell proliferation and not cell 
aggregation (Pastrana et al., 2011). Overall, these results suggest that tumoursphere 
formation and thus anchorage-independent growth is a malignant phenotype possessed 
by prostate CSCs in vitro. It is not currently known whether this is a property of CSCs 
in a tumour microenvironment in vivo, highlighting the need to verify all findings in 
vivo before any conclusions are made regarding the existence of prostate CSCs.  
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1.3.3.1.3 Xenograft transplantation assays 
In vitro assays have limited utility in characterising cancer stem cells, as they take 
isolated epithelial cells out of the context of their tumour microenvironment. A well-
established test for in vivo self-renewal comes from xenograft transplantation assays. 
Low titres of CSCs – isolated from cell lines (van den Hoogen et al., 2010) or from 
dissociated human primary (van den Hoogen et al., 2010) and xenograft (Rajasekhar et 
al., 2011) prostate tumours are injected into immunodeficient mice. Prostate CSCs with 
a variety of markers such as high aldehyde dehydrogenase activity, primary tumours 
(Cho et al., 2012; van den Hoogen et al., 2010; Rajasekhar et al., 2011; Li et al., 2010) 
or metastases (van den Hoogen et al., 2010) at this limiting dilution are proposed to 
have a cancer stem cell phenotype. To provide more evidence for the CSC identity of 
the cells, xenograft tumour formation assays can be done serially using purified 
dissociated cells from previous xenograft tumours (Li et al., 2010). The ability to 
serially generate tumours at limiting dilution is an indicator of self-renewal in vivo. 
Large tumour size and high tumour-forming capacity are indicators of an aggressive 
subpopulation of cells in vivo. Although this does not fully represent tumour formation 
in situ, especially as the adaptive and innate immune systems are compromised, these 
models are versatile and demonstrate tumorigenicity and proliferative capacity in vivo. 
In fact, this approach was perhaps the gold standard model for studying CSCs, until the 
advent of in vivo lineage tracing approaches (see Chapter 1.3.3.2.3). 
1.3.3.2 Multipotency 
1.3.3.2.1 Matrigel assays 
Another defining characteristic of normal stem cells and, hypothetically, cancer stem 
cells, is their ability to differentiate. Differentiation can be induced in vitro by culturing 
cells in a scaffold of matrigel, and multipotent prostate cancer cells may produce 
glandular structures that recapitulate prostate cancer architecture in vivo (Gu et al., 
2007). Unlike culture in serum-free media, matrigel induces differentiation, causing 
putative prostate stem cells to form glandular structures. CSCs may also differentiate in 
standard mammalian cell culture with added serum and dihydrotestosterone (Collins et 
al., 2005; Hurt et al., 2008), losing stem cell markers and concurrently expressing 
differentiated prostate epithelial cell proteins such as AR and prostatic acid phosphatase 
(Hurt et al., 2008). This assay demonstrates that prostate CSCs may assume more 
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specialised cell types when exposed to the appropriate differentiation factors, 
recapitulating another of the characteristic stem cell properties in vivo. 
1.3.3.2.2 Tissue recombination assays 
To provide more evidence for differentiation capacity in vivo, prostate CSCs can be 
recombined with inductive rat urogenital sinus mesenchyme and grafted under the renal 
capsule of immunodeficient mice. With a stromal component provided, gland-like 
structures form that recapitulate the structures and cell types found in the original 
prostate (Goldstein et al., 2010) or human prostate tumour (Gu et al., 2007), thus 
demonstrating a stem-like capacity for differentiation. The renal graft model can also be 
used to assay for malignant transformation capacity, by recombining selected prostate 
epithelial cells with cancer-associated fibroblasts from human prostate tumours (Taylor 
et al., 2012). This assay highlights the importance of the stromal microenvironment for 
differentiation and cell transformation, which appears to be as relevant for prostate 
CSCs as normal stem cells. While these assays do provide a stromal component which 
better recapitulates the in vivo situation, the removal of putative prostate CSCs from 
their original tumour context may create a false impression of stemness behaviour that 
does not truly exist in the tumour proper: stem cells are highly dependent on their stem 
cell niche (Foster et al., 2002). For example, AR expression in the prostatic 
mesenchyme is necessary for the prostate gland and its secretory epithelium to form 
(Kurita et al., 2001). As with normal stem cells, the existence of prostate CSCs cannot 
be proven until such cell behaviours are observed in tumours in situ and in vivo – 
something that is very difficult to achieve in human tumours. To better address this 
question, in vivo lineage tracing studies have been employed in the mouse to model the 
development of prostate cancer. 
1.3.3.2.3 In vivo lineage-tracing 
The presence of prostate CSCs in human prostate cancer remains to be proven. 
However, the lineage-tracing technique, which irreversibly marks a cell population and 
its progeny for long-term tracing of cell fate, was described in Chapter 1.1.3, and has 
been used in mouse models to monitor prostate epithelial cells following an oncogenic 
insult. Lineage-tracing evidence is limited for the prostate cancer, but some studies have 
been conducted to probe potential cells of tumour origin. Luminal castration-resistant 
NKX3-1-expressing cells, which are a putative luminal stem/progenitor cell population 
in the developing prostate, can act as a cell of origin for prostate carcinoma when PTEN 
Chapter 1: Introduction 
Benjamin Peter Sharpe - November 2016    73 
is deleted in a model of prostate regression and regeneration (Wang et al., 2009), 
resulting in a tumour with a luminal phenotype and loss of basal cells. These alterations 
recapitulate those seen in human prostate tumours as detailed in Chapter 1.2.3. A 
potential criticism is that most mouse models of prostate cancer already make use of a 
luminal-specific promoter to drive expression of transgenes, such as the probasin 
promoter or its stronger derivative ARR2PB (Majumder et al., 2008), and therefore the 
finding of tumorigenesis from this compartment may not be novel. However, a more 
recent lineage-tracing study found that stabilisation of beta-catenin in Axin2-expressing 
luminal cells, which were demonstrated to be unipotent luminal progenitors in the 
mouse prostate during development, resulted in adenocarcinoma in situ with luminal 
differentiation and expression of proliferative marker Ki-67 (Lee et al., 2015b). The 
results of lineage-tracing experiments so far suggest that transformation in putative 
luminal stem/progenitor compartments can result in prostate carcinoma in mice. 
Interestingly, basal cells can also be the targets for oncogenic transformation. The same 
group that generated NKX3-1-driven PTEN-null mouse tumours later demonstrated that 
luminal phenotype prostate tumours could also be generated from the basally expressed 
promoter CK5 using the same PTEN deletion as an oncogenic insult (Wang et al., 
2013). Basal-origin tumours progress slower to carcinoma than luminal-origin tumours, 
but they are histologically similar at the equivalent stages (Wang et al., 2013), perhaps 
suggesting that the basal transformation process to carcinoma takes a longer time due to 
a preceding basal-to-luminal differentiation event.  
While stem cell compartments can be transformed into carcinoma in mouse lineage-
tracing models, it remains to be seen whether tumour-forming cell populations in the 
mouse prostate continue to act as prostate CSCs during development of the disease, or 
whether they only contribute to initiation in this model. These cells satisfy some of the 
requirements for being prostate CSCs in that they have considerable self-renewal as 
well as apparent differentiation potential. However, the contribution of Axin2, CK5 or 
NKX3-1-expressing tumour cells to recurrence, therapy resistance or metastasis, which 
are also functionally important aspects of CSC behaviour, has yet to be demonstrated. 
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1.3.4 Other properties of prostate CSCs 
1.3.4.1 Expression of stem cell markers 
As mentioned in the previous section, some prostate CSC markers are also stem cell 
markers, and a recapitulation of stem-like expression patterns and behaviours is one of 
the hallmark characteristics of a CSC. Many embryonic stem (ES) cell pluripotency 
factors – such as Nanog, Oct4 and Sox2 - are known to be expressed in both adult stem 
cells and CSCs, and embryonic stem cell gene expression signatures have been found to 
identify poorly differentiated tumours from several types of human cancer including 
prostate cancer (Ben-Porath et al., 2008), and this has been verified in subsequent 
studies (Rye et al., 2014; Markert et al., 2011). Given this trend, stem cell factors likely 
underlie many of the phenotypes observed in prostate CSCs, as they may underpin 
important cancer stem cell phenotypes such as self-renewal. DU145 prostate 
tumoursphere cells express the ES pluripotency factors Nanog, Oct4 and Sox2 (Rybak 
et al., 2011), as do telomerase-immortalized human prostate cancer epithelial cell 
cultures (Gu et al., 2007). In human BM18  xenograft prostate tumours, rare CD44+ 
stem-like cells have also been found to express Nanog (Germann et al., 2012). DU145 
and PC-3 cells that express GFP under a Nanog promoter reporter construct have been 
shown to have increased clonogenicity and tumoursphere formation capacity, as well as 
having forming larger tumours in murine xenografts (Zhang et al., 2014). Interestingly, 
in both the xenograft and tumoursphere settings, Nanog promoter activation was present 
in tumours or spheres that were derived from GFP-negative cells, suggesting dynamic 
regulation of Nanog expression in the putative prostate CSC population (Zhang et al., 
2014). The functional role of Nanog expression in these cells appears to be cell cycle 
progression, as GFP-positive cells had greater levels of CDK2, cyclin E, and cyclin A 
protein than GFP-negative cells, suggesting that Nanog expression promotes entry into 
S-phase (Zhang et al., 2014). In primary human prostate carcinoma, expression of 
Nanog and Oct4 has been reported to be enriched in Gleason grade 5, an indicator of 
poor prognosis (Mathieu et al., 2011). This evidence suggests that the presence of stem 
cell markers may be a common feature of poor-prognosis tumours.  
However, the association between pluripotency factors and CSC properties remains 
controversial and incompletely understood, especially in patient tumours. Sox2 
expression was recently found to be repressed by signalling through the Androgen 
Receptor in prostate cancer cell lines (Kregel et al., 2013), and was associated with 
castration-resistant prostate carcinoma tissues assessed by IHC. Expression in human 
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prostate tumours was not consistent with a CSC population, as it was broadly expressed 
throughout Sox2-positive tumour epithelium (Kregel et al., 2013). Conversely, an IHC 
study showed that Sox2 was expressed in both benign prostate and prostate cancer in a 
small subpopulation of <10% of cells, which is more consistent with a stem cell 
population.  
In addition, both Oct4 (Sotomayor et al., 2009) and Nanog (Das et al., 2011; Booth and 
Holland, 2004) have multiple pseudogenes and splice variants which could  have 
differing importance to prostate CSCs and thus complicate the interpretation of the 
overall roles of these proteins in these cell populations. For example, in patients with 
primary prostate carcinoma, the Oct4 isoform Oct4A is expressed in the nuclear 
compartment and is associated with a shorter biochemical recurrence-free survival, 
whereas Oct4B is expressed in the cytoplasm and associated with a longer biochemical 
recurrence-free survival (de Resende et al., 2013), suggesting different roles for the two 
isoforms of the protein.  
Nanog mRNA is expressed mainly through the functional pseudogene NANOGP8 in 
prostate cancer cell lines, including LNCaP, DU145 and PC-3 (Jeter et al., 2011; Zhang 
et al., 2014), and Nanog protein levels positively correlate with CD44 protein levels 
(Jeter et al., 2011). In HPCa38 and HPCa39 prostate cancer xenografts and in PC-3 and 
DU145 cells, shRNA-mediated knockdown of Nanog levels results in inhibition of 
proliferation and clonogenicity, whereas knockdown of Oct4 does not have a clear 
inhibitory effect on proliferation (Jeter et al., 2011). In summary, while there seems to 
be a more consistent role for Nanog expression in prostate CSCs, the expression pattern 
and significance of Oct4 and Sox2 expression in both prostate tumours and their 
putative CSCs is still unclear, but it seems unlikely that prostate CSCs are a simple 
recapitulation of embryonic stem cell transcription in cancer cells.   
1.3.4.2 Expression of prostate epithelial cell lineage markers 
Markers that identify specific cell types of the prostate are often used in attempt to 
characterise candidate prostate cancer stem cells. This is important, as the normal 
prostate cell type that prostate cancer stem cells most resemble remains controversial. 
For example, populations of castration resistant stem-like cells persist in DuCaP and 
HPET cell lines in vitro (Pfeiffer et al., 2011; Gu et al., 2007) and in prostate cancer 
xenografts in vivo (Germann et al., 2012). Germann et al. have suggested that the CSCs 
found in the BMI18 xenograft model are of luminal or possibly neuroendocrine cell 
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origin, detecting elevated expression of the luminal marker Cytokeratin 18 and 
neuroendocrine cell marker Chromogranin A following castration (Germann et al., 
2012). Conversely, another group observed upregulation of basal-specific cytokeratin 5 
in the DuCaP cell line under androgen deprivation, but could not detect expression of 
the neuroendocrine marker Nestin (Pfeiffer et al., 2011). However, when comparing 
expression profiles of castration resistant and non-resistant human prostate tumours by 
microarray, the group found that both basal (Cytokeratin-5) and neuroendocrine 
(Nestin) markers were upregulated along with the putative cancer stem cell markers 
CD44 and c-Kit. Immortalised prostate cancer epithelial cells generated by Gu et al. 
(2007) also express Nestin along with embryonic stem cell markers, consistent with a 
neuroendocrine-like CSC phenotype. Markers of prostate lineage differentiation can 
also be absent: docetaxel-resistant 22Rv1 and DU145 CSCs are negative for both 
luminal and basal cell cytokeratins as well as androgen receptor (Domingo-Domenech 
et al., 2012). The variability of expression patterns in multiple models of prostate cancer 
suggests that cancer stem cells may be more than one distinct subpopulation. It could 
also be a reflection of the phenotypic plasticity of cancer stem cells that has been 
recently modelled in breast cancer cell lines in vitro, where cancer cells reach an 
equilibrium of available differentiation states even once purified for a specific 
differentiation state (Gupta et al., 2011; Chaffer et al., 2011) and in xenografts of these 
lines in vivo (Chaffer et al., 2011). Potential examples of this in the prostate include 
spontaneous interconversion of CD44+ and CD44- cell states in LAPC-4 and LAPC-9 
prostate cell line xenografts (Patrawala et al., 2006), and interconversion of Nanog+ and 
Nanog- cell states in PC-3 and DU145 xenografts (Zhang et al., 2014). Regardless, 
determining the cell type of origin – and the heterogeneity thereof - is important in order 
to further establish the identity of prostate cancer stem cells.   
Overall, the epithelial cell type that putative prostate CSCs most resemble is still 
unclear. Biomarkers are useful for probing all aspects of cancer stem cells but given the 
apparent heterogeneous nature of cancer stem cells, currently no single marker is ideal 
and the best current practice is to use combinations of markers analysed in tandem for 
effective phenotypic characterization.  
1.3.4.3 Regulation by microRNAs 
Cancer stem cell phenotypes appear to be modulated in part by microRNA-mediated 
mechanisms which contribute to the expression of stem cell markers in prostate CSCs. 
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miR-34a, a microRNA that is a transcriptional target of p53, downregulates CD44 
expression and is consequently downregulated in CD44+ and CD133+ prostate cancer 
stem cells from three xenograft models (Liu et al., 2011a). In prostate cancer cell lines, 
miR-34a expression results in reduced clonogenicity and sphere formation in vitro as 
well as reduced tumour growth and metastasis when implanted into mice in vivo (Liu et 
al., 2011a). This appears to be largely due to suppression of CD44 expression, although 
expression of miR-34a in vitro can also lead to apoptosis and cell cycle arrest in G1-
phase (Tarasov et al., 2007). Administration of miR-34a may thus have a potential 
therapeutic use, and highlights the clinical potential inherent in the inhibition of CSC 
phenotypes. 
Like miRNA-34a, Let-7 is upregulated by p53 expression (Tarasov et al., 2007) and is 
responsible for the silencing of oncogenes c-MYC (Liu et al., 2012), k-RAS (Johnson et 
al., 2005; Liu et al., 2012) and HMGA2 (Lee and Dutta, 2007), which enhance cell 
proliferation. Let-7 expression also silences the stem cell markers OCT3/4, SOX2 and 
NANOG in PC-3 cells in vitro, and Let-7 levels themselves are reduced by expression 
of an RNA binding protein known as Lin28B (Kong et al., 2010). Lin28B is inhibited 
by expression of another microRNA, miR-200 (Kong et al., 2010), whose expression in 
PC-3 cells that have an EMT-like phenotype causes them to undergo MET and have 
reduced clonogenic and sphere-forming capacity in vitro. Lin28B also reduces 
expression of NOTCH1, another stem cell marker (Kong et al., 2010). Lin28B is 
implicated in the acquisition of CSC phenotypes and pluripotency gene expression 
through suppressing Let-7 in oral squamous cell carcinoma cells (Chien et al., 2015) 
and in ALDH activity and pluripotency gene expression in a variety of other carcinoma 
cell lines (Yang et al., 2010), suggesting that the regulation of CSC phenotypes by this 
miRNA network may be independent of tumour origin.  
Interestingly, ETS factor EHF, which has previously been shown to repress EMT and 
pluripotency-related genes as well as being reduced in prostate cancer (Albino et al., 
2012), regulates the expression of LIN28B by transcriptional repression of its promoter 
(Albino et al., 2016). Thus, a network of microRNAs and their regulators is involved in 
the regulation of stemness and EMT phenotypes in prostate cancer, which appear to 
coordinate with one another in a cancer stem cell context. In general, many tumour-
suppressing miRNAs are commonly downregulated in most prostate CSCs to promote 
these phenotypes, but the patterns of miRNA regulation appear to be distinct in CD44+, 
CD133+, integrin α2β1high and side-population cells (Liu et al., 2012). This would 
Prostate Cancer Stem Cells: Potential New Biomarkers 
  Benjamin Peter Sharpe - November 2016 78 
suggest that, while all of these markers enrich for CSC phenotypes, the CSC population 
is heterogeneous and each of these subpopulations may have different properties. With 
further characterisation, these microRNA expression profiles could be a useful method 
for profiling cancer stem cell phenotypes in vitro. 
1.3.4.4 Resistance to Therapy 
The segregation of cancer stem cells from a cell population may be achieved by 
selecting for their resistance to standard cancer treatments. This is based on the 
observation that cancer stem cell populations tend to survive exposure to 
chemotherapeutic agents in vitro.  Similarly, cancer stem cells have been proposed to be 
resistant to radiation and androgen withdrawal.  
1.3.4.4.1 Castration resistance 
In an androgen-sensitive human xenograft model, Germann et al. have recently 
identified subpopulations of cancer cells that repopulate the tumour following a cycle of 
androgen deprivation and replacement (Germann et al., 2012), implying a potential role 
for cancer stem cells in the development of castration-resistant prostate cancer. Miki et 
al. have shown that inducing differentiation in culture can cause stem-like AR- 
tumoursphere cells to become AR+ (Miki et al., 2007), suggesting that lack of AR 
expression may be an important cancer stem cell phenotype. The anti-androgens 
bicalutamide and enzalutamide have the effect of amplifying the CD133+ CSC 
population and sphere-forming capacity in prostate cancer cell lines (Wen et al., 2016), 
and it is tempting to speculate that hormone therapy could bring about amplifications in, 
or select for, the CSC population in patient tumours which might contribute to 
castration resistance. Testing for androgen sensitivity and AR expression are important 
characterization steps for any prostate cancer stem cell population. 
1.3.4.4.2 Chemoresistance 
It is thought that CSCs within prostate tumours will be more resistant to chemotherapy, 
thus resulting in a subpopulation that could contribute to recurrence. CD44+ CSCs have 
been found to have slow cycling times in vitro (Patrawala et al., 2006), a phenotype 
which could hypothetically contribute to their ability to survive cytotoxic 
chemotherapy. There are several lines of evidence that support some prostate CSCs 
being chemoresistant.  
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Firstly, potentially chemoresistant cells exist in the side population, where live cells are 
stained with lipophilic dyes such as Hoechst 33342. Stem-like cells have a greater 
capacity for efflux of the dye, allowing for their separation from the rest of the 
population by cell sorting (Hirschmann-Jax et al., 2004). Side populations that efflux 
lipophilic dyes have been identified in both benign prostate tissue and prostate tumours, 
comprising a subpopulation of less than 5% of cells in all cases (Mathew et al., 2009; 
Brown et al., 2007). However, only LAPC-9 xenograft tumours were found to have a 
detectable side population in one study (Patrawala et al., 2005) and while CWR-R1, 
DU-145 and RWPE-1 cell lines had a detectable side population, BPH-1, LAPC-4 or 
PC-3 did not (Mathew et al., 2009). Considering that cells with CSC-like phenotypes 
have been observed in many of these cell lines, this suggests that either the side 
population is not a distinguishing feature of all prostate CSCs, or that the side 
population of some cell lines is too small to detect. 
Secondly, the ability to efflux lipophilic dyes is linked to the expression of ABC 
transporters such as ABCG2 (Zhou et al., 2001; Hirschmann-Jax et al., 2004) and 
ABCA3 and is a property shared with stem cell populations in the bone marrow 
(Hirschmann-Jax et al., 2004). ABC transporter expression may be involved in the 
efflux of chemotherapeutic drugs such as mitoxantrone in a variety of cancer cell lines 
from many tumour types (Hirschmann-Jax et al., 2004), including in prostate cancer cell 
line CWR-R1, where ABCG2 knockdown sensitises cells to mitoxantrone, docetaxel 
and toptecan (Xie et al., 2008). Expressing ABCG2 in LNCaP cells also reduces the 
sensitivity to these drugs. The profound effect of ABCG2 expression on drug resistance 
in vitro potentially means that this cell population is therapeutically. However, the 
expression of ABCG2 may have other roles outside of drug resistance: while side 
population cells from LAPC-9 xenograft tumours are at least 100 times more 
tumorigenic in murine xenografts than their non-side population counterparts, this is not 
due solely to ABCG2 expression, which is present only in a minority of side population 
cells (Patrawala et al., 2005). ABCG2- and ABCG2+ prostate cancer cell line 
subpopulations can interconvert and are similarly tumorigenic (Patrawala et al., 2005). 
Patrawala and colleagues propose that the ABCG2+ population actually marks highly 
proliferative progenitor cells, while the ABCG2- cells represent cancer stem cells, based 
on the finding that many more ABCG2+ cells are mitotic.  
Thirdly, drug resistant cells are enriched in prostate CSC and stem cell markers. 
Recently, ABCG2 has been found to be expressed along with a panel of prostate CSC 
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biomarkers (CD133+/CD44+/ABCG2+/CD24-) in tumoursphere cultures from human 
prostate cancer explants (Castellon et al., 2012). CSC markers may have functional 
relevance in the context of drug resistance: when CD44 splice variant CD44v6 is 
knocked down in vitro, prostate cancer cell lines LNCaP, PC-3M and DU145 are 
sensitised to a variety of chemotherapeutic drugs including paclitaxel, docetaxel, 
doxorubicin and methotrexate (Ni et al., 2014). Conversely, docetaxel-resistant cell 
lines derived from the 22Rv1 and DU145 cell lines show decreased expression of both 
epithelial cytokeratins and androgen receptor, as well as upregulation of CD44 and the 
Notch and Hedgehog signalling pathways (Domingo-Domenech et al., 2012). 
Hedgehog signalling has been described to mediate chemoresistance, EMT and CSC 
properties in several non-prostate cancer cell lines in vitro (Kong et al., 2015). This 
would suggest that dedifferentiation and the acquisition of a CSC phenotype are 
important for the development of chemoresistance. 
1.3.4.4.3 Radiation resistance 
Some isolated cancer stem cells show resistance to ionizing radiation treatment. Cancer 
stem cells have been found to be radiation resistant in breast cancer cell lines (Yin and 
Glass, 2011; Fu et al., 2012) and glioblastoma (Bao et al., 2006). Currently this 
phenotype has not been widely characterized in prostate cancer stem cells. In the few 
prostate cancer cell lines that have been investigated, the radiation responses are 
variable (Cho et al., 2012), with LNCaP tumoursphere-derived CSCs showing increased 
survival and reduced DNA damage compared to total cells, and DU145 CSCs showing 
no difference. However, the survival of CSCs in this assay was only apparent after a 
week of recovery, suggesting a period of DNA repair or adaptation is required. This 
phenotype may in part be mediated by CD44: knockdown of CD44 splice variant 
CD44v6 in prostate cancer cell lines LNCaP, PC-3M and DU145 sensitises them to a 
single dose of 4Gy of radiation (Ni et al., 2014), reducing colony formation in vitro. 
Consistent with this, in human primary prostate tissue CD44 protein expression is 
elevated following radiotherapy (Cho et al., 2012). Although these studies suggest a 
possible role for prostate CSCs in resistance to radiation, the mechanisms for this are 
unknown, and more work is required to determine whether radiation resistance is a 
distinguishing characteristic of prostate cancer stem cells. 
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1.3.5 Summary 
The cancer stem cell hypothesis recognises that tumours are not homogeneous, but 
instead contain subpopulations of tumour cells with different properties. CSCs have 
been shown to recapitulate many stem-like properties in a cancer context, including 
expression of stem cell markers, the ability to self-renew and ‘differentiate’ to give rise 
to tumour cells with different properties, and therefore repopulate a tumour. CSC 
properties appear to be regulated by stem cell programmes, along with a network of 
microRNAs and pluripotency factors. Perturbing prostate CSCs in cell line and animal 
models has shown that many CSCs also survive common therapies for prostate cancer 
and therefore are critical may be causative agents of recurrence. However, this aspect of 
prostate CSCs requires much more characterisation. Additionally, it is currently unclear 
what prostate epithelial cell type prostate CSCs resemble, and in vivo lineage-tracing 
studies have found that multiple prostate epithelial cell types may act as cells of origin 
for prostate carcinoma, which may not necessarily be CSCs.  
There is evidence to suggest that the properties of CSCs predispose towards a more 
malignant phenotype in vivo, although there are still no consensus markers or 
definitions for this heterogeneous cell population. If prostate cancer cells can switch 
stochastically between differentiation states, as has been shown in breast cancer cells 
and may be apparent in some prostate CSCs, it raises the possibility that non-stem 
cancer cells can give rise to stem-like cancer cells, which further complicates the 
definition of a CSC. Although the presence of CSCs in human tumours remains to be 
proven, the phenotypic characteristics of prostate CSCs identified so far make them a 
lucrative target for the development of new therapies and new biomarkers for prostate 
cancer.  
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1.4 Aims of this thesis 
The goal of the thesis is to identify new prognostic biomarkers for predicting recurrence 
in patients with prostate cancer, using what has been learned about cancer stem cells to 
guide the search. There are three main aims: 
i. To identify potential prognostic biomarkers relating to cancer stem cells or 
recurrence using published literature and bioinformatic approaches; 
ii. To test these potential biomarkers in prostate carcinoma specimens, determining 
their relationship to recurrence and other clinical parameters; 
iii. To further investigate and characterise any candidates generated through this 
approach in prostate carcinoma tissue. 
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2 MATERIALS AND METHODS 
2.1 Materials 
All general laboratory reagents were of molecular biology grade and purchased from 
Sigma-Aldrich or Fisher Scientific unless otherwise stated. Buffers and stock solutions 
were stored at room temperature unless otherwise specified. 
2.1.1 Buffers 
Phosphate Buffered Saline (PBS): 
1 tablet of Dulbecco’s PBS (Thermo Scientific) was dissolved per 100mL ddH2O to 
make a solution of 1x PBS. To make a 10x stock solution, 10 tablets of Dulbecco’s PBS 
were dissolved per 100mL ddH2O. Solutions were autoclaved to sterilise. 
Phosphate Buffered Saline + 0.05% Tween 20 (PBST): 
5 Dulbecco’s PBS tablets (Thermo Scientific) were dissolved in 500mL ddH2O, and 
250µL of Tween-20 was added to a final concentration of 0.05% (v/v), stirred 
thoroughly to dissolve. 
10mM Sodium Citrate Heat Induced Epitope Retrieval (HIER) Buffer (pH 6.0) 
2.94g tri-sodium citrate (dihydrate) was dissolved in 1L ddH2O and stirred to dissolve. 
pH was adjusted to 6.0, 500µL of Tween-20 was added and stirred thoroughly. 
Tris/EDTA HIER Buffer (pH 9.0) 
1.21g Tris base and 0.37g di-sodium EDTA was dissolved in 1L ddH2O and stirred to 
dissolve. pH was adjusted to 9.0, then add 500µL of Tween-20 and mixed.  
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Immunohistochemistry (IHC) /Immunofluorescence (IF) Blocking Buffer: 
1mL fetal bovine serum (Sigma-Aldrich) to 10% (v/v), 0.5% (w/v) bovine serum 
albumin, 1mL 10x PBS, 8mL ddH2O. Used immediately or stored at 4ºC until use. 
10% Neutral Buffered Formalin: 
90mL ddH2O, 1 PBS tablet. Stir to dissolve, then add 10mL Formalin (37-40% 
formaldehyde solution stabilised with methanol) (Sigma-Aldrich). 
Mowiol 4-88 Mountant: 
2.4g Mowiol 4-88 (Calbiochem) was added to 6g glycerol and stirred to mix. 6mL 
ddH2O was added and left to stir for 2 hours. 12mL 200mM Tris (pH 8.5) was added 
and the solution then went through repeated cycles of heating to 50ºC for 10 minutes 
and stirring for 10 minutes, until all the Mowiol had dissolved. The solution was 
clarified by centrifugation at 5000g for 15 minutes. 2.5% (v/v) Dabco 33-LV (Sigma-
Aldrich) was added to the supernatant. Aliquoted and stored at -20ºC in the dark until 
use. 
  
Chapter 2: Materials and Methods 
Benjamin Peter Sharpe - November 2016    85 
 
2.1.2 Antibodies 






Nestin	 Mouse	 Millipore	(MAB5326)	 IHC-P	–	1:200	(Citrate	HIER)	
BMI1	 Mouse	 Millipore	(05-637)	 IHC-P	–	1:50	(Tris/EDTA)	
ALDH7A1	 Rabbit	 Abcam	(ab80187)	 IHC-P	–	1:200	(Tris/EDTA	HIER)	
AR	 Rabbit	 Santa	Cruz	Biotechnology	(sc-816)	 IHC-P	–	1:1000				(Tris/EDTA	HIER)	
MUC1-C	 Mouse	 KeraFAST	(EDF002)	 IHC-P	–	1:1000	(Citrate	HIER)	
Cytokeratin-5	 Rabbit	 Abcam	(ab24647)	 IHC-P	–	1:1000	(Citrate	HIER)	
Syndecan-1	 Mouse	 Novus	Biologicals	(NB100-64980)	 IHC-P	–	1:200	(Citrate	HIER)	
Syndecan-1	 Rabbit	 Santa	Cruz	Biotechnology	(sc25590)	
IHC-P	–	1:50	(Citrate	HIER)	IF-P	(Immunofluorescence,	paraffin	sections)	–	
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1:50	(Citrate	HIER)	
SLC31A1	 Rabbit	 Novus	Biologicals	(NB100-402)	 IHC-P	–	1:250	(Tris/EDTA	HIER)	
RS1	 Rabbit	 Sigma-Aldrich	(SAB1100315)	 IHC-P	–	1:500		(Citrate	HIER)	
p63	 Mouse	 Abcam	(ab735)	 IHC-P	–	1:50	(Tris/EDTA	HIER)	
PSA	 Rabbit	 DAKO	(A0562)	 IF-P	–	1:50								(Citrate	HIER)	
CD31	 Mouse	 DAKO	(M0823)	 IF-P	–	1:30								(Citrate	HIER)	
S100	 Rabbit	 DAKO	(Z0311)	 IF-P	–	1:2000						(Citrate	HIER)	
N-Cadherin	 Rabbit	 Abcam	(ab18203)	 IF-P	–	1:100						(Citrate	HIER)	
E-Cadherin	 Mouse	 Zymed	(33-4000)	 IF-P	–	1:25								(Citrate	HIER)	
Vimentin	 Mouse	 Santa	Cruz	Biotechnology	(sc-620)	 IF-P	–	1:50								(Citrate	HIER)	
Pan	Cytokeratin	 Mouse	 Sigma-Aldrich	(C2931)	 IF-P	–	1:100						(Citrate	HIER)	
CD45	 Rabbit	 Santa	Cruz	Biotechnology	(sc-25590)	 IF-P	–	1:50								(Citrate	HIER)	
CD19	 Rabbit	 Abcam	(ab134114)	 IF-P	–	1:250						(Citrate	HIER)	
CD27	 Rabbit	 Abcam	(ab131254)	 IF-P	–	1:100						(Citrate	HIER)	
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Table 2.2: Secondary antibodies and dyes used in this thesis 
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2.2 Methods 
All incubations and reactions were performed at room temperature unless otherwise 
stated. 
2.2.1 Differential Gene Expression Analysis 
2.2.1.1 Base methodology 
Differential gene expression analysis on archived RNA microarray datasets was 
conducted using R version 3.2.0. Expression set data was acquired through the Gene 
Expression Omnibus database directly in R using the package GEOquery (ver. 2.34.0), 
and samples were filtered into categories based on the phenotypic data (e.g. Recurrence 
Status) or on expression levels based on a single probeset in the array (see Extremes of 
Expression Analysis). Differentially expressed genes between the groups were 
identified by fitting a linear model to the data using the limma package (ver 3.24.10) 
and the eBayes function within this package was used to generate empirical Bayes test 
statistics for each probe within the array. The function topTable was used to report the 
results, sorting by adjusted P-value (False Discovery Rate (FDR)) of the test for each 
probe to produce a list of top differentially expressed genes. The Benjamini and 
Hochberg (1995) FDR correction was used to account for multiple testing. An 
FDR<0.05 was considered statistically significant differential expression. Heat maps 
were generated for significant probes using the heatmap.2 function from the gplots 
package (ver. 2.17.0), hierarchical clustering was performed and samples were labelled 
using the initial filtering criteria. 
2.2.1.2 Extremes of Expression Analysis 
To analyse the changes in gene expression that occur at the extremes of gene expression 
of candidate genes, differential gene expression analysis was performed as above, using 
the 10th and 90th percentiles of normalised signal of a probe to dichotomise the samples 
into ‘low’ and ‘high’ expression groupings and exclude data lying in the intermediate 
ranges from the analysis. A list of statistically significant genes meeting the FDR<0.05 
criterion were passed into downstream gene ontology analysis and exported in a tabular 
CSV format, and a heat map was constructed to visualise differential expression 
patterns as described above. R code for this analysis technique is listed in Appendix 1. 
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2.2.1.3 Gene Ontology (GO) Analysis 
GO analysis for lists of differentially expressed genes from Extremes of Expression 
Analysis was performed in R version 3.2.0 using the TopGO package (ver. 2.20.0). A 
set of custom functions listed top overrepresented GO terms for up-regulated and down-
regulated genes in patient subsets highly expressing a candidate gene. A list of genes 
whose probes were present on the array platform were extracted from the microarray 
expression set and duplicates and probes not mapping to genic regions were discarded. 
The resulting gene list was known as the ‘gene universe’, and was used as the 
background set for comparison with differentially expressed gene lists. Current GO 
annotations for each gene in the gene universe were extracted from the ensembl 
database using the biomaRt package (ver 2.24.0). Differentially expressed gene lists 
were divided into up-regulated and down-regulated genes by separating them on the 
basis of log fold-change >0 and <0. Fisher’s Exact tests were then used to compare the 
GO terms mapped to each gene list with GO terms in the gene universe, and GO terms 
with significant enrichment (p<0.05) in the differentially expressed gene list were 
output in a tabular CSV format. R code for this analysis technique is listed in Appendix 
1. 
2.2.2 Immunohistochemistry (IHC) on Formalin-Fixed Paraffin-Embedded 
(FFPE) Tissue 
2.2.2.1 Coating of glass microscope slides with silane 
To ensure robust adhesion of tissue sections to glass slides during antigen retrieval for 
immunohistochemistry and immunofluorescence, slides were coated with (3-
aminopropyl)triethoxysilane (APTS). Slides were cleaned in absolute acetone for 2 
minutes before allowing to dry in a fume hood. They were then immersed in a solution 
of 2% (v/v) APTS in absolute acetone for 2 minutes, washed in two changes of absolute 
acetone for 2 minutes each and left to air-dry again. Silane-coated slides were kept in 
the original slide boxes to keep them free of dust and debris before use. 
2.2.2.2 Sectioning and staining method 
FFPE tissue blocks were chilled to 4ºC before use, and 5µm thick sections were cut 
using a Leica RM2155 microtome or a Jung Biocut microtome fitted with disposable 
low-profile microtome blades (Fisher Scientific). Sections were floated out onto a 45ºC 
water bath, allowed to flatten, and then picked up onto silane-coated glass microscope 
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slides with a frosted edge. Sections were allowed to air-dry on a hot-plate set to 37ºC 
overnight before storage at room temperature or use in downstream staining protocols. 
Prior to IHC staining, slides were deparaffinised in two changes of Histo-Clear for 2 
minutes each, and Histo-Clear was removed from the sections using two changes of 
absolute ethanol for 1 minute each. Sections were rehydrated in a graded ethanol series 
by immersing for 1 minute in each solution: 95% (v/v) ethanol in ddH2O; 90% (v/v) 
ethanol in ddH2O; 70% ethanol in ddH2O; 50% ethanol in ddH2O. A final step of 2 
minutes in ddH2O was added to complete hydration. 
To begin IHC staining, sections were washed twice in PBST. Nuclei were permeablised 
by incubation with 0.5% (v/v) Triton X-100 in PBS for 30 minutes, washed twice in 
PBST, and subjected to heat-induced epitope retrieval for 30 minutes at 90ºC in sodium 
citrate buffer (pH 6.0) or tris/EDTA buffer (pH 9.0) in a water bath, as optimised for the 
antigen to be detected. Slides were allowed to cool in the buffer bath at room 
temperature for 20 minutes and washed twice with PBST. Areas of tissue were circled 
with an ImmEdge hydrophobic barrier pen (Vector Laboratories) to ensure adequate 
coverage of reagents, and endogenous peroxidase activity was quenched with DAKO 
EnVision+ Peroxidase Block for 10 minutes. After washing twice with PBST, non-
specific antibody binding was blocked with IHC blocking buffer for 30 minutes. Excess 
blocking buffer was drained off with a tissue and primary antibodies were added to the 
sections at the appropriate dilution (Table 2.1) in DAKO Antibody Diluent. Primary 
antibodies were incubated with the sections overnight at 4ºC in a humidified chamber. 
The next day, sections were washed three times with PBST, and ready-to-use goat anti-
mouse or goat anti-rabbit polymer-HRP-conjugated secondary antibodies were applied 
from the DAKO EnVision+ system (Table 2.2) for 30 minutes with gentle agitation on a 
rocking platform. Sections were washed three times, and signal was developed with the 
HRP substrate 3,3’-Diaminobenzidine (DAB) chromogen for 5 minutes, following the 
instructions according to the DAKO EnVision+ kit. Sections were washed three times 
with ddH2O to terminate the reaction. Nuclei were counterstained with Gill’s 
Haematoxylin (Vector Laboratories) for 1 minute, sections were rinsed under running 
tap water for 3 minutes, then differentiated by three dips in 1% (v/v) HCl in 70% (v/v) 
ethanol and ‘blueing’ in 0.25% (v/v) NH3 in 70% (v/v) ethanol. Sections were 
dehydrated by going through the graded ethanol series in reverse order to finish with 
two changes of absolute ethanol. Tissues were cleared in two changes of Histo-Clear for 
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2 minutes each before mounting in DPX (Sigma-Aldrich) under a 22x50mm glass 
coverslip. Mounted slides were allowed to dry overnight in a fume hood before 
visualising under a Nikon Eclipse E800 widefield microscope using brightfield 
illumination. Images were captured on an attached Nikon Digital Sight DS-U1 CCD 
camera using NIS-F or NIS-D software. 
2.2.3 Scoring of Immunohistochemical Stains 
To quantify IHC staining patterns, a maximum of 15 random fields under a 20x 
objective were acquired from each tissue sample under each stain. 5 images were 
selected at random for quantification, although images had to contain epithelium to be 
considered for analysis. In some cases, biopsied tumour tissue was scant and in these 
cases, a minimum of 2 epithelium-containing images were required, or samples were 
excluded from the assessment. Stains were quantified according to the localisation of 
their staining patterns: BMI1, ZSCAN4, AR, ALDH7A1 and RS1 displayed epithelial 
nuclear staining patterns and were quantified by the Histo-scoring method (H-Score). 
The following cytoplasmic stains were scored using a cytoplasmic scoring method: 
Nestin, ALDH7A1, RS1, SDC1.  
For H-Score assessment, all epithelial nuclei were counted and sorted into four different 
arbitrary categories based on observed DAB staining intensity: 0 – no staining; 1 – 
weak staining; 2 – intermediate staining; 3 – strong staining. The H-score !was 
calculated by applying the following formula, where " is the intensity category and #$ is 
the percentage of nuclei in an image in intensity category " as a proportion of total 
nuclei. The H-score can take any value from 0 to 300. 
 
! =	 "#$'$()  
For quantification of cytoplasmic staining, the intensity and proportion of cells stained 
was estimated subjectively by placing the images into categories. Intensity categories 
were: 0 – no staining; 1 – weak staining; 2 – intermediate staining; 3 – strong staining. 
Proportion categories were: 0 – no staining; 1 - <25% epithelium stained; 2 – 25-50% 
epithelium stained; 3 – 50-75% epithelium stained; 4 – 75-100% epithelium stained. For 
SDC1 staining, where the proportion of cells stained varied, the Cytoplasmic Score was 
derived from the sum of intensity and proportion scores for a range of 0, 2-7. Where 
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stains varied only in intensity and 100% of epithelial cells were consistently stained, 
Cytoplasmic Score was derived from intensity score only for a range of 0-3. The 
following cytoplasmic stains were scored using the cytoplasmic intensity score: Nestin, 
ALDH7A1, RS1.  
The burden of prostate cancer SDC1+ stromal positive (PCSP) cells was quantified in 
SDC1-stained prostate tissue samples by counting the number of PCSP cells per field, 
and measuring their area and shape parameters using ImageJ (NIH), calibrating the 
software to measure actual size by scale. 
The means of every score from each set of five images was calculated and assigned to 
the sample as its overall score for each stain, regardless of score type. Differences in 
scores between relapsing and non-relapsing groups and benign and malignant tissue 
were statistically tested using Student’s t-tests in R version 3.2.0. 
2.2.4 Haematoxylin and Eosin (H&E) Staining of FFPE Tissue 
FFPE tissue blocks were chilled to 4ºC and sections were cut at 5µm thickness, floated 
out onto silane-coated slides and air-dried as before. Prior to staining, sections were 
deparaffinised and rehydrated as described previously. Nuclei were stained with Gill’s 
Haematoxylin (Vector Laboratories) for 2 minutes, rinsed with running tap water for 3 
minutes, differentiated in 1% (v/v) HCl in 70% (v/v) ethanol for 30 seconds and ‘blued’ 
in 0.25% (v/v) NH3 in 70% (v/v) ethanol for 1 minute. Sections were washed in 70% 
ethanol for 1 minute before counterstaining in 0.5% (w/v) Eosin Y (Raymond A Lamb) 
in ddH2O for 5 minutes. This was followed by immersion in 95% (v/v) ethanol for 15 
seconds, two changes of absolute ethanol for a minute each, and clearing in two changes 
of Histo-Clear for 2 minutes each. Excess Histo-Clear was blotted off of the slides and 
mounting was then achieved under a 22x50mm coverslip using DPX. Mounted slides 
were allowed to dry overnight in a fume hood before imaging using a Nikon Eclipse 
E800 widefield microscope under brightfield illumination, as described previously. 
2.2.5 Immunofluorescence (IF) on FFPE Tissue 
FFPE tissue blocks were chilled to 4ºC and sections were cut at 5µm thickness, floated 
out onto silane-coated slides and air-dried as before. Prior to staining, sections were 
deparaffinised and rehydrated as described previously. Washing, permeablisation and 
antigen retrieval was all performed as described previously. Sections were ringed with 
an ImmEdge hydrophobic barrier pen (Vector Laboratories) and blocked for 30 minutes 
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using IHC blocking buffer as in IHC, before incubation with primary antibodies (Table 
2.1) diluted in DAKO Antibody Diluent (DAKO) overnight at 4ºC in a humidified 
chamber. For double immunolabelling experiments, two antibodies recognising 
different antigens and raised in different host species were mixed together at their 
respective dilutions for simultaneous labelling. 
The next day, sections were washed three times in PBST and fluorescent labelling was 
performed in the dark for 30 minutes at room temperature with gentle agitation. Alexa 
Fluor 488-labelled goat anti-mouse IgG and Alexa Fluor 568-labelled goat anti-rabbit 
IgG antibodies were used, and both fluorescently labelled antibodies (Table 2.2) were 
mixed together at 1:200 dilutions in DAKO Antibody Diluent (DAKO) for 
simultaneous labelling. After incubation, sections were washed three times in PBST and 
then a modified protocol from Viegas et al. (2007) was used to quench endogenous 
tissue autofluorescence: samples were incubated with a filtered solution of 0.1% (w/v) 
Sudan Black B in 70% (v/v) ethanol for 10 minutes to quench endogenous tissue 
autofluorescence. Sections were rinsed briefly with PBST to remove any stain debris, 
then washed three times for 5 minutes each before mounting in Mowiol with 600nM 
DAPI (Sigma-Aldrich) for nuclear counterstaining. Samples were allowed to dry 
overnight in the dark at room temperature, or for at least two hours at 37ºC, before 
imaging on an LSM510 META laser scanning confocal microscope. Imaging was 
conducted using 405nm, 488nm and 543nm laser lines for excitation of fluorescent dyes 
and fields of view were collected under a 40x objective. Samples were stored at 4ºC in 
the dark and imaged within several days of staining for best results. 
2.2.6 Tissue microarray (TMA) preparation and construction 
2.2.6.1 Specimen acquisition and preparation 
All tissues except prostate were FFPE archival specimens collected by Dr Asha Recino 
in September 2007. Mouse prostate tissues were harvested from adult CD-1 mice at 10 
weeks of age after killing by a schedule 1 method. Whole urogenital sinuses were 
dissected from male mice and the prostate was isolated using the method detailed in 
Lukacs et al. (2010a), where ureters, fat, seminal vesicles, bladder and ureters are 
sequentially dissected away with forceps. Tissues were fixed for 24 hours in neutral 
buffered formalin, then processed using standard histological procedure. Samples were 
dehydrated in a graded ethanol series ranging from 70%-100% (v/v) concentration for 2 
hours in each station; cleared in two changes of HistoClear for 2 hours each; and 
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infiltrated with three changes of HistoPlast paraffin wax (Thermo Scientific) at 65ºC for 
2 hours each. Prostates were embedded whole, ventral side down, into molten 
HistoPlast wax and allowed to set. 
2.2.6.2 TMA construction 
Tissue microarrays were constructed manually using 1mm dermal biopsy punches 
(IHCWorld) inlaid into a premade recipient block (UNITMA) of 10x12 1mm diameter 
holes. A single tissue core of 1mm in diameter was taken from each specimen, guided 
by identification of representative regions on an H&E-stained whole section of the 
corresponding tissue block. Cores were inlaid into the tissue block, with blank 
remaining holes being filled with cores containing HistoPlast paraffin wax only. The 
TMA was processed according to manufacturer’s instructions. A filled recipient block 
was heated to 70°C in an embedding mould on a hotplate until the array matrix was 
transparent, and molten HistoPlast paraffin wax and an embedding cassette was added 
as per the standard wax embedding protocol. The completed TMA contained 48 cores of 
mouse tissue from 13 different organs, and could be sectioned and stained using routine 
histological methods described in this thesis. 
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3 IDENTIFICATION OF 
POTENTIAL BIOMARKERS 
FOR RELAPSING PROSTATE 
CARCINOMA 
3.1 Introduction 
In order to identify new biomarkers for prostate carcinoma, a strategy for selecting 
potential biomarkers to test must be identified. Candidate markers must be selected and 
initially tested and characterised. This section will describe some of the recent progress 
in biomarkers for prostate cancer and review methods for identifying new biomarkers. 
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3.1.1 Recent progress in prostate cancer biomarkers 
The National Institutes of Health have defined a biomarker as: “a characteristic that is 
objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmaceutical responses to a therapeutic intervention” 
(Bensalah et al., 2007). Though there are many forms of biomarker, this thesis will 
consider a biomarker as a feature – commonly molecular features such as DNA, RNA 
or protein – that indicates a disease state. This section will summarise the different types 
of biomarkers in prostate cancer, and review some of the recent developments in 
prostate cancer biomarkers. 
3.1.1.1 An overview of biomarkers 
There are several main classes of biomarkers in prostate cancer. Diagnostic biomarkers 
indicate the presence or absence of prostate cancer in a patient, such as the previously 
mentioned serum PSA test (see Chapter 1.2.2). Prognostic biomarkers provide 
information about the predicted disease course of a patient with prostate cancer and help 
to stratify patients into poor outcome and favourable outcome categories (Bensalah et 
al., 2007). The current best examples of clinical use of prognostic prostate cancer 
biomarkers are Gleason grade, tumour staging and PSA velocity, all covered in Chapter 
1.2.2. Therapeutic target biomarkers identify the best courses of therapy for a patient 
(Bensalah et al., 2007), and currently there are no such biomarkers in clinical use for 
prostate cancer. However, there are recent progresses in this area, with ligand-
independent splice variants of AR such as AR-V7 being functionally implicated in 
castration resistance in patients undergoing hormone therapy (Hu et al., 2009). As the 
aim of this thesis is to identify a prognostic biomarker, this section will focus on 
prognostic biomarkers. Molecular biomarkers are commonly assayed at several levels in 
patient samples: serum, urine, or tissue. Each carry advantages and disadvantages, as 
reviewed below. 
3.1.1.2 Serum biomarkers 
Serum biomarkers can give information as to the biological processes active within a 
tumour, without the need for a tissue biopsy. For example, shedding of the ectodomain 
of heparan sulphate proteoglycan Syndecan-1 (SDC1) is mediated by matrix 
metalloproteinases, and high levels of the shed SDC1 in patient serum are associated 
with metastasis and high Gleason grade tumours, and independently predict both shorter 
overall and disease-specific survival (Szarvas et al., 2016a). Serum biomarkers can also 
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allow for the monitoring of normal organ function in the context of prostate carcinoma, 
which can provide useful information that tissue biopsies cannot. Patients that have 
been treated with radical prostatectomy can be separated into prognostic groups based 
on serum levels of the enzyme butyrylcholinesterase, which is synthesised in the liver 
and decreases in patients with liver damage or inflammatory conditions (Koie et al., 
2016). Patients with low levels of the enzyme prior to surgery have a 55% biochemical 
recurrence-free survival rate, whereas patients with high levels have a 77.7% rate. It 
suggests that patients may develop conditions secondary to prostate carcinoma that 
cause such a response, although the exact causes of this elevation are not known (Koie 
et al., 2016).  
Another advantage of serum biomarkers is that they can be analysed in the absence of 
tumour material needed for a biopsy, such as in a screening programme. Elevated 
plasma levels of insulin-like growth factor IGF-1 and its binding protein IGFBP-3 were 
found to be associated with an increased risk of developing advanced stage prostate 
carcinoma, even though the blood samples were taken on average 9 years before a 
diagnosis of carcinoma was reached (Chan et al., 2002). Given the natural history of 
prostate carcinoma detailed in Chapter 1.2, it is possible that a biomarker could function 
as an early predictor of carcinoma in later life. Unfortunately, IGF-1 and IGFBP-3 were 
inadequate diagnostic tools, underperforming PSA in the diagnosis of carcinoma, which 
limits their utility. However, the study highlights the power of serum biomarkers, where 
samples can be taken even before a tumour is identified and thus they make ideal 
screening tools. Since systemic levels of the analyte are measured, there are fewer 
sources of error introduced by sampling: tissue biopsies normally sample only a small 
fraction of the prostate, which can lead to misrepresentation of the overall tumour mass 
(King and Long, 2000). There are no serum prognostic biomarkers currently in use, and 
it is a future area of interest and potential. 
3.1.1.3 Urinary biomarkers 
Urine provides another minimally invasive source of biomarkers for prostate cancer. 
However, this field has yet to yield significant amounts of potential prognostic 
biomarkers. PCA3, a prostate cancer-related antigen, is established for the detection of 
prostate cancer using urine (Sokoll et al., 2008; Merola et al., 2015). Following digital 
rectal examination, both PCA3 mRNA levels are quantified in the urine and normalised 
to PSA mRNA, presumably from liberated cells of the prostate epithelium post-
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examination. The method is suitably sensitive and specific for the detection of prostate 
cancer (Sokoll et al., 2008; Merola et al., 2015) and is currently considered for 
diagnostic use. However, it is unclear whether PCA3 may also be a prognostic 
biomarker. Urinary PCA3 levels may positively correlate with Gleason grade of 
primary tumours (Merola et al., 2015; Wei et al., 2015) and with the presence of 
advanced stage tumours (Wei et al., 2015), although other studies have found no 
association with Gleason grade (Augustin et al., 2013) and there is still controversy 
regarding the association between urinary PCA3 mRNA levels and measures of tumour 
aggressiveness such as Gleason grade or stage (Augustin et al., 2013; Leyten et al., 
2014).  
Recent studies have found that a similar detection of TMPRSS2-ERG fusion mRNA in 
urine can be combined with PCA3 mRNA tests in urine to provide a more specific 
cancer diagnostic ability than PSA assessment alone (Tomlins et al., 2016; Leyten et al., 
2014), especially when detecting high-grade prostate cancer (Tomlins et al., 2016). 
TMPRSS2-ERG mRNA levels positively correlate with Gleason grade and tumour 
stage in the urine, although PCA3 mRNA may not share this attribute (Leyten et al., 
2014). Because of the minimal invasiveness of urine collection, it is possible to adapt 
these assays for use in a primary care setting: a sensitive test for TMPRSS2-ERG fusion 
transcripts in urine has been developed using an isothermal transcription-mediated 
amplification method (Koo et al., 2016), which requires no specialist equipment and has 
an easily interpretable binary output. This offers many advantages, including potentially 
speeding up decision-making processes in primary care, and would be invaluable if 
applied to a suitably prognostic biomarker. However, the urinary biomarker field has 
yet to yield a significant amount of potential urinary prognostic biomarkers. It remains 
to be determined if TMPRSS2-ERG, PCA3 or any other marker can fulfil such roles, 
especially as long-term follow-up information on recurrence and survival is absent in all 
studies so far. 
3.1.1.4 Tissue biomarkers 
Despite the benefits of fluid biopsies such as urine and serum, there are several 
advantages to tissue biomarkers. IHC techniques for tissue biomarkers are already in 
use in pathology laboratories for diagnostic applications, meaning that inclusion of a 
new antibody for staining is simple, existing equipment may be used, and existing core 
needle biopsies may be used, which reduces the need for additional procedures for 
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sample collection. Additionally, they provide protein localisation data that may help to 
inform a diagnostic or prognostic prediction. For example, the fibroblast growth factor 
homologous factor FGF13 is elevated at the protein level in prostate cancer compared to 
high-grade PIN and normal tissue (Yu et al., 2016). Whereas cytoplasmic FGF13 IHC 
staining is associated with shorter recurrence-free survival, low cytoplasmic staining 
and high nuclear staining is associated with a much better prognosis (Yu et al., 2016). 
IHC therefore has the potential to provide much more information about patient 
outcome than measurement of a single level in urine or serum, because both protein 
levels and localisation can be observed. 
Another role of tissue biomarkers is in the molecular subtyping of tumours. A good 
example of this is in breast cancer, where the IHC detection of estrogen receptor, 
progesterone receptor and HER2 allows for the classification of patients into molecular 
subtypes and tailored treatment (Dent et al., 2007). For example, patients with no 
expression of the three markers are in the poor prognostic category known as ‘triple-
negative’ breast cancer and will not benefit from tamoxifen or Herceptin therapies, 
whereas patients with HER2-expressing tumours will benefit from Herceptin, and 
hormone receptor-positive patients will benefit from tamoxifen (Dent et al., 2007).  
There have been recent advances in prostate cancer subtyping with the finding of ETS-
ERG fusions and SPOP mutations (Abeshouse et al., 2015), as well as with SPINK1 
overexpression (Tomlins et al., 2015) that might support such a panel in prostate cancer. 
In patients with initially diagnosed bone metastatic prostate carcinoma, expression of 
the serine protease inhibitor SPINK1 at the protein level was detected in 13.5% of 
patients (Pan et al., 2016) and indicated a 1.7-fold greater risk of progression to 
castration-resistant prostate cancer. Similarly, in patients treated with primary hormone 
therapy, SPINK1 protein expression is found in 10% of tumours and is associated with 
disease recurrence (Leinonen et al., 2010). Conversely, other studies of SPINK1 
expression in patients undergoing prostatectomy found no association between SPINK1 
and recurrence or Gleason grade (Grupp et al., 2013; Flavin et al., 2014), which might 
show evidence of treatment-specific differences in SPINK1 association. Interestingly, 
SPINK1 expression seems to be mutually exclusive with ERG expression, suggesting a 
separate subtype of prostate tumour (Pan et al., 2016; Grupp et al., 2013; Bismar et al., 
2012). SPINK1 overexpression may also be associated with PTEN-deletion in ERG-
negative tumours (Bismar et al., 2012), although this is controversial (Flavin et al., 
2014). Analysis of microarray data on large cohorts confirms that ERG+, ETS+ and 
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SPINK1+ are distinct molecular subtypes of prostate carcinoma, along with a fourth 
triple-negative classifier. Such molecular classification of prostate tumours apparently 
has very limited prognostic utility in prostate cancer (Tomlins et al., 2015) compared 
with breast cancer. However, as this data is limited to radical prostatectomy patients, it 
is still possible that these classifications may provide additional information about the 
best course of treatment. Thus, a panel of biomarkers such as ETS/ERG, SPINK1 and 
PTEN antibodies for IHC could still be of clinical use. 
Taken together, there are considerable advantages to the use of serum and urinary 
biomarkers in the diagnosis and prognostication of prostate cancer. However, the 
additional protein localisation information provided by IHC and the ease with which a 
new biomarker can be implemented in pathology laboratories makes tissue biomarkers 
an indispensable tool for prostate pathology.  
3.1.2 Identification of new biomarkers 
The first step in this project was to identify biomarkers to test. There are multiple 
methods of identifying biomarkers, each with individual strengths and weaknesses. 
Some common approaches are reviewed below. 
3.1.2.1 Transcriptomics 
An increasingly popular approach for identifying new biomarkers in large clinical 
cohorts is to investigate changes in the transcriptome of patient tumours, usually by 
cDNA microarray or high-throughput RNA sequencing. In many cases these biomarkers 
take the form of gene signatures, where the expression levels of multiple genes in a 
microarray are used to predict disease state. The first example of this was demonstrated 
in 1999 when a 50-gene signature obtained from microarray data was used to accurately 
classify patients as having Acute Myeloid Leukaemia or Acute Lymphoblastic 
Leukaemia, independent of other biological knowledge (Golub et al., 1999). This 
approach has experienced some success in predicting recurrence (Sun and Goodison, 
2009) and in predicting outcome in multiple tumour types (Glinsky et al., 2005), 
including predicting therapy resistance in prostate cancer (Rajan et al., 2014) as well as 
in differentiating disease subtypes in prostate cancer (Ben-Porath et al., 2008). 
However, the approach relies upon multi-gene models and often requires higher 
throughput methods with which to evaluate patient samples. Integrative computational 
approaches which make use of microarray data combined with a priori biological 
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knowledge, pathway annotations and clinical data are increasingly being adopted, but 
require extensive validation and new modelling methods due to high data 
dimensionality compared to sample size (Iuliano et al., 2016).  
Removing single genes from multi-gene models in order to use them independently 
removes them from the context of their selection, and it is possible that genes used 
singly will not have the utility that the multi-gene model possessed. Due to over-
identification, it is important that these biomarkers have independent experimental 
validation. However, these studies supply an ever-growing source of candidate markers 
for investigations to validate or to characterise at other levels, such as on the genomic or 
protein levels.  
3.1.2.2 Proteomics 
Protein-based assay techniques such as IHC and ELISA are important tools in 
diagnostic pathology. Biomarkers at the protein level have been identified in screens 
using proteomics on tumour tissue or urine samples and compared to benign 
counterparts, although this is still a comparatively underused approach compared to 
transcriptomics. For example, a Stable Amino Acid Labelling in Cell Culture (SILAC) 
and mass spectrometry technique was used to identify the biomarker proneuropeptide-Y 
as a marker of progression and poor outcome in primary prostate tumour tissue, and was 
validated in patient tissue microarrays using immunohistochemistry (Iglesias-Gato et 
al., 2016). In contrast, a proteomics study conducted in prostate fluid and urine failed to 
identify a single biomarker that could distinguish patient subgroups (Kim et al., 2016), 
suggesting that while the approach is effective in identifying biomarker panels, a single 
protein might not be sufficient for such a task. Another study investigated the proteome 
of exosomes in patient serum, and found an enrichment of known cancer-associated 
proteins as well as novel ethnicity-specific proteins that could serve as useful ethnicity-
specific cancer biomarkers (Turay et al., 2016). These studies demonstrate that the 
approach has promise, especially with respect to the profiling of liquid biopsies, which 
could serve as a minimally invasive source of biomarkers. As with transcriptomics 
assays, they provide a wealth of potential biomarkers for further follow-up studies. 
3.1.2.3 Literature Searching 
Literature searching to identify potential new biomarkers can be as simple as a series of 
keyword searches and manual examination and curation of the literature. The advantage 
of such approaches is that no knowledge of text-mining and no benchmarking of search 
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methodology is required. The knowledge and experience of the curator(s) is used to 
critically evaluate the literature while it is being collected, allowing for effective (albeit 
subjective) collection of relevant literature material for decision-making. However, such 
approaches are time intensive: one extensive literature searching approach to identify 
pancreatic cancer biomarkers took approximately 7000 person hours to complete 
(Harsha et al., 2009).  
The additional caveat of manual search approaches is that, because the search is time-
consuming, by the time a literature review is completed there will be yet more currently 
published biomarkers to add to the list for review. This leads to a continuous build-up of 
evidence, and the rate of evidence accumulation far surpasses the rate at which the 
evidence can be tested and evaluated. This abundance of biomarker information is 
largely due to published ‘omics’ datasets which routinely identify overexpressed 
proteins in a variety of pathological situations. However, it is arguable that this 
abundance of information is difficult to objectively hone down into just a small number 
of useful biomarkers which would go forward for further study.  
To resolve this problem, automated computer-based approaches have been devised to 
extract key information from published abstracts and main texts, such as gene and 
protein names, evidence categories and statistics (Younesi et al., 2012). The information 
is ranked and scored in a defined, objective manner using algorithms. The search terms, 
sensitivity and specificity of the searching approach can be tailored to meet the needs of 
the researcher. Regardless, the increasing wealth of biomarker information means that a 
centralised database for storing and interrogating biomarker evidence is becoming 
increasingly important (Harsha et al., 2009). 
Such automated approaches are less time-intensive whilst requiring more skill in 
informatics, but it is still unclear whether there are other defined benefits to quantitation 
of the literature over a manual searching approach. Automated search approaches 
require manual verification and may eliminate useful literature and biomarker leads that 
a trained individual could manually identify, but do so systematically and consistently. 
The human element of a manual search is both an advantage and a disadvantage, as this 
can make the literature search less systematic and potentially result in the incorporation 
of additional sources of bias. An additional flaw of both manual and automated 
literature searching approaches is that they are not suitable for identifying novel 
combinations of biomarkers in multi-biomarker panels, which may be more accurate 
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and informative in classifying disease state than any single biomarker (Kim et al., 
2016). However, all literature searching approaches have the advantage of testing 
biomarkers that have already been studied to some degree by other experimental 
approaches, meaning that, while not strictly novel, a thorough literature search should 
result in an increased chance of identifying a successful biomarker.   
3.1.2.4 The contribution of tissue microarrays to biomarker validation 
Having identified potential biomarkers, tissue microarrays provide a means to section, 
stain and analyse a larger number of samples of FFPE or frozen tissue specimens. The 
throughput capability is higher than a whole section study can accomplish, which is 
achieved by arranging representative cores of tissue in an array format prior to 
sectioning. This allows routine IHC or in situ hybridisation procedures to investigate 
selected biomarkers in a higher throughput setting with reductions in time, cost and 
precious sample material (Hassan et al., 2008). Multiple replicate cores can be included 
to better represent tissue heterogeneity in each specimen block. This technique ensures 
consistent and uniform sample treatment while also benefiting from the increased 
statistical resolving power that comes from testing a larger patient cohort. For example, 
Ruiz et al. used two tissue microarray blocks consisting of over a thousand prostate 
tumour samples together to evaluate NRBP1 (2012), and the Melling et al. study on 
HOOK3 expression in prostate cancer used more than 12,400 samples in their tissue 
microarray (2015).  
The main disadvantage of using TMA technology to validate biomarkers is that, like all 
IHC studies, they require an antibody that performs reliably when used for the 
application. When these antibodies are ultimately destined to be used in a clinical 
pathology setting, this may also be considered as an additional filtering characteristic of 
the approach. There is also the problem of tissue size: the cores used in a tissue 
microarray can be as small as 0.6mm in diameter, and there is concern as to whether this 
is representative of the heterogeneity of prostate tumours when compared to whole 
tissue sections, especially where staining patterns are focal or heterogeneous 
(Merseburger et al., 2003). This can be overcome by including more than one replicate 
core per specimen in a tissue microarray, ensuring that more of the heterogeneity is 
encompassed for a more representative result (Mucci et al., 2000). Such limitations are 
also counterbalanced by the increased density of information available when such large 
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numbers of patients are tested simultaneously (Varambally et al., 2002; Melling et al., 
2015). 
Tissue microarrays are often accompanied by patient clinical data and are designed for 
multiple purposes tailored to the screening approach. For example, a tissue microarray 
for disease progression or diagnostic biomarkers might contain a mixture of normal 
prostate tissue, benign mimics, high-grade PIN and prostate carcinoma to ensure that 
the tested antibodies can distinguish those tissue types by IHC. A microarray of this 
type was recently used to show that the RNA-binding protein hnRNPA2 is more highly 
expressed in high grade tumours (Stockley et al., 2014), and the same approach has 
been taken to characterise NRBP1 (Ruiz et al., 2012).  
Similarly, a tissue microarray for a prognostic biomarker might contain tumour samples 
from patients with a wide range of clinical outcomes, and include at least five years of 
clinical follow-up data. When such clinical data are available, it is possible to test the 
relationship between biomarker expression status and recurrence (Melling et al., 2015; 
Ruiz et al., 2012; Leclerc et al., 2016) and other patient metadata, such as ERG 
rearrangement status (Melling et al., 2015). An additional advantage of tissue 
microarrays is that adjacent sections can be stained with other antibodies and staining 
patterns examined and correlated. For example, by staining an adjacent section with an 
anti-Ki-67 antibody, which is a marker of proliferation, it is possible to identify 
associations between biomarker expression and Ki-67 expression, suggestive of an 
effect on cell proliferation (Ruiz et al., 2012; Melling et al., 2015). 
In summary, while there are technical challenges to be overcome with the technology, 
the tissue microarray has numerous benefits for high-throughput analysis of patient 
cohorts for biomarker validation, and provides a useful platform that could be utilised in 
the current study for the purpose of distinguishing recurrent from non-recurrent patient 
tumours. 
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3.1.3 Aims 
This chapter will begin the project by addressing the following initial aims: 
i. Identify potential new biomarkers that be investigated in subsequent chapters, 
using two different methodologies:  
a. A literature search to identify promising candidates that require further 
characterisation, and; 
b. A bioinformatic approach using publically-available microarray datasets 
to identify other potential biomarkers using an unbiased, computational 
method. 
ii. Develop and use bioinformatic methods to gather more information about the 
selected biomarkers and further inform the decision making processes. 
iii. Establish tissue microarray construction and staining protocols that can be used 
to construct a tissue microarray from precious prostate biopsy samples to be 
analysed in future chapters.  
iv. Perform initial antibody optimisation for IHC on this tissue microarray platform.  
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3.2 Results 
3.2.1 Identification of potential biomarkers through literature review 
The first step in identifying new biomarkers was to select candidate markers to test. 
Because of the versatility and ease of implementation of tissue biomarkers, it was 
decided to search for tissue biomarkers for this study. In order to identify candidate 
markers for testing, two approaches were used: a literature searching approach, and a 
bioinformatics approach.  
The first approach was to conduct a thorough literature review using Web of Science 
(www.webofknowledge.com. Date accessed: November 2012). A total of 116 potential 
biomarkers were identified (Figure 3.1A) based on their manually-curated relationship 
in the literature with five criteria. These were: prostate cancer; recurrence (in any cancer 
type); other non-prostate cancers; cancer stem cells; and tissue stem cells (Figure 3.1B). 
The search began with a generic search, using the terms “prostate cancer relapse” and 
“prostate cancer stem cell”, branching out by including markers identified in this initial 
pass using a more specific search strategy: i.e. searches with the marker name and 
“prostate cancer”, “cancer”, “stem cell” and “cancer stem cell”.  
This search method was driven by the need to identify markers that may be important in 
tumour recurrence, but also to identify biomarkers that might be of wider relevance in 
the cancer field and gone unstudied in prostate cancer. For example, the Polycomb 
group protein BMI1 was first identified to be a haematopoietic stem cell-related protein 
(Alkema et al., 1997), but further studies showed it to be involved in maintaining the 
intestinal stem cell niche (Sangiorgi and Capecchi, 2008) and that it was expressed in 
putative prostate stem cells as well as being important for malignant transformation 
(Lukacs et al., 2010b). Similarly, tumours and stem cells often share expression 
characteristics which appear to correspond to levels of plasticity and differentiation state 
(Palmer et al., 2012), and as stem-like expression signatures have been shown to be 
associated with poor outcomes in a variety of tumour types including prostate cancer 
(Ben-Porath et al., 2008; Markert et al., 2011), it was important to identify biomarkers 
that met these criteria.  
I selected a range of candidate markers with different extents of characterisation and 
literature coverage, including well-studied candidates already flagged for biomarker use 
such as BMI1, and poorly-studied candidates whose expressions had not yet been 
reported in prostate cancer, such as ZSCAN4. This was done in order to spread risk 
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associated with a literature searching approach and increase the chances of success: 
allowing higher-risk, briefly-characterised candidates to be investigated for potentially 
novel findings (such as ZSCAN4 and ALDH7A1), while also having lower-risk, well-
characterised candidates to study (such as BMI1 and SDC1). A long list of 116 
candidate markers was identified (Figure 3.1A). From this, 12 were shortlisted for 
further consideration. The 12 shortlisted biomarkers, complete with curated evidence 
from the time of decision making in 2012-2013, are shown in Table 3.1. Of these, 6 
candidates were chosen for experimental study, based on an assessment of the evidence 
presented for their utility as biomarkers: relationship to clinical parameters, including 
relapse status; and any interesting biological characteristics, such as a relationship to 
cancer stem cell behaviour, metastasis or hallmarks of cancer. These candidates were: 
ALDH7A1, BMI1, Nestin, MUC1-C, ZSCAN4 and SDC1. As before, candidates were 
chosen to represent differing degrees of coverage in the literature, ranging from 
candidates with prior links to clinical outcome (BMI1, SDC1, MUC1-C) and/or 
castration resistance (NES, MUC1-C) to candidates with no clinical associations in the 
literature but interesting biological characteristics (ALDH7A1, ZSCAN4). These 
markers are reviewed with current literature in Chapter 4.1.1. 
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Figure 3.1: Graphical representation of literature searching results overall and by 
evidence category. 
(A) Schematic overview showing all 116 potential biomarkers looked at in this study. 
The size of each protein name is proportional to the amount of literature identified that 
met the search criteria, with the biomarkers chosen for further study shown in red. 
Literature searching identified many types of markers, including stem cell markers such 
as NANOG and OCT4, canonical CSC markers CD44 and CD133, and EMT markers 
such as TWIST and SLUG. (B) Venn diagram showing classification of biomarkers by 
criteria they are associated with: prostate cancer; tissue/embryonic stem cells; cancer 
stem cells; recurrence (in any cancer); or relationships with other cancers. 
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Table 3.1: A sample of 12 shortlisted biomarkers for potential analysis. 
A description of each marker is included underneath the marker name. Markers in bold 










BMI1 expression is highly enriched in 
stem-like prostatospheres generated from 
multiple cell lines (Rybak et al., 2011; 
Lukacs et al., 2010b; Zhang et al., 2012a), 
prostate cancer biopsies and invasive 
xenograft tumours and cell lines.  
BMI1 is overexpressed in prostate cancer 
biopsies and may be an independent 
prognostic indicator, predicting PSA 
recurrence (van Leenders et al., 2007). 
Expression increases with increasing 
tumour stage in human prostate cancers 
(Siddique et al., 2013a). It is also a 
biomarker for prostate cancer diagnosis in 











This protein is overexpressed in many 
cancers, particularly adenocarcinomas such 
as breast cancer (Engelmann et al., 2008). 
Functionally, MUC1-C has many roles 
including in maintaining embryonic stem 
cell pluripotency (Hikita et al., 2008). No 
studies suggesting a CSC link in prostate 
cancer, but expression of the C-terminal 
domain has been associated with relapse, 
high tumour grade and advanced tumour 
stage (Lapointe et al., 2004). It represses 
androgen receptor expression and is 
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membrane	protein	through	its	highly	
glycosylated	PTS	repeat	motifs.	
involved in castration resistance and 
chronic inflammation (Rajabi et al., 2012). 
Blocking oligomerisation of MUC1-C 
causes regression of xenograft prostate 










Nestin was expressed in prostate cancer 
stem cells generated by immortalization of 
human prostate tumour cells (Gu et al., 
2007). Nestin is expressed in lethal 
metastatic CRPC (Kleeberger et al., 
2007a). Expression of nestin and Ki-67 
together are associated with biochemical 
failure, recurrence and metastasis – but 
nestin alone is not associated with 
clinicopathological variables(Gravdal et al., 
2009). In another study, nestin is 
upregulated in metastatic CRPC when 
compared to non-castrated, metastatic 







Aldehyde dehydrogenase activity identified 
a subset of cells with tumour-initiating 
capacity in prostate cancer cell lines 
(Hellsten et al., 2011; van den Hoogen et 
al., 2010; Qin et al., 2012) when also 
sorted for other cancer stem cell markers 
such as CD44 and α2β1 integrin. Prostate 
CSCs isolated in this way displayed 
quiescence and resistance to 
chemotherapeutic agents and androgen 
deprivation (Qin et al., 2012). ALDH7A1 
is highly expressed in prostate cancers (van 
den Hoogen et al., 2011) and is also in 
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matched bone metastases. ALDH7A1 
knockdown reduces bone metastasis in 
mouse xenografts. Therefore, ALDH 
activity is linked to cancer stem cell 
properties – and ALDH7A1 in particular is 







ZSCAN4 is known to be necessary for pre-
implantation development of mouse 
embryos and is expressed heterogeneously 
in mouse ES cells (Falco et al., 2007). 
Exogenous expression of ZSCAN4 
increases induction efficiency of induced 
pluripotent stem cells, and replaces Myc in 
their induction (Hirata et al., 2012). This 
suggests it has a role in regulating 
stemness. Additionally, ZSCAN4 regulates 
telomere elongation in ES cells (Zalzman et 
al., 2010),which is important for avoiding 
senescence in stem cells. However, 
ZSCAN4 expression has not been 
investigated thoroughly in adult tissues or 
cancer, with one paper (Ko et al., 2013) 
suggesting that its expression may be 
amplified along with stem cell markers 







Altered Syndecan expression appears to be 
associated with a greater risk of PSA 
relapse in patients with clinically localized 
prostate cancer (Ledezma et al., 2011; 
Chen et al., 2004b). It is also associated 
with the expression of EMT markers 
(Contreras et al., 2010). 
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Very well studied in many cancers, and 
often linked to cancer stem cells.  It has 
mainly been characterized in prostate 
cancer cell lines via FACS. Thought to be 
responsible for the ‘side population’ 
phenotype whereby CSCs and other stem 
cells are resistant to chemotherapeutic 
agents and can efflux Hoechst 33342 dye 
(Zhou et al., 2001). Stem-like 
prostatospheres generated from prostate 
cancer cell lines overexpressed ABCG2 
along with CD44 and other cancer stem cell 
markers (Zhang et al., 2012a) and were 
resistant to chemotherapeutic agents. In the 
murine prostate, adult stem-like prostate 
cells with high ALDH activity also highly 






USP22 expression has been identified in a 
stem-like gene expression signature related 
to therapy failure in multiple cancers – 
including prostate cancer (Glinsky et al., 
2005). USP22 expression correlates with 
poor prognosis, especially with BMI-1 
expression, in multiple cancers. High 
expression of USP22 in patients with is 
associated with poor clinical outcome in 
breast cancer (Zhang et al., 2011) and 
gastric cancer (Yang et al., 2011). In 
colorectal cancer, USP22 expression is 
elevated in metastases and its increased 
expression in is associated with poor 
response to therapy (Liu et al., 2011b). As 
the prognostic value of USP22 is often 
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improved when combined with expression 
of BMI1 (Yang et al., 2011; Hu et al., 
2012), it is presumed to activate the BMI1 





Related to the Hoechst side population, 
ABC transporter expression and drug 
resistance. May interact with Nanog in ES 
cells (Wang et al., 2006). Expressed in 
early stages of breast cancer (Kobayashi et 
al., 2011b) and lung cancer (Kobayashi et 
al., 2011a) independent of tumour stage. 
Overexpression and knockdown of SALL4 
in HEK293 cells leads to increased and 
decreased drug resistance and expression of 
ABC transporters (Jeong et al., 2011). 
Overexpression of SALL4 in MCF7 breast 
cancer cells results in an expansion of the 
stem-like side population. In the prostate 
cancer cell line PC-3, stem-like cells 
expressing PDGF-D have upregulated 
SALL4 expression (Kong et al., 2010), 







Related to prostate stem cells as it is 
upregulated in the mouse urogenital sinus, 
which is enriched in stem cells and forms 
the prostate during development (Blum et 
al.). Expression of E2F3 negative correlates 
with survival in prostate cancer patients, 
with highly expressing tumours having a 
poor prognosis independent of stage 
(Foster et al.) E2F3 has been identified as 
part of a panel of 5 genes that predict 
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biochemical recurrence in prostate cancer 









aV Integrin is enriched in CD44+/CD24- 
breast cancer stem cells when compared to 
the non-CSC population (Murohashi et al., 
2010).  aV Integrin is involved in the 
response of prostate cancer stem cells to 
vitronectin, which is the component of 
serum that causes CSC-like cells to 
differentiate in vitro (Hurt et al., 2010). 
Conversely, culturing PC-3M cells with an 
aV integrin antagonist decreases the stem-
like ALDH-high population and attenuates 
metastasis in another study (van der Horst 







Inhibition of STAT3 reduces CSC 
phenotypes in stem-like colon cancer cells 
(Hellsten et al., 2011) and breast cancer 
xenografts (Dave et al., 2012). STAT3 is 
upregulated in stem-like prostatosphere 
cells and in invasive prostate carcinoma 
(Mathews et al., 2010). STAT3 inhibition 
reduced invasion in prostate cancer cell 
lines. However, STAT3 function with 
regard to the expression of stem cell related 
genes has not been investigated. 
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3.2.2 Identification of candidate biomarkers through bioinformatics 
The second approach to identify candidate biomarkers was a bioinformatics approach. 
This provided an unbiased approach which complemented the literature searching 
approach. To do this, I used a cDNA microarray dataset (GEO Accession: GDS4109) 
published by Sun and Goodison (2009), which contains 79 primary prostate tumour 
samples divided into two categories: 39 were classified as recurrent, defined as 
biochemical recurrence with a rising PSA at three consecutive measurements, whilst 40 
were non-recurrent in the first 5 years of follow-up. Samples were log2-transformed and 
differential gene expression analysis was conducted between these two groups of 
patients in order to identify genes that were significantly differentially expressed 
between recurrent and non-recurrent patient tumours. The hypothesis was that 
differentially expressed genes between these two groups could be candidate biomarkers, 
and could be able to distinguish between the primary tissue of relapsing and non-
relapsing patients at the protein level. 
Interestingly, differential gene expression analysis revealed that only two genes were 
significantly differentially expressed (corrected p-value<0.05) between recurrent and 
non-recurrent patient tissues in this dataset. The differentially expressed genes were 
SLC31A1, a copper transporter, and RS1, an extracellular matrix protein (Table 3.2), 
both of which were expressed more highly in recurrent than non-recurrent patient 
samples (Figure 3.2A).  A member of the melanoma antigen family, MAGEA10, was 
expressed at lower levels in recurrent than non-recurrent patient samples, but had a p-
value marginally higher than the significance threshold (p=0.0559) and was excluded 
from the list of candidates. 
The bioinformatics approach provided two additional candidate biomarkers to 
investigate, and while testing antibodies on patient tissue (Chapter 4), further 
bioinformatic characterisation was performed on the more experimentally successful 
candidate RS1. The cBioportal (http://www.cbioportal.org/), a publically available 
toolset for performing meta-analysis on multi-dimensional microarray datasets in 
cancer, was used to investigate the mutation status of the RS1 locus in ten large prostate 
cancer microarray datasets. Mutations in the coding sequence of RS1 were rarely 
observed in prostate tumours, no matter the subtype (Figure 3.2B). Amplification of the 
RS1 locus occurred at a low frequency in localised prostate tumours (1.5 and 2.1% of 
cases in TCGA datasets) with four of six primary tumour datasets having no detected 
alterations at the RS1 locus. However, RS1 amplification was a considerably more 
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frequent phenomenon in metastatic and castration resistant prostate tumours, with 
between 7.3% and 31.8% of patients in these four metastatic/CRPC datasets having 
altered copy number at the locus. These data suggest that RS1 expression could be 
altered during tumour progression at the level of copy number, and the findings add 



















Table 3.2: Top 10 differentially expressed genes between recurrent and non-
recurrent prostate tumours in the Sun and Goodison dataset (GDS4109). 
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216937_s_at	 retinoschisin	1	 RS1	 Xp22.13	 0.551621798	 0.004651396*	
203971_at	 solute	carrier	family	31	(copper	transporter),	member	1	 SLC31A1	 9q32	 0.495047908	 0.018742401*	
210295_at	 melanoma	antigen	family	A,	10	 MAGEA10	 Xq28	 -0.733052962	 0.055949495	
207683_at	 forkhead	box	N1	 FOXN1	 17q11-q12	 -0.755986662	 0.078262367	
203095_at	 mitochondrial	translational	initiation	factor	2	 MTIF2	 2p16.1	 -0.898023549	 0.078262367	
215285_s_at	 putative	homeodomain	transcription	factor	1	 PHTF1	 1p13	 0.316130005	 0.101162106	
207111_at	 egf-like	module	containing,	mucin-like,	hormone	receptor-like	1	 EMR1	 19p13.3	 0.440721739	 0.101162106	
214146_s_at	 pro-platelet	basic	protein	(chemokine	(C-X-C	motif)	ligand	7)	 PPBP	 4q12-q13	 0.752298133	 0.101162106	
221969_at	 paired	box	5	 PAX5	 9p13	 -0.508480391	 0.101162106	
208099_x_at	 tubulin	tyrosine	ligase-like	family,	member	5	 TTLL5	 14q24.3	 -0.644293208	 0.101162106	
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Figure 3.2: Differential gene expression analysis based on recurrence status from 
Sun and Goodison (GDS4109) and subsequent meta-analysis of the identified 
biomarker RS1. 
(A) Differential gene expression analysis performed on the Sun and Goodison (2009) 
dataset, showing the two significant (P<0.05) differentially expressed genes between the 
non-recurrent (n=40, blue labels) and recurrent (n=39, red labels) patient groups. Z-
scores are plotted with red and green indicating lower and higher than average 
expression in the recurrent group, respectively. (B) Stacked bar chart showing a 
cBioportal meta-analysis of 10 prostate cancer microarray datasets. The frequency of 
amplifications, deletions and mutations of the RS1 locus in each dataset is shown as a 
percentage of the total cases, with the type and proportion of samples shown in a pie 
chart underneath: primary tumours; metastatic castration resistant prostate carcinomas 
(CRPC); or metastatic neuroendocrine prostate tumours (NEPC). Each bar is labelled 
with a study identifier as it is known in cBioportal. 
3.2.3 Estimation of biomarker functions through bioinformatics 
3.2.3.1 Extremes of expression analysis 
Having identified candidate biomarkers to test using two different methods, I first 
wanted to learn more about the functions of these biomarkers in relevant cell types, 
particularly for the less well-characterised biomarkers such as ZSCAN4, where little or 
no information may be known about its relevance to tumour biology and the functions it 
performs. To do this, I developed a new method of analysis using existing large 
microarray datasets. By segregating the samples in each dataset to correspond to the 
highest and lowest 10% of intensity values for a given probe on the array, discarding the 
samples in between and comparing the two groups, I hypothesised that it would be 
possible to learn more about the gene expression environment that arises in the context 
of elevated biomarker expression levels. Thus, the approach is a differential gene 
expression based analysis using a gene’s expression levels as a grouping system, with 
exclusion of the intermediate values providing greater contrast to the comparison. Full 
code for this method can be found in Appendix 1.  
Differentially expressed genes can be fed into a gene ontology (GO) annotation package 
and visualised, in this case using REVIGO (http://revigo.irb.hr/) meaning that gene 
functions that are overrepresented as a consequence of high biomarker expression can 
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be found and visualised (Supek et al., 2011). These ontologies do not represent the 
specific function of the biomarker, but rather the collective functions of the genes whose 
expression changes as a result of changes in biomarker expression. REVIGO takes gene 
ontology categories and groups them using semantic similarity methods, meaning that 
similar gene ontology terms are clustered together in space. For ease of visualisation 
and interpretation, only the top 20 gene ontology terms are used in this analysis. It is 
expected that these gene ontologies will cluster together in groups that are linked to the 
function of the biomarker itself within the context of the tissues or cells being studied. 
The aim was to study biomarkers of interest within prostate cancer datasets. 
3.2.3.2 Method validation 
To validate this method of analysis, a gene with known functions was investigated, and 
the 10th and 90th percentiles of expression were compared to assess functional categories 
of the differentially expressed genes. Two datasets were chosen for this analysis. The 
first was a single platform of the Grasso dataset (GEO accession: GSE35988, platform 
GPL6480) which consists of 88 patients: 49 primary prostate tumours, 27 metastatic 
castration resistant prostate tumours and 12 benign prostate tissue samples. The second 
was the larger CamCaP dataset (GEO accession: GSE70768) which consists of 199 
primary prostate samples: 125 prostate tumours and 74 matched benign prostate tissue 
samples. Aurora A Kinase (AURKA) was chosen as a control, given its well-established 
function as a mitotic kinase involved in the regulation of multiple mitosis checkpoints, 
including chromosomal alignment and spindle assembly. Therefore, differentially 
expressed genes between samples with high and low AURKA expression would be 
expected to include those with roles in mitosis, and gene ontology terms should be 
consistent with this.  
In agreement with this hypothesis, upregulated genes in samples with a high AURKA 
expression were significantly enriched for gene ontology biological process terms to do 
with the cell cycle, cell division, chromosome segregation and protein complex 
disassembly among others (Figure 3.2A and B), when compared to samples with low 
AURKA expression. This finding is consistent among two large microarray datasets of 
prostate cancer patient tissue (Table 3.2) and is also consistent with the known functions 
of AURKA in the control of the mitotic cell cycle and spindle assembly checkpoint 
(Nikonova et al., 2013), demonstrating that the extremes of expression method works 
for this gene in several prostate cancer datasets. 
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Figure 3.3: Gene ontology (GO) classification of upregulated genes in prostate 
cancer patients with high AURKA expression in two independent cohorts. 
(A) Visual representation of GO terms enriched in patients with high AURKA 
expression in the Grasso cohort (GSE35988). GO terms are grouped together in 
semantic space using REVIGO, where terms group together into those involved in the 
cell cycle, DNA repair and nuclear division as expected. (B) Visual representation of 
GO terms enriched in patients with high AURKA expression in the CamCaP cohort 
(GSE70768), where terms involving the cell cycle, cell division and protein complex 
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Table 3.3: Top 5 significantly enriched gene ontology terms when AURKA 




GO	Term	 Annotated	 Signif.	 Expect.	 p-val	
Grasso	
1	 cell	cycle	 1564	 93	 21.04	 <	1e-30	
2	 mitotic	cell	cycle	 923	 72	 12.42	 <	1e-30	
3	 cell	cycle	process	 1161	 79	 15.62	 <	1e-30	
4	 mitotic	cell	cycle	process	
793	 67	 10.67	 <	1e-30	
5	 nuclear	division	 495	 55	 6.66	 <	1e-30	
Cam	
CaP	
1	 mitotic	cell	cycle	 927	 48	 17.24	 8.20E-11	
2	 translational	termination	
176	 20	 3.27	 1.00E-10	
3	 translational	elongation	
205	 21	 3.81	 2.40E-10	
4	 cellular	protein	complex	disassembly	
273	 24	 5.08	 2.90E-10	
5	 protein	complex	disassembly	
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3.2.3.3 Investigation of SDC1 in human transcriptomic datasets 
Having validated the extremes of expression methodology, I used the method to carry 
out investigations of our candidate markers. Only markers for which preliminary data 
was promising in initial human testing (presented in the next two chapters) were 
investigated – RS1, SDC1 and ZSCAN4. Unfortunately, intensity values of RS1 probes 
on the Grasso and CamCaP datasets were too low and many samples had undetectable 
expression of RS1 in the probesets, which excluded RS1 from this analysis method. I 
began by identifying the gene ontology terms associated with the expression of SDC1. 
As before, both datasets were separated into their 10th and 90th percentiles, with 
extremes compared and intermediate samples removed from the analysis. 
When extremes of expression analysis was applied to study the effects of varying SDC1 
expression in the context of prostate cancer datasets (Grasso and CamCaP), the 
prominent GO terms represented were different between both datasets. In Grasso, high 
expression of SDC1 was associated with an enrichment of gene expression involved in 
chromosome and organelle organisation and segregation (Figure 3.4A). 125 genes were 
also annotated to the acute immune response (Table 3.3). In the CamCaP dataset, the 
high expression of SDC1 was not associated with chromosome organisation or immune 
response GO terms, but instead with genes involved in epithelial morphogenesis, 
epithelial development, cell motility and cell adhesion (Figure 3.4B). Interestingly, 
while SDC1 has potential roles in cell adhesion, development, motility and the immune 
response, a relationship between SDC1 expression and chromosome organisation has 
not been previously established. The generation of different GO enrichments for both 
datasets indicates that there is considerable variability between individual microarray 
datasets. 
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Figure 3.4: Gene ontology classification of upregulated genes in prostate cancer 
patients with high or low SDC1 expression in the CamCaP Cohort.  
(A) Visual representation of GO terms enriched in patients with high SDC1 expression 
in the Grasso cohort (GSE35988). GO terms are grouped together in semantic space 
using REVIGO, showing a diverse range of terms concerning chromosome 
organisation, the acute inflammatory response, complement activation, cell cycle, 
metabolism and cell projection. (B) Visual representation of GO terms enriched in 
patients with high SDC1 expression in the CamCaP cohort (GSE70768), where terms 
involving the epithelial development, cell adhesion and motility are represented. 
 
Table 3.4: Top 5 significantly enriched gene ontology terms when SDC1 expression 




GO	Term	 Annotated	 Signif.	 Expect.	 p-value	
Grasso	
1	 chromosome	
organization	 931	 24	 11.45	 0.00046	
2	 single-organism	
organelle	organization	 2242	 45	 27.57	 0.00046	
3	 organelle	organization	 3178	 58	 39.08	 0.00066	
4	 chromosome	
segregation	 239	 10	 2.94	 0.00076	
5	 acute	inflammatory	




development	 1054	 57	 22.36	 4.20E-11	
2	 anatomical	structure	
morphogenesis	 2465	 97	 52.28	 2.30E-10	
3	 morphogenesis	of	an	
epithelium	 466	 34	 9.88	 3.30E-10	
4	 tissue	morphogenesis	 600	 38	 12.73	 1.60E-09	
5	 anatomical	structure	
development	 4754	 151	 100.83	 2.20E-09	
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3.2.3.4 Investigation of ZSCAN4 expression in human transcriptomic datasets 
Given that very little was known about ZSCAN4 expression in human tissues prior to 
this study, I first investigated where ZSCAN4 might be expressed using high throughput 
sequencing data from the ENCODE project (Dunham et al., 2012), using the Integrative 
Genomics Viewer to visualise it (Robinson et al., 2011; Thorvaldsdottir et al., 2013).  
ENCODE Chip-Seq data was visualised along with Illumina Bodymap 2.0 RNA-Seq 
data for a variety of normal human tissues and cell lines and it was found that placenta 
tissue expressed the ZSCAN4 transcript (Figure 3.5). Prostate tissue expressed the 
transcript to a much lower level. However, in both cases it was found that the cDNA 
sequencing reads extended much further to the 5’ of the ZSCAN4 ORF than would be 
expected, with reads in both placenta and prostate tissues being detected as far as 
approximately 17kb upstream of the ZSCAN4 ORF (Figure 3.5, arrows), with a small 
Pseudogene located just downstream of this location. This raised the hypothesis that 
there might be multiple transcription start sites for the ZSCAN4 gene, with one 
approximately 4.5kb upstream of the ZSCAN4 ORF and the other approximately 17kb 
upstream. 
In attempt to confirm this finding, information was gathered from normal human 
epidermal keratinocyte (NHEK) cells, which had ENCODE Chip-Seq data, to look for 
histone marks indicative of transcription start sites in the region including the activating 
histone marks H3k9ac, H3k4me3 and H3k27ac and repressing histone mark H3k27me3. 
Additionally, Cap Analysis Gene Expression (CAGE) data, where the 5’ ends of 
transcripts are captured and sequenced, was taken from normal prostate tissue and 
overlayed onto RNA-Seq and Chip-Seq data. Clear peaks were observed corresponding 
to activating histone marks in NHEK cells at both hypothetical transcription start sites, 
with prostate CAGE data also showing peaks of sequenced 5’ transcripts at these sites 
(Figure 3.5, arrows). Repressive histone marks were absent. Taken together, the data 
suggest that ZSCAN4 is expressed in the human placenta, which could serve as a 
possible positive control tissue for later use. It also suggests that there may be longer 
ZSCAN4 transcripts than previously documented, with possible alternative 
transcriptional start sites, although this would require further experimental validation.
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Figure 3.5: Chip-Seq and RNA-Seq data from human cells and tissues in the 
ENCODE and Illumina Bodymap 2.0 projects, showing the ZSCAN4 locus and the 
region immediately upstream. 
Refseq data shows the genomic region containing the ZSCAN4 transcript (blue, bottom 
panel), whilst two regions approximately 4.5kb and 17kb away from the annotated 
ZSCAN4 transcript have regions of histone methylation consistent with active 
transcription start sites (arrowheads), such as H3k9ac, H3k4me3 and H3k27ac as 
determined by Chip-Seq. Repressive chromatin marks such as H3k27me3 are absent.  
Similarly, CAGE data from prostate tissue captures the 5’ end of transcripts at both 
TSS-like areas (arrowheads). While prostate tissue has low expression of ZSCAN4, 
placenta tissue shows evidence of more complete ZSCAN4 transcripts as determined by 
RNA-Seq. Transcripts are present from the -17kb position to the end of the last 
ZSCAN4 exon. GENCODE data reveals a small pseudogene mapped downstream of 
the -17kb putative transcription start site. Data were visualised in Integrative Genomics 
Viewer. 
In order to interrogate the potential functions that ZSCAN4 might be having in tissues 
where it is expressed, I first identified the effects that variations in its expression would 
have in a tissue that we predicted would express ZSCAN4, based on transcriptomics 
data. ZSCAN4 probe intensity values were often very low or absent, making it difficult 
to assess the function of ZSCAN4 expression in the Grasso and CamCaP datasets. 
Instead, we used the human placenta microarray dataset from Bruchova et al. (2010) 
which contained 76 samples (GEO accession GDS3793) and performed extremes of 
expression analysis on it based on extremes of ZSCAN4 expression levels. A placental 
dataset was chosen because of the prior identification of ZSCAN4 transcripts expressed 
in placental RNA-seq datasets (Figure 3.5). In samples with high ZSCAN4 expression, 
GO terms involving metabolism and intracellular transport were overrepresented (Table 
3.5 and Figure 3.6). Although comparisons with the literature are difficult given the lack 
of documentation of ZSCAN4 expression in placenta, together with only brief 
characterisation outside of ES cells, this analysis reveals a hypothetical role for 
ZSCAN4 in metabolism, and it would be interesting to see if future functional analysis 
of ZSCAN4 reveals such roles.  
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Figure 3.6: Gene ontology classification of upregulated genes in normal placenta 
tissue samples with high ZSCAN4 expression in the Bruchova Cohort. 
Visual representation of GO terms enriched in patients with high ZSCAN4 expression 
in the Bruchova cohort (GDS3793). GO terms are grouped together in semantic space 
using REVIGO, with the majority of terms relating to metabolism and intracellular 
transport, with pregnancy, Notch signalling, endothelial cell fate, and other diverse 
terms also represented.  
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Table 3.5: Top 10 significantly enriched gene ontology terms when ZSCAN4 









1 metabolic process 10633 567 521.46 5.30E-05 
2 
intracellular 
transport 1642 111 80.53 0.00025 
3 
cellular metabolic 
process 9066 486 444.61 0.00066 
4 
macromolecule 








transport 1338 91 65.62 0.00078 
7 
organic substance 
metabolic process 9277 495 454.96 0.00088 
8 
establishment of 
localization in cell 2350 146 115.25 0.00109 
9 
asparagine 
biosynthetic process 5 3 0.25 0.00109 
10 
positive regulation of 
transcription of 
Notch receptor target 5 3 0.25 0.00109 
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3.2.4 Optimisation of anti-biomarker antibodies for use in IHC 
When the potential biomarkers had been selected by both approaches and 
characterisation had been done at the bioinformatic level, the next step was to establish 
and test methods for the IHC procedure to be used on human samples. Since the initial 
aim was to construct a tissue microarray of precious material such as prostate biopsies 
and prostatectomy samples, it was important to test a method for constructing tissue 
microarrays from FFPE tissue samples. In addition, it was necessary to ensure that IHC 
procedures would work on the constructed tissue microarray, and some antibodies 
raised against candidate markers could be tested in this setting. Therefore, I tested a 
method for constructing and staining tissue microarrays using a range of normal FFPE 
tissue from mice. 
3.2.4.1 Development of a mouse tissue microarray for testing 
Mouse tissue is a readily available source of control material which does not require 
extended ethical consideration to obtain, and tissue preparation can be controlled and 
standardised by the end user. This made it suitable for construction of a trial tissue 
microarray in which construction and staining protocols could be tested. Additionally, a 
wide range of different tissue types could be harvested from the mice so that a multi-
tissue survey could be conducted on this tissue microarray, and archived mouse FFPE 
tissue blocks that were already prepared by Dr Asha Recino in 2007 were used for most 
of the source cores, with the exception of prostate tissue which was prepared freshly for 
the purpose of producing the TMA.  
H&E staining of whole sections from blocks of mouse tissue was carried out, and tissue 
microarrays were constructed using the whole sections to guide core punch placement. 
This resulted in a tissue microarray containing 48 cores of mouse tissue from 13 
different organs (Figure 3.7), making it a useful resource for surveying protein 
expression patterns in the mouse. The tissue microarray was arranged into a defined, 
asymmetrical pattern of tissue cores divided between three sectors (Figure 3.7) to ensure 
consistent orientation and simplify navigating the array under a microscope. Sectors 
were divided by a row of blank paraffin cores and the array was lined by a single layer 
of blank paraffin cores to aid in sectioning. 8 cores of prostate tissue were included in 
order to describe the heterogeneous tissues present in the four murine prostate lobes.  
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Figure 3.7: Schematic of tissue microarray cores in the mouse tissue microarray. 
Tissues are colour keyed, numbered by specimen number and gender denoted where 
known. The design is asymmetric, with an orientation core of dyed agarose placed in 
the corner to assist in microarray orientation during sectioning.  
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H&E staining performed on the tissue microarray confirmed that cellular morphology of 
organs was intact after microarray construction: liver (Figure 3.8A); kidney (Figure 
3.8B); lung (Figure 3.8C); intestine (Figure 3.8D); brain (Figure 3.8E); skin (Figure 
3.8F); testis (Figure 3.8G); pancreas (Figure 3.8H); and skeletal muscle (Figure 3.8I) 
were all consistently retained in the tissue microarray. In addition, some tissues too 
brittle to easily section whole, such as liver and skeletal muscle (Figures 3.8A & I), 
were successfully retained in microarray sections. From a single section of tissue 
microarray, morphological features of three prostate lobes were apparent (Figure 3.9). 
Following H&E staining, prostate cores retained gross glandular architecture and the 
surrounding fibromuscular stroma (Figure 3.9A). Ventral prostate glands displayed 
characteristic focal tufting and cuboidal epithelium (Figure 3.9B, arrow), while anterior 
prostate showed glandular infolding (Figure 3.9C, arrow) and prominent eosinophilic 
secretions. The epithelium of the dorsolateral prostate (Figure 3.9D) was cuboidal and 
surrounded by a loose connective tissue.  
Tissue types where available tissue was scant, such as ovary and spleen, showed 
frequent core loss when IHC was conducted. Over 21 IHC staining reactions performed 
on sections of the tissue microarray, the mean percentage of cores lost was 29.7%. As 
the majority of tissue types were intact in this array, this high rate of core loss was 
considered acceptable for the initial IHC studies. 
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Figure 3.8: H&E staining of representative mouse tissue microarray cores at 20x 
magnification. 
Images of H&E stained cores of a single mouse tissue microarray section: (A) Liver; 




Figure 3.9: H&E staining of mouse prostate tissue microarray cores viewed at high 
and low magnification. 
 (A) Low power view of a whole core of ventral prostate, demonstrating that the 
glandular and stromal architecture remains intact after sectioning. (B) High power view 
of a murine ventral prostate gland as in (A) demonstrating focal tufting (arrow). (C) 
Anterior prostate with glandular infolding (arrow) and prominent eosinophilic 
secretions. (D) Dorsolateral prostate with small nuclei and compact, cuboidal 
epithelium. Scale bars – (A) 500µm, (B-D) 50µm. VP – ventral prostate; AP – anterior 
prostate; DLP – dorsolateral prostate.  
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3.2.4.2 Establishing the mouse tissue microarray as an IHC testing platform 
In order to demonstrate the suitability of the tissue microarray for downstream IHC 
analysis when applied to prostate tumour specimens, initial IHC staining was performed 
on the mouse tissue microarray and some candidate marker antibodies were tested in the 
process. Initial optimisation of IHC protocols was performed on two of six candidates 
identified in the literature: ZSCAN4 and ALDH7A1. Where known, expression patterns 
across mouse tissues were cross-checked with the results obtained in this study. The 
antibodies for the other four markers, BMI1, NES, SDC1 and MUC1-C, were raised 
against human antigens and not shown to identify the murine homologues in the 
literature, or found not to react with the mouse tissue microarray. For this reason, these 
four markers were not optimised using the mouse tissue microarray. 
In addition to testing antibodies with the staining procedure, the level of non-specific, 
background staining was assessed by carrying out parallel negative controls in which 
the same secondary detection system was used, but the primary antibody was not 
applied. As with the test antibody slides, negative control slides were scored for their 
staining patterns where they were present. It was found that murine lung, kidney, spleen 
and heart tissue demonstrated diffuse cytoplasmic reactions even in the absence of 
primary antibodies, regardless of which species the secondary detection system was 
designed to detect (Appendix 2). However, the remaining tissues were largely clear of 
non-specific background signals and were suitable for assessment. Given this, it is 
likely that the background staining is a tissue-specific phenomenon, and therefore the 
array as a whole is suitable for assessment of antibody staining patterns provided that 
these background-prone tissues are taken into account. 
3.2.4.3 ALDH7A1 staining was predominantly nuclear in most murine tissues 
Expression of ALDH7A1 was detected in the nuclei of the majority of murine tissues 
stained, with considerable heterogeneity in intensity between individual cells. For 
example, a subset of hepatocytes showed stronger staining than surrounding cells 
(Figure 3.11A, arrow), while the murine pancreas contained a mixture of strongly 
positive and negatively staining nuclei (Figure 3.11B) and renal tubular epithelium had 
stronger nuclear staining than surrounding cells (Figure 3.11C). In contrast, prostate 
glands showed cytoplasmic staining of glandular epithelium with no nuclear staining 
(Figure 3.11D), or with weak to intermediate nuclear staining as shown in the lateral 
prostate (Figure 3.11E). Negative controls, where no primary antibody was added, 
confirm that the secondary detection systems are free of detectible background in 
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prostate specimens (Figure 3.11F). When the localisation of the ALDH7A1 staining 
pattern was scored, localisation was found to be nuclear within the vast majority of 
tissues over the course of three independent experimental replicates, with the exception 
of prostate where the predominant localisation was cytoplasmic (Appendix 3).  
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Figure 3.10: ALDH7A1 expression in adult mouse tissues assessed by IHC.  
(A) Liver hepatocytes show weak to intermediate nuclear staining of ALDH7A1 
(arrow). (B) Murine pancreas showing strong heterogeneous nuclear staining, with islets 
of Langerhans showing cytoplasmic and nuclear staining (arrow). (C) Kidney cells stain 
nuclear positive, with individual strongly staining tubules visible (arrow). (D) Prostates 
show uniform, weak to intermediate cytoplasmic staining of glandular epithelium, as 
seen in the anterior prostate and (E) lateral prostate. (F) Negative control material is 
anterior prostate tissue with no primary antibodies added. Images representative of 3 
independent experiments. Scale bars – 50µm. 
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3.2.4.4 ZSCAN4 was diffuse and weak to negative in all murine tissues 
Although expression of ZSCAN4 has been reported in several human tissue types at the 
transcript level, including placenta, lung, kidney, liver and pancreas (Ko et al., 2013), 
its expression at the protein level in adult tissues has not been thoroughly studied and 
expression in the prostate has not been reported. In order to characterise its expression 
and optimise the antibody for downstream IHC staining protocols with precious biopsy 
tissue, we used immunohistochemistry on mouse tissue microarray sections. ZSCAN4 
staining was detected at a low level in most tissues, with weak, diffuse cytoplasmic 
staining patterns being observed in all tissue types examined. Within the murine 
prostate, staining was weak to negative within the glandular epithelium (Figure 3.12A 
and B) with moderate staining of fibromuscular prostate tissue components (Figure 
3.12B). Murine pancreas, a tissue previously demonstrated to contain a subset of 
ZSCAN4+ staining cells in all tissue compartments (Ko et al., 2013), was diffusely and 
weakly positively stained with the antibody (Figure 3.12C), which does not match the 
published finding of Ko et al. (2013). Staining in the testis was limited to Leydig cells 
(Figure 3.12D, arrows), whereas in the liver staining was weak and diffuse across all 
hepatocytes (Figure 3.12E). Negative controls, where no primary antibody was added, 
demonstrate that the detection method has a low background (Figure 3.12F). However, 
the diffuse and weak/negative nature of the staining across all tissues (Appendix 4), as 
well as the lack of corroboration with previously published data, suggests that this 
antibody is ineffective for detecting ZSCAN4 protein of mouse origin. 
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Figure 3.11: ZSCAN4 expression in adult mouse tissues.  
(A) Prostate tissue shows weak diffuse glandular cytoplasmic staining, or (B) no 
staining in glandular epithelium, with a moderate intensity reaction in fibromuscular 
stroma (separated by dotted line). (C) Pancreatic tissue shows weak cytoplasmic 
staining. (D) ZSCAN4 expression in the testis is weak and cytoplasmic, being confined 
to Leydig cells (arrows). (E) Liver hepatocytes show weak, diffuse cytoplasmic 
staining. (F) Negative control is anterior prostate with no primary antibodies added. 
Figure 3.8A is representative of 2/3 experiments. Other images representative of 3/3 
independent experiments. Scale bars - 50µm. 
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3.3 Discussion 
In this chapter, potential biomarkers were selected using two different methods: six via 
a literature searching method and an additional two by a bioinformatics method using 
pre-existing cDNA microarray data from prostate cancer. A further bioinformatics 
approach was designed to interrogate the potential functions of biomarkers using cDNA 
microarray datasets. Following this, a tissue microarray was constructed using FFPE 
mouse tissue from a variety of tissue types. Using IHC it was confirmed that the 
platform was suitable for the technique, and some initial testing of anti-biomarker 
antibodies was performed. 
3.3.1 Identification of biomarkers by literature review 
The literature review approach generated a wide range of biomarkers which have been 
studied to differing degrees, ranging from candidates selected from transcriptomics 
screens to individually studied and well characterised oncogenes and cancer stem cell 
markers. Key cancer stem cell markers such as CD44 and CD133 were not chosen due 
to their already high degree of coverage and assessment in the literature (see Figure 
3.1A), with the consideration that any biomarker utility would already have been 
demonstrated.  
Since transcriptomics studies were common, it would have been possible to include 
many markers from a small number of such studies, but this approach was avoided in 
favour of concentrating on key markers that were clearly identified and focused on 
singly within the individual studies, especially with respect to prognosis or outcome. 
This is because the level of characterisation of individual markers in transcriptomics 
studies is minimal, and biomarkers derived from prognostic gene signatures may not 
have individual prognostic utility. 
It is impossible to evaluate the efficacy of the search methods employed, but they have 
yielded over 116 targets for potential investigation by the laboratory. In hindsight, the 
use of a text-mining-based approach to complement the manual literature searching 
such as the SCAIView tool (Younesi et al., 2012) would have provided additional 
benefits: reductions to the time spent searching, and increases to the number of 
candidates identified and the amount of evidence accrued for each biomarker. However, 
the approaches adopted in this project did yield 6 potential biomarkers for further 
analysis. 
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3.3.2 Identification of biomarkers by bioinformatics 
Differential gene expression analysis identifies the genes that are significantly 
differentially expressed between two or more groups of samples. In the dataset studied, 
only two genes were discovered to be differentially expressed to significant levels – 
RS1 and SLC31A1 were overexpressed in patients that experienced recurrence within 
five years. The relatively small number of significant genes is interesting, as this 
suggests that when patients with and without a 5-year biochemical recurrence were very 
similar on the gene expression level. However, it could also be an indicator of 
heterogeneity in prostate tumours, a phenomenon which is already well known to 
impede attempts to create prognostic signatures using molecular profiles (Sboner et al., 
2010). Such variability is particularly prominent in higher risk prostate tumours (Wyatt 
et al., 2014) and would reduce the resolving power of a differential gene expression 
analysis, making truly differentially expressed genes more difficult to detect. 
A subsequent cBioportal meta-analysis identifies a subset of metastatic and castration 
resistant prostate carcinomas with amplification of the RS1 locus. Interestingly, this 
amplification was not seen in tumours of primary origin. RS1 is located at genomic 
location Xp22.13, and amplifications of the whole X chromosome are an observed 
event in prostate tumours (Visakorpi et al., 1995), most notably in metastatic disease 
(Braun et al., 2013). Therefore, it is unclear whether RS1 amplification is a 
consequence of this phenomenon and/or contributes a function in the context of prostate 
cancer progression. However, taken together with the increase in RS1 expression in 
recurrent primary tumours, this makes the candidate biomarker a more desirable target 
to study, and demonstrates that a combination of bioinformatic approaches can inform 
biomarker selection processes. 
3.3.3 Extremes of expression analysis 
3.3.3.1 Alternative methods 
The extremes of expression method was designed to identify functional roles associated 
with genes of interest. It has been known for decades that there is a demonstrable 
tendency for genes with similar and coordinated expression patterns to show closely 
related functions (Eisen et al., 1998), and the effect has recently been confirmed within 
gene ontology classifications in prostate cancer datasets (Jiang et al., 2014). Therefore, 
clustering genes based on similarity of expression patterns over two or more 
experimental conditions is a common approach and it often makes use of correlation 
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coefficients to demonstrate co-expression (Reynier et al., 2011). Functional annotation 
follows, with top-ranking genes in the correlation analysis being fed into a gene 
ontology annotation package. It has the advantage of working with smaller as well as 
with larger datasets, and could potentially combine data from multiple expression array 
platforms. However, while this method of analysis is a good test of similarity for 
expression patterns, correlation tests fail to take into account the magnitude of 
differences in gene expression over the range of expression of the gene of interest. 
Additionally, while there are more complex methods for functional analysis that take 
into account gene networks, copy number and mutation data within a prostate cancer 
context (Jiang et al., 2014), they focus on a genome-wide analysis rather than focusing 
on a single gene of interest. 
The extremes of expression method has less resolving power for gene expression 
pattern similarities, given that the data is dichotomised into two extreme groupings 
based on expression level of a gene of interest. However, this method tests for 
magnitudes of difference in gene expression levels between the two groupings, making 
it better able to resolve genes that are differentially expressed to a larger degree when 
the expression of the gene of interest changes. With further refinements it would be 
possible to adapt the method for a more robust multi-probe approach, by summing or 
averaging the intensity values from each probe corresponding to a gene of interest on an 
array, instead of relying on the readings from a single probe. 
3.3.3.2 Method reliability 
Using a gene with experimentally-validated and well characterised functions, AURKA, 
it was demonstrated that the extremes of expression method accurately identifies 
biological process annotations associated with the gene in the literature. Since the 
method has only been applied to transcriptomic datasets, it remains to be seen whether 
this method only works for genes that are regulated chiefly at the transcriptional level. 
For those that are regulated at the protein level, it would be interesting to see if such a 
method applied to an antibody array, which profiles the proteome using a matrix of 
different antibodies, would yield additional information. However, extremes of 
expression analysis of SDC1 also revealed known biological process annotations 
associated with the gene, whose biological activities are also regulated at the enzymatic 
level by cleavage to liberate a soluble ectodomain (Purushothaman et al., 2010; Ramani 
and Sanderson, 2014). It suggests that the approach is suitable for the study regardless 
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of whether or not the protein directly regulates transcription as a transcription factor 
would. 
3.3.3.3 SDC1 
Many GO terms revealed by this analysis were consistent with known functions of 
SDC1, such as cell adhesion, cell migration, ECM organisation and regulation of 
immune response. In particular, endothelial SDC1 expression is important for regulating 
immune cell adhesion, with SDC1-knockout endothelium showing increased immune 
cell adhesion during shear stress (Voyvodic et al., 2014), while SDC1-knockout 
macrophages exacerbated the inflammatory response and resulting damage associated 
with aortic aneurysm in another mouse model (Xiao et al., 2012). These phenotypes 
suggest that SDC1 has a likely effect on inflammation that relies upon the interplay of 
cell adhesion and cell migration events.  
GO terms such as epithelial morphogenesis and development were also strongly 
represented in SDC1high patients, suggesting that genes associated with a developmental 
programme are activated in the context of high SDC1 expression. This would be 
consistent with several reports in murine models, which suggest that some tissues 
require SDC1 for maintaining normal differentiation programme during development 
and in adult homeostasis. For example, SDC1 knockdown in murine neural progenitor 
cells resulted in premature differentiation and a reduction in beta-catenin levels in vivo 
(Wang et al., 2012b), suggestive of an inability to respond to Wnt signalling. SDC1 
homozygous knockout mice also suffer from an inability to respond to cold stress, and 
in this model SDC1 is required for adipocyte differentiation in vivo (Kasza et al., 2014), 
and this effect is due to SDC1-mediated positive regulation of PPARγ signalling. 
Additionally, SDC1 expression is required for the maintenance of a putative cancer 
stem cell population in the prostate cancer cell line PC-3 (Shimada et al., 2013). Given 
this evidence, it is possible that SDC1 expression in prostate tumours is part of a 
recapitulation of developmental signalling programmes, although this would have to be 
experimentally confirmed. 
3.3.3.4 ZSCAN4 
Analysis of ZSCAN4 expression variation in a placental dataset revealed an enrichment 
of GO terms involving metabolism and intracellular transport in samples that highly 
expressed ZSCAN4. Unfortunately, given the lack of prior information about ZSCAN4 
expression in placenta, it is not yet possible to place this finding in a meaningful 
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biological context. Currently known functions of ZSCAN4 have been characterised in 
mouse embryonic stem cells, where it is thought to be expressed in self-renewing 
pluripotent cells (Amano et al., 2013; Sharova et al., 2016). It serves to regulate 
telomere length and telomere elongation in these cells (Zalzman et al., 2010; Zhang et 
al., 2016; Nakai-Futatsugi and Niwa, 2016), and appears to be modulated by PI3K 
signalling (Storm et al., 2014), DNA damage (Storm et al., 2014) and retinoic acid 
(Tagliaferri et al., 2016; Sharova et al., 2016).   
However, such data may be misleading, as they are all characterised in mouse cells. The 
results obtained from extremes of expression analysis may suggest that ZSCAN4 may 
have additional roles in metabolism in human datasets, and it would be interesting to see 
if future functional studies match up with these findings. This data also identifies 
transcription of ZSCAN4 mRNA in human placenta, and analysis of ENCODE and 
Illumina BodyMap 2.0 high throughput sequencing data from RNA-Seq, CHIP-Seq and 
CAGE studies reveals that there may be a longer ZSCAN4 transcript in this tissue – and 
possibly others – than was previously identified. However, there is a pseudogene just 
downstream of this putative transcription start site which is too small to represent this 
transcript in full. Given these findings, experimental characterisation is required to 
understand the functions of ZSCAN4 in human cells, and it is still very poorly 
characterised with respect to cancer, with only two papers reporting ZSCAN4 
expression in cancer cell lines, where it seems to interact with telomere-related proteins 
(Lee and Gollahon, 2014, 2015). 
3.3.4 Development of a mouse tissue microarray 
In order to test the process of constructing tissue microarrays and conducting staining, 
an FFPE mouse tissue microarray was generated. Given that tissue microarray 
construction was successful, H&E staining and IHC staining was undertaken. 
3.3.4.1 ALDH7A1 staining on the mouse microarray 
Anti-ALDH7A1 IHC conducted on the mouse tissue microarray revealed that most 
tissue types demonstrated consistent nuclear staining with the antibody, except prostate 
tissue which demonstrated cytoplasmic staining. The change in protein localisation in 
the prostate suggests that ALDH7A1 is fulfilling a different function or being regulated 
differently here than in other tissues. ALDH7A1 has both a nuclear localisation signal 
and a nuclear export signal, as well as an additional mitochondrial transport signal 
present in a splice isoform (Brocker et al., 2010), and previous functional studies of 
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ALDH7A1 in cell culture have suggested that changes in localisation from cytoplasm to 
nucleus occur throughout the cell cycle (Chan et al., 2011). However, Chan et al. also 
show changes in protein localisation from the nucleus to the cytoplasm during phases of 
the cell cycle, which we did not observe in our tissues: staining was either solely 
nuclear or solely cytoplasmic.  There was considerable variation in nuclear signal 
intensity, with the most heterogeneous pattern observed in pancreas:  negative cells 
were present next to neighbouring weakly and strongly staining cells. Aldehyde 
dehydrogenase activity has previously been reported to fluctuate in cell culture 
conditions, where cells displaying low activity can give rise to cells with high activity 
and vice versa (Doherty et al., 2011). Although this phenotypic plasticity has not been 
demonstrated specifically for ALDH7A1, varied expression in tissues could be 
explained by asynchronous cell cycle progression by cells in the tissue, as ALDH7A1 
staining by immunohistochemistry appears to be affected by phases of the cell cycle 
(Chan et al., 2011). Overall, the ALDH7A1 staining patterns observed by IHC are 
consistent with the published literature on ALDH7A1 localisation and expression 
patterns within mouse tissues by western blot and by IHC (Brocker et al., 2010). The 
antibody reaction conditions are suitably optimised for further testing in human tissue. 
3.3.4.2 ZSCAN4 staining on the mouse microarray 
Anti-ZSCAN4 IHC conducted on the mouse tissue microarray showed a diffuse and 
weak cytoplasmic staining in most tissues examined. For example, both liver and 
pancreas presented diffuse cytoplasmic staining patterns with no preference for cell 
type. However, portions of the pancreas displayed no staining. This is not consistent 
with previous descriptions of ZSCAN4 expression in the mouse pancreas, which 
displayed a small proportion of strongly nuclear and cytoplasmic positive cells in 
pancreatic tissue including islets (Ko et al., 2013). This is surprising, given that the 
group used the same antibody clone for their anti-ZSCAN4 immunohistochemistry, 
present at the same working dilution. However, there is no other literature to 
corroborate the evidence provided by Ko et al. (2013). If expressed at all, ZSCAN4 
staining would be predicted to be present in the nucleus given its status as a 
transcription factor, as well as its documented roles in responding to DNA damage 
(Storm et al., 2014) and maintaining telomere length (Zalzman et al., 2010; Storm et al., 
2014). Therefore, the diffuse staining in all mouse tissues is suspected to be background 
staining from non-specific primary antibody binding. Taken together, the results suggest 
that the anti-ZSCAN4 antibody does not suitably recognise the antigen in mouse tissues, 
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and further testing in human FFPE tissues is the next step for further benchmarking this 
antibody. 
3.3.4.3 Overall utility of the microarray 
When subjected to IHC procedures, core loss rate across the entire array averaged at 
approximately 30%. In some tissue microarray studies, the rate of core loss can be as 
low as 2% (Tennstedt et al., 2012), but in tissue microarrays constructed from scant 
tissue such as prostate biopsies, the core loss can be as high as the 24% reported by 
(Singh et al., 2007). The high rate of core loss in the mouse tissue microarray could be 
attributed to a lack of tissue depth in many mouse tissue blocks, such as ovary and 
testis. Another possibility for tissue microarray core loss is removal during the harsh 
antigen retrieval procedures, although this was not observed to occur in these IHC 
experiments.  
In attempt to resolve the problem of scant tissue, in some cases multiple partial cores 
were packed into a single core to increase the amount of tissue available for analysis. 
Although this should not be a problem for radical prostatectomy and TURP chip 
samples given their large size and specimen thickness, it suggests that prostate biopsies 
may be insufficient material for tissue microarray construction – a conclusion also 
supported by Singh et al. (2007), especially when these prostate biopsies have already 
been sectioned through for prior pathology use and may have a considerably reduced 
specimen content. In these cases, whole sectioning of single samples would need to be 
carried out for IHC. However, overall tissue microarray construction was deemed to be 
successful, with the inclusion of a wide variety of mouse tissues that could be 
simultaneously subjected to IHC. It is hoped that in the future, in addition to being a 
useful platform for optimising some antibody staining procedures via IHC, it will also 
be a useful resource to this and other laboratories for the expression profiling of markers 
of interest in mouse tissues. 
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4 ASSESSMENT OF CANDIDATE 
BIOMARKERS IN THE BATH 
COHORT 
4.1 Introduction 
Having identified a group of proteins that could be potential biomarkers for testing by 
IHC, and optimising the conditions required to obtain a satisfactory IHC signal, 
potential biomarker expression patterns were evaluated in human prostate tissue from 
benign and cancerous regions of clinical prostate biopsies and surgical samples. Clinical 
data was used to determine the relationship between biomarker staining patterns and the 
clinical features of patients with prostate adenocarcinoma. The main aim was to 
evaluate the prognostic utility of potential biomarkers to be tested on a small scale, so 
that candidate biomarkers can be taken forward for further investigation. Hypotheses 
concerning each potential biomarker are described below. 
4.1.1 Hypotheses concerning prospective biomarkers 
4.1.1.1 BMI1 expression will be positively associated with biochemical recurrence 
BMI1, a Polycomb group protein, is associated with stem cell and self-renewal activity. 
It is expressed in fractions of prostate cancer cultures that have greater tumour-initiating 
(Lukacs et al., 2010b) and sphere-initiating capacity (Rybak et al., 2011), and BMI1 
expressing cells have been associated with stem-like phenotypes in multiple studies 
(Zhang et al., 2012a; Hurt et al., 2008; Lukacs et al., 2010b). Overexpressing BMI1 in 
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prostate cancer cell lines and xenografts results in increased cell proliferation and a 
resistance to chemotherapeutic drugs, as well as an increase in anti-apoptotic protein 
BCL2 and Cyclin-D1 (Siddique et al., 2013b). BMI1 is also thought to inhibit prostate 
cancer cell senescence by repressing transcription of p16Ink4a (Ammirante et al., 
2013). Serum levels of BMI1 are positively associated with increased tumour stage 
(Siddique et al., 2013b; Siddique et al., 2013c). and mRNA levels of BMI1 and other 
proteins in its pathway have been used as part of a multi-cancer poor prognosis gene 
expression signature (Glinsky et al., 2005). BMI1 is upregulated following castration in 
mouse models of prostate cancer and promotes castration-independent and tumour 
growth, a phenomenon that appears to be dependent on activation of the IkB kinase 
Ikkα and its subsequent E2F1-mediated transcription of BMI1 (Ammirante et al., 2013). 
The current literature therefore suggests that BMI1 may be important in the patient 
response to chemotherapy and hormone therapy. I hypothesise that BMI1 staining levels 
will be higher in patients that will go on to develop recurrent disease, compared to those 
with non-recurrent disease. 
4.1.1.2 ALDH7A1 will be positively associated with biochemical recurrence 
Aldehyde dehydrogenase (ALDH) activity is routinely used as a marker of stem-like 
cancer cells in multiple types of tumour, including in breast (Wang et al., 2011) and 
prostate cancer (Vesuna et al., 2009; van den Hoogen et al., 2010). Some aldehyde 
dehydrogenases catalyse the biosynthesis of retinoic acid, which is an important 
molecule involved in differentiation (Alison et al., 2010). They also participate in 
aldehyde and alcohol metabolism. Thus, ALDH enzymes may be functionally involved 
in self-renewal and resistance to alkylating agents such as cyclophosphamide. Enzymes 
of the ALDH family are also associated with poor prognosis in a number of cancers 
(Alison et al., 2010). In particular, ALDH1A1 and other stem cell markers are 
upregulated in castration resistant prostate cancer compared to non-castrated metastatic 
disease (Pfeiffer et al., 2011), suggesting a role for ALDH1A1 in the response to 
androgen deprivation. Indeed, high ALDH1A1 expression in prostate cancer specimens 
has been associated with cancer stem-like phenotypes, higher Gleason scores and 
stages, as well as a poor prognosis (Li et al., 2010). It is therefore possible that other 
ALDH enzymes are implicated in prostate CSCs and may have utility in prostate cancer 
prognostication. In prostate cancer cell lines, knockdown of ALDH7A1 expression has 
been found to reduce expression of regulators of epithelial-mesencyhmal transition and 
to reduce the putative cancer stem cell subpopulation (van den Hoogen et al., 2011), 
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with a concomitant decrease in bone metastatic capacity. Currently there are no studies 
investigating its relationship with recurrence or patient outcome. However, due to its 
influence on invasion and aggressiveness of tumours, I hypothesise that ALDH7A1 will 
be expressed more strongly in patients that go on to experience recurrence than in non-
recurrent patients. 
4.1.1.3 SLC31A1 will be positively associated with biochemical recurrence 
SLC31A1 was identified in this study as being overexpressed at the mRNA level in 
patients with recurrent prostate tumours in Chapter 3.3.2. SLC31A1 is the major 
transporter for copper uptake in humans (Jong and McKeage, 2014). Maintaining 
copper homeostasis is important in both benign and malignant prostate cancer cells, as 
copper chelation reduces cell viability in both cases (Safi et al., 2014). Both prostate 
cancer cell lines and xenografts all having a high accumulation of copper and, though 
the reason for this accumulation is unknown, it allows for effective pharmacological 
targeting of castration-resistant prostate xenografts and cell lines (Safi et al., 2014). AR 
activity positively regulates the expression of SLC31A1 and subsequent copper intake 
by the VCaP cell line (Safi et al., 2014). Additionally, there may be a link between 
SLC31A1 and ERK signalling, as mouse embryonic fibroblasts with a homozygous loss 
of SLC31A1 fail to phosphorylate and activate ERK when stimulated by ligands of its 
upstream receptor tyrosine kinases, such as FGF, PDGF and EGF (Tsai et al., 2012). 
This suggests that intracellular copper is important for activating the ERK pathway that 
is commonly dysregulated in cancer. However, a survey of normal and malignant 
human tissue for SLC31A1 protein levels by IHC found no detectable levels of the 
protein in either benign prostate or prostate carcinoma (Holzer et al., 2006). The data on 
SLC31A1 in prostate cancer is limited and, given the findings in Chapter 3 and the 
description of SLC31A1 expression in prostate cancer cell lines, further investigation is 
warranted. I predict that SLC31A1 will be more highly expressed in patients with 
recurrent tumours than those that remain in remission. 
4.1.1.4 The C-terminal domain of MUC1-C will be positively associated with 
biochemical recurrence 
Mucin 1 transmembrane protein (MUC1) was initially identified as being relevant to 
prostate cancer in a microarray experiment attempting to subset prostate cancer patients 
into clinically relevant categories (Lapointe et al., 2004). The functions of MUC1 
outside of its normal roles in mucous membrane formation are incompletely understood, 
as MUC1-null mice do not have a discernible phenotype in a pathogen-free 
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environment (Hattrup and Gendler, 2008). However, MUC1 is cleaved during protein 
folding and the C-terminal domain (MUC1-C) is thought to serve as a signalling 
molecule which binds to kinases such as EGFR family members, as well as non-kinases 
such as beta-catenin (Hattrup and Gendler, 2008). Phosphorylation of tyrosines on 
MUC1-C can enhance its binding to beta-catenin, resulting in its loss from adherens 
junctions, enhanced beta-catenin nuclear activity and thus facilitating anchorage-
independent growth (Hattrup and Gendler, 2008).  
With respect to prostate cancer, MUC1 expression was associated with a more 
aggressive subset of the disease in a clustering analysis (Lapointe et al., 2004). 
Subsequent IHC on a tissue microarray of 225 primary prostate tumours revealed that 
increased MUC1 protein levels are associated with a shorter time to recurrence and are 
an independent predictor of cancer recurrence (Lapointe et al., 2004). It was later found 
to be expressed in the CSC-like side population of MCF7 breast cancer cells which 
showed other putative cancer stem cell characteristics such as being CD44+/CD24- 
(Engelmann et al., 2008). Castration-resistant cell lines DU145 and PC-3 express 
MUC1, whereas Androgen-sensitive LNCaP cells do not (Joshi et al., 2009). In MUC1-
expressing prostate cancer cell lines DU145 and PC3, inhibition of oligomerisation of 
MUC1-C results in necrotic cell death and reduces cell proliferation, while in xenografts 
this treatment strikingly induces complete regression of tumours (Joshi et al., 2009), 
suggesting that the molecular activity of MUC1-C is of potential clinical relevance. 
Furthermore, MUC1-C expression was found to suppress AR expression, as well as 
associating with AR and binding to the PSA promoter (Rajabi et al., 2012); 
overexpression of MUC1-C in LNCaP cells resulted in increased invasion, upregulation 
of vimentin and downregulation of E-cadherin that would be associated with an 
epithelial-mesenchymal transition, as well as androgen-independent growth (Rajabi et 
al., 2012). The current evidence suggests that MUC1-C is at least partly responsible for 
the association between MUC1 and aggressive prostate tumours. Given this 
information, I hypothesise that MUC1-C will be more highly expressed in patients that 
have experienced biochemical recurrence within 5 years than those that remain in 
remission. 
4.1.1.5 Nestin will be positively associated with biochemical recurrence 
The utility of the intermediate filament Nestin as a biomarker has been demonstrated 
before, in a dual IHC setting to identify microvascular proliferation in prostate tumours 
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alongside Ki-67 (Gravdal et al., 2009). High expression of Nestin in this context is 
associated with biochemical failure, recurrence and metastasis. Nestin expression alone 
maybe associated with high grade tumours and the presence of metastasis (Jani et al., 
2010). However, Nestin expression is generally also associated with the progression of 
tumours (Kleeberger et al., 2007a) and tumour cell lines (Pfeiffer et al., 2011) to an 
androgen-independent state. I hypothesise that Nestin will be more highly expressed in 
patients that go on to experience recurrence than in non-recurrent patients. 
4.1.1.6 ZSCAN4 will be expressed in malignant but not benign tissue, and will be 
positively associated with biochemical recurrence 
There is currently no clinical analysis on the expression of the pluripotency-related 
transcription factor, ZSCAN4, in tumours, to the author’s knowledge. However, it is 
known that ZSCAN4 has a very restricted expression pattern during development, being 
expressed at the 2-cell stage of mouse embryonic development and in embryonic stem 
cells (Falco et al., 2007), where it controls telomere elongation (Zalzman et al., 2010),  
the response to DNA double-strand breaks (Storm et al., 2014) and also long-term self-
renewal ability (Storm et al., 2014; Amano et al., 2013). Gollahon et al. have since 
proposed that ZSCAN4 performs similar telomere-related roles in cancer cell lines (Lee 
and Gollahon, 2014, 2015). In mouse embryonic stem cells, ZSCAN4 is regulated by 
PI3K signalling, and introduction of a specific inhibitor that targets the p110α catalytic 
isoform reduces ZSCAN4 expression by 80% (Storm et al., 2014). Given its highly-
restricted expression pattern, its relationship with pluripotency and its association with 
PI3K signalling, we hypothesise that ZSCAN4 will be exclusively expressed in 
malignant but not benign prostate epithelium, and that its expression will be greater in 
patients that go on to experience recurrence than in non-recurrent patients. 
4.1.1.7 RS1 will be positively associated with biochemical recurrence 
The secreted extracellular protein RS1 has not been studied with respect to cancer. 
Instead, its functions are largely studied in the eye, where it is involved in organising 
cells of the retina and mutations of this protein lead to X-linked Retinoschisis (Xu et al., 
2011). Prior data in this thesis suggested that it is overexpressed at the mRNA level in 
the prostate tumour tissue of patients that would later experience recurrence, and is 
amplified in metastatic and neuroendocrine prostate tumours (Chapter 3.2.2). Using this 
novel data, we predict that this trend will continue at the protein level, and RS1 will be 
more highly expressed in the primary tumour tissue of patients that have suffered 
recurrence. 
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4.1.2 Androgen Receptor expression and its association with prognosis 
Androgen Receptor (AR) signalling is a key driver in prostate cancer progression and its 
path to recurrence (Chapter 1.2.3), with mutations and amplifications of the AR gene 
frequently being acquired during the acquisition of castration resistant phenotypes, as 
well as the deregulation of AR-mediated transcriptional control through alterations in 
co-activators such as ERG. On the other hand, some putative prostate CSCs are AR-
negative, which would also be consistent with their enrichment upon androgen 
withdrawal (Chapter 1.3.4). Reducing or perturbing AR signalling can induce the 
expression of putative cancer stem cell markers such as MSI-1, Nanog, CD44 and 
SOX2 (Schroeder et al., 2014). Conversely, the expression of the stem cell marker GLI1 
in the androgen-dependent cell line LNCaP causes AR expression to be lost and an 
androgen-independent phenotype is acquired (Nadendla et al., 2011). In prostate 
tumours, AR staining assessed by IHC positively correlates with the expression of 
proliferative markers Ki-67 and phosphorylated histone H3 (Goltz et al., 2015), and the 
combination of these factors has greater prognostic relevance than the proliferative 
markers alone. Given that alterations of AR expression and activity are of importance to 
prostate cancer and to prostate cancer stem cells, measuring AR levels and correlating 
this expression to the expression of potential biomarkers in this chapter would help to 
further characterise the regulation of these markers and, potentially, add prognostic 
utility. 
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4.1.3 Aims 
Now that prospective biomarkers have been chosen and hypotheses assigned, their 
utility as biomarkers and their expression in prostate cancer must be addressed. This 
chapter will address the following aims: 
i. To determine the expression patterns and levels of potential biomarkers in 
benign and malignant prostate tissue, and the ability of biomarkers to distinguish 
between normal and disease states. 
ii. To identify if candidate biomarkers are differentially expressed between patients 
that will relapse within 5 years and those that will remain in remission. 
iii. To assess any associations between candidate biomarkers and androgen receptor 
expression status. 
4.2 Results 
4.2.1 Study Design 
4.2.1.1 Objectives 
The first step in testing was to design the study, produce a protocol and submit it for 
NHS ethical and Research & Development approval. In order to test the relationship 
between the chosen candidate markers and recurrence, study was designed to compare 
recurrent patients and patients that have not recurred after 5 years, in each of two 
treatment modalities: prostatectomy and hormone therapy. The primary endpoint of the 
study was biochemical (PSA) recurrence at 5 years from the date of diagnosis.  
4.2.1.2 Principle Inclusion/Exclusion Criteria 
To assess patients records for their suitability in the study, inclusion and exclusion 
criteria were established and published in a study protocol (Appendix 5) that was 
approved prior to consenting patients. 
To be included in the study, patients met all of these criteria: Older than 18 years of age 
at the time of diagnosis; Were male; Had a minimum of 5 years of retrospective follow-
up time (in the case of non-relapsing patients); Must have had no evidence of metastatic 
disease at the time of sample acquisition; Had stored clinical data, to include: age, 
Gleason grading, TNM staging, treatment modalities used, and time to biochemical 
recurrence; Must have signed written informed consent forms as detailed by the Human 
Tissue Act of 2004. 
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Patients were excluded from the study if they met any of these criteria: Patients have 
had previous or concurrent cancer(s) that is distinct in primary site of histology from the 
tumour being evaluated, with the exception of treated basal cell carcinomas or 
superficial bladder tumours; Patients have not been assessed for lymph node 
involvement or metastases; Patients treated with neoadjuvant hormone therapy or 
chemotherapy prior to their primary therapy; Insufficient amounts of archived tumour 
tissue available for the patient to conduct the assays; Patients that have withdrawn 
informed consent for use of their archived tissue at any time during the study. 
The inclusion criteria ensure that the obtained data is suitable for downstream analysis 
and that protocols are compliant with the Human Tissue Act 2004. Exclusion criteria 
exclude patients that would present with confounding variables or introduce additional 
sources of bias. For example, neoadjuvant therapies could alter the expression of 
biomarkers prior to biopsy and alter patient survival outcomes. Similarly, a co-existing 
tumour and/or prior cancer therapies have the potential to alter treatment choices, 
survival profiles and the biomarker expression profiles of the patients. 
4.2.1.3 Patient identification and consent 
Patient records were searched and suitable candidates identified byRUH clinicians Dr 
Mark Beresford and Dr Rebecca Bowen. Patients were contacted using a one-page 
study invitation letter (Appendix 6) inviting them to learn more about the study. They 
were then presented with patient information sheets (Appendix 7) briefly summarising 
the purposes of the study, and detailing any study risks, benefits and considerations for 
participants. Patients were then asked if they wished to sign a consent form (Appendix 
8) for inclusion in the study, where their anonymised clinical data and archived tissue 
samples would be taken for the subsequent analysis. Samples were stored securely on 
site at the Department of Biology and Biochemistry, University of Bath, under 
conditions that when the study ends, the remaining samples return to the Department of 
Pathology at the RUH or be destroyed. 
4.2.1.4 Sample size calculations, protocol and changes to objectives during study 
development 
Estimated required sample sizes were determined by power calculations performed by 
Dr Gordon Taylor (Reader in Medical Statistics, University of Bath) using estimated 
assay sensitivity and specificity values of 80% for distinguishing recurrent from non-
recurrent patients. It was estimated that 20 patients would be required for each test 
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group to resolve this level of difference. Therefore, initial plans were to collect 20 
patients for each of the relapsing and non-relapsing categories, for each of the two 
treatment groups, for a total of 80 patients. The initial aim was to construct a tissue 
microarray including single cores of tissue from each patient. However, due to the scant 
nature of tissue taken from prostate biopsies in this study, whole sections of each tissue 
specimen were evaluated by IHC rather than constructing a tissue microarray on which 
to conduct staining. 
NHS ethical and Research & Development approval was obtained (REC reference: 
13/WS/0153; IRAS project ID: 112241). Tissues were obtained from the primary 
tumour at or prior to time of treatment (either by biopsy or obtained from 
prostatectomy) or from transurethral resection of the prostate for symptomatic relief. 
Because of the small number of samples in the Bath Cohort, whole sections of each 
tissue specimen were evaluated by IHC rather than constructing a tissue microarray to 
conduct the staining on. 
Identifying suitable patient records was time-intensive, as patients diagnosed from the 
time period of 1997-2012, when the samples were initially taken, had their clinical 
information stored in a variety of different clinical databases, which made it difficult to 
compile. Due to the limited amount of samples that could be obtained within a 
practicable time frame, the pilot study was reduced in size to a total of 27 patients (10 
non-recurrent and 17 recurrent) with a mix of primary treatment modalities 
representative of prostate cancer patient intake at the RUH. The full structure of the 
Bath Cohort is described in the next section.  
4.2.2 Structure of the Bath Cohort 
The Bath patient cohort consisted of 27 patients diagnosed with prostate cancer at the 
Royal United Hospital, Bath, between 1997 and 2012. The cohort was retrospectively 
acquired, with samples obtained from a range of surgical or diagnostic procedures, 
depending on the individual treatment course of the patient. Samples were: diagnostic 
core needle biopsies (22/27, 81.5%); portions of the radical prostatectomy specimen 
(3/27, 11.1%); or chips from transurethral resection of the prostate (2/27, 7.4%). 
Available data included age, TNM staging, Gleason grading, PSA levels at diagnosis, 
and biochemical recurrence status at 5 years. A summary of these data is presented in 
Table 4.1. The majority of patients were treated with radiotherapy (10/27, 37.0%) or 
hormone therapy (6/27, 22.2%) as a primary modality, but other treatment options 
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included surveillance and radical prostatectomy. No patients in this cohort were 
assigned a primary Gleason grade of 5. Two patients (7.4%) presented with metastatic 
disease at the time of diagnosis. Subsequent therapies varied widely and overlapped in 
their usage, with the three most common treatment option being hormone therapy 
(18/27, 66.7%), Radiotherapy for palliative or non-palliative intent (6/27, 22.2%), and 




















Table 4.1: Clinical characteristics of patients from the Bath cohort. 
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Radiotherapy	 10 37.0 
Radical	prostatectomy	 3 11.1 
Hormone	therapy	 6 22.2 
Chemotherapy	 1 3.7 
Surveillance	 4 14.8 
Data	not	available	 3 11.1 
Subsequent	Therapies:	
  
Hormone	Therapy	(LHRHa,	MAB,	Antiandrogens)	 18 66.7 
Radiotherapy	(non-palliative)	 4 14.8 
Radiotherapy	(palliative)	 2 7.4 
High	Intensity	Focused	Ultrasound	 1 3.7 
Docetaxel	 3 11.1 
Carboplatin	+	Etoposide	 1 3.7 
Samarium	 1 3.7 
PSA	Nadir	(if	treated	during	follow-up):	   
<=0.5ng/mL	 16 59.3 
0.6-1.0ng/mL	 1 3.7 
>1.0ng/mL	 5 18.5 
N/A	 2 7.4 
Data	not	available	 3 11.1 
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4.2.3 Expression Patterns of Candidate Biomarkers in Human Prostate 
Tissue 
4.2.3.1 ALDH7A1 is expressed in the cytoplasm and nucleus of both benign and 
malignant prostate glands 
Expression of ALDH7A1 was first investigated by immunohistochemistry on prostate 
biopsies and radical prostatectomy blocks, and staining in histologically benign tissue 
was compared against carcinoma tissue. ALDH7A1 was expressed in both benign 
(Figure 4.1A and 4.1B) and malignant prostate epithelia with widely varying staining 
intensities in both groupings. Staining intensity ranged from strong (Figure 4.1C) to 
intermediate (Figure 4.1D), weak (Figure 4.1E) and negative (Figure 4.1F). As reported 
before in Immunohistochemical studies in mouse (Brocker et al., 2010), ALDH7A1 is 
expressed in the kidney and the human tissue also appears to serve as a positive control 
with cytoplasmic staining in the proximal renal tubules (Figure 4.1G). Negative 
controls, where no primary antibody was added, never resulted in a positive staining 
reaction (Figure 4.1H). 
Localisation was predominantly cytoplasmic in all cases, but nuclear staining of 
ALDH7A1 was also present at a low and variable frequency in both benign and 
malignant prostate epithelium (Figure 4.1, arrows). Cytoplasmic staining was generally 
uniform across prostate (Figure 4.1A) and carcinoma glands (Figure 4.1C), with 
expression in both the basal and luminal cell layers of benign prostate epithelium and no 
staining in stromal areas. There were no significant differences observed in the mean 
scored intensity of the cytoplasmic stain (p=0.6844) or in the frequency of epithelial 
cells staining nuclear positive between benign and malignant samples (p=0.5835) 
(Figure 4.2A and B respectively). There was no significant difference in ALDH7A1 
nuclear or cytoplasmic expression between low Gleason grade (≤3+4) or high Gleason 
grade (≥4+3) tumours (p=0.5969 and 0.8691 respectively). 
4.2.3.2 ALDH7A1 staining does not predict 5-year biochemical recurrence status 
In order to assess the potential influences of ALDH7A1 immunoreactivity at biopsy on 
patient outcome, patients were divided into two groups based on the time from 
diagnosis to biochemical recurrence. Neither mean ALDH7A1 nuclear H-Score 
(p=0.6661) nor mean cytoplasmic score (p=0.8763) were significantly different between 
5-year recurrent and non-recurrent patients, and there was comparable heterogeneity in 
ALDH7A1 staining among patients in both groups (Figure 4.2C and D). Therefore, the 
data is not consistent with a significant effect of ALDH7A1 expression on recurrence. 
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Figure 4.1: Anti-ALDH7A1 IHC in benign and malignant prostate tissue.  
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ALDH7A1 is expressed variably in the nuclei and cytoplasm of benign prostate 
epithelium, ranging from a moderate cytoplasmic intensity and some nuclear staining 
(A, arrows) to weak cytoplasmic staining intensity and no nuclear staining (B). 
ALDH7A1 expression in prostate cancer (PCa) also occurs in the nuclei and cytoplasm 
of the epithelial cells, but ranges in intensity from strongly staining (C) with many 
positive nuclei (arrows), to intermediate staining (D, arrows), weak cytoplasmic staining 
with occasional nuclear expression (E, arrows) and negative staining of both nuclear 
and cytoplasmic compartments (F). ALDH7A1 is expressed in renal tubular epithelium 
as a positive control (G), whilst a section of prostate tissue with no primary antibody 
added was used as a negative control and showed no staining (H). Antibody binding is 
visualised with DAB (brown) and nuclei are counterstained with haematoxylin (blue). 
Representative fields of view are shown at 20x magnification, with representative 
epithelial cells shown inset. Scale bars are labelled with their respective sizes. 
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Figure 4.2: Quantification of nuclear and cytoplasmic ALDH7A1 staining in 
benign prostate and prostate adenocarcinoma tissue. 
IHC staining of ALDH7A1 was quantified in the Bath cohort using the H-Score for 
nuclear stains and the cytoplasmic score. Boxplots of ALDH7A1 (A) nuclear H-score 
and (B) cytoplasmic score were compared between benign (n=5) and malignant prostate 
tissue (n=24), showing no significant difference between the two groupings. 5-year 
recurrence-free (n=7) and recurrent (n=15) patients were also compared for ALDH7A1 
(C) nuclear H-Score and (D) cytoplasmic score, where there was no significant 
difference. Data represent the mean of five random fields of view per sample. Two-
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4.2.3.4 Anti-SLC31A1 antibody shows intense background staining 
Four prostate biopsies from the newly available Bath Cohort were stained with an 
antibody recognising human SLC31A1 in order to optimise it, as it would be unlikely to 
give a good staining result in mouse tissue due to its species specificity. SLC31A1 
staining was intense in the glandular epithelium of prostate tumour tissue (Figure 4.3A), 
but also in the surrounding stromal area (Figure 4.3B), making interpretation of the stain 
difficult, even though no primary antibody controls turned out negative (Figure 4.3C). 
This could be explained by a ubiquitous expression of the transporter, but an important 
feature of any candidate biomarker is a clearly interpretable staining result. Because of 
this, the marker was excluded from further analysis. 
4.2.3.5 MUC1 C-terminal antibody shows no staining in prostate specimens 
To ensure that the anti-MUC1 C-terminal antibody was reliable for usage in a large 
number of precious prostate specimens, its staining was tested with four prostate tumour 
biopsies using staining protocols optimised by the antibody manufacturer. However, 
this antibody displayed negative (Figure 4.4A) or weak diffuse cytoplasmic staining 
(Figure 4.4B) of glandular prostate tumour epithelium that was deemed insufficient for 
downstream analysis. No primary antibody negative controls, as before, were clear of 
background staining (Figure 4.4C). In light of these data, MUC1-C was excluded from 
further analysis. 
  
Chapter 4: Assessment of Candidate Biomarkers in the Bath Cohort 
Benjamin Peter Sharpe - November 2016   169 
 
 
Figure 4.3: SLC31A1 expression in human prostate tumour tissue. 
(A) Prostate tumour tissue shows strong cytoplasmic staining of glandular epithelium 
(arrow) in addition to (B) widespread, diffuse moderate staining in surrounding stromal 
tissue. (C) Negative control is prostate tumour tissue with no primary antibodies added. 
All staining performed in a single experiment due to limited sample material. Scale bars 
– 100µm (A & B) or 50µm (C). 
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Figure 4.4: MUC1 C-terminal domain expression in human prostate tumour 
tissue. 
(A) Prostate tumour tissue shows no staining in glandular epithelium using an antibody 
recognising the C-terminal domain of MUC1. (B) Weak cytoplasmic staining of 
glandular epithelia in another prostate tumour specimen. (C) Negative control is 
prostate tumour tissue with no primary antibodies added. All staining is performed in a 
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4.2.3.6 Nestin is weakly expressed in both benign and malignant prostate tissue 
Anti-Nestin immunohistochemistry was conducted on benign and malignant prostate 
samples and scored by the cytoplasmic scoring method for intensity alone. A diffuse 
and uniform cytoplasmic staining reaction was observed in the glandular epithelium of 
both histologically benign and malignant samples. Cytoplasmic staining was either 
negative (Figure 4.5A) or weak (Figure 4.5B) in benign epithelium, with infrequent 
staining of stromal cells in close proximity to epithelium (Figure 4.5A, arrows). Prostate 
tumours displayed a range of staining intensities from intermediate (Figure 4.5C) to 
weak (Figure 4.5D) to negative (Figure 4.5E). Diffuse stromal staining was also 
observed in some malignant prostate samples, which was observed to be of similar 
intensity to the corresponding epithelial stain and so was not scored (Figure 4.5C and 
D). As expected, Nestin was detected in glomeruli within the kidney (Figure 4.5F) and 
in nerves within the prostate tumours (Figure 4.5G), serving as positive controls for the 
reliability of the immunostain. Negative (no primary antibody) controls verified that the 
background from the detection system was very low (Figure 4.5H). There was no 
significant difference in scored cytoplasmic staining intensity between benign and 
malignant prostate tissue (p=0.7988) (Figure 4.6A). There was also no association 
between Nestin expression and whether tumours were of a low Gleason grade (≤3+4) or 
a high Gleason grade (≥4+3) (p=0.6528). 
4.2.3.7 Nestin is not significantly associated with 5-year biochemical recurrence status 
Nestin immunoreactivity scores were compared between non-recurrent and recurrent 
patient groups using 5 years or more of biochemical recurrence-free survival as the cut-
off (Figure 4.6B). No significant difference was observed in Nestin expression between 
these two patient groups (p=0.7383), indicating no discernible association between 
Nestin epithelial staining and the response of patients over the first five years of 
treatment. 
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Figure 4.5: Anti-Nestin IHC in benign and malignant prostate tissue 
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Nestin staining is either negative (A) or weak (B) in the cytoplasm of benign prostate 
epithelium, although weak staining was observed in stromal cells in some cases (A, 
arrows). Malignant tissue (PCa) displays a similar cytoplasmic staining pattern ranging 
from intermediate (C) to weak (D) and negative (E) cytoplasmic staining in the tumour 
epithelium with some diffuse stromal staining. Glomeruli in the kidney (F) and nerves 
within the prostate tumours (G) were Nestin positive as expected, demonstrating the 
specificity of the antibody. Negative controls are free of background staining, as shown 
by the no primary antibody control in prostate carcinoma tissue (H). Antibody binding 
is visualised with DAB (brown) and nuclei are counterstained with haematoxylin (blue). 
Representative fields of view are shown at 20x magnification, with representative 
epithelial cells shown inset. Scale bar – 100µm. 
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Figure 4.6: Quantification of Nestin cytoplasmic staining in benign and malignant 
prostate tissue. 
IHC staining of Nestin was quantified in the Bath cohort using the Cytoplasmic Score. 
Boxplots of Nestin Cytoplasmic Score were compared between benign (n=5) and 
malignant prostate tissue (n=27) (A), showing no significant difference between the two 
groupings. 5-year recurrence-free (n=8) and recurrent (n=15) patients were also 
compared for Nestin Cytoplasmic Score (B), where there was no statistically significant 
difference. Data represent the mean of five random fields of view per sample. Two-
sample t-tests were conducted to determine statistical significance for each set of 
conditions. 
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4.2.3.8 BMI1 is expressed in the nuclei of benign and malignant prostate epithelia 
Histologically benign and malignant prostate tissue was subjected to anti-BMI1 
immunohistochemistry and scored by the nuclear H-score method. Consistent with 
previously published findings (van Leenders et al., 2007), BMI1 expression was 
observed in the nuclei of benign prostate tissue (Figure 4.7A), but was widely variable 
between patients with some having negative or low BMI1 H-scores (Figure 4.7B). 
Malignant prostate tissue also had widely varying frequencies of nuclear BMI1 staining, 
from strong widespread staining (Figure 4.7C and D, arrows) to weak and scattered 
staining (Figure 4.7E, arrows) and negative staining (Figure 4.7F, arrows). Negative 
control prostate tissue with no added primary antibodies came out as consistently 
negative (Figure 4.7G). There was no significant difference between the mean BMI1 
nuclear H-scores of benign and malignant prostate tissue samples, which were 20.3 and 
16.4 respectively (p=0.7178) (Figure 4.8A). Interestingly, paired benign and malignant 
samples from the same patient both showed high nuclear BMI1 H-Scores (Figure 4.7A 
and C respectively). However, there was no significant difference in BMI1 expression 
between low Gleason grade (≤3+4) or high Gleason grade (≥4+3) tumours (p=0.7369). 
4.2.3.9 BMI1 has lower mean expression in 5-year biochemical recurrent samples 
To assess the relationship of BMI1 with relapse in the Bath cohort, patients were again 
dichotomised on 5-year biochemical recurrence status. There was a trend towards lower 
BMI1 expression in patients that experienced biochemical recurrence before five years 
compared to those that had not (Figure 4.8B), with mean H-Scores of 18.7 and 12.1 
respectively, although this difference was not statistically significant (p=0.337). This 
observed trend, while not significant, warrants investigation with a larger cohort of 
patients. 
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Figure 4.7: Anti-BMI1 IHC in benign and malignant prostate tissue. 
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BMI1 is expressed heterogeneously in the nuclei of benign prostate epithelium, ranging 
from scattered, moderately to strongly-staining nuclei (A, arrows) to no nuclear staining 
(B). Similarly, prostate carcinoma (PCa) samples showed large variation of BMI1 
staining. The sample in (C) is the paired tumour region from the sample in (A), showing 
a similar expression pattern to the matched benign sample. Staining was also 
heterogeneous in carcinoma epithelium, showing a range from strong nuclear staining 
(D) to weak and scattered staining (E) and a complete absence of nuclear stain (F). 
Negative controls are free of background staining, as shown by the no primary antibody 
control in prostate carcinoma tissue (G). Antibody binding is visualised with DAB 
(brown) and nuclei are counterstained with haematoxylin (blue). Representative fields 
of view are shown at 20x magnification, with representative epithelial cells shown inset. 
Scale bar – 100µm. 
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Figure 4.8: Quantification of BMI1 nuclear staining in benign prostate and 
prostate adenocarcinoma tissue. 
IHC staining of BMI1 was quantified in the Bath cohort using the H-Score for nuclear 
stains. Boxplots of BMI1 nuclear H-score were compared between benign (n=5) and 
malignant prostate tissue (n=24) (A), showing no significant difference between the two 
groupings. 5-year recurrence-free (n=7) and recurrent patients (n=15) were also 
compared for BMI1 nuclear H-Score (B), where there was no statistically significant 
difference, although there was a trend towards decreased BMI1 expression in recurrent 
tumours. Data represent the mean of five random fields of view per sample. Two-
sample t-tests were conducted to determine statistical significance for each set of 
conditions. 
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4.2.3.10 ZSCAN4 is overexpressed in a subset of prostate carcinomas 
To continue to characterise the expression of stem cell markers in prostate carcinoma 
and their association with outcome, expression of the stem cell-related transcription 
factor ZSCAN4 was investigated by IHC. Since ZSCAN4 expression has not been 
reported in the prostate before, a positive control was required. ZSCAN4 expression is 
generally thought to be under tight spatiotemporal regulation during development, being 
present almost exclusively at the 2-cell stage of embryonic development (Falco et al., 
2007) and expressed in embryonic stem cells (Storm et al., 2014). Therefore, positive 
control tissue for the IHC experiments would be difficult to obtain. Having previously 
identified that ZSCAN4 was transcribed at an mRNA level in placental tissue (Chapter 
3.2.3.4), we hypothesised that human placental tissue would express ZSCAN4 protein 
and could serve as a positive control tissue. Normal human placenta was stained 
alongside benign and malignant prostate samples, and the Bath cohort was scored using 
the H-Score for nuclear antigens. 
When stained with an anti-ZSCAN4 antibody, normal prostate tissue either expressed 
ZSCAN4 at low frequencies in the nuclei of glandular epithelium, either without diffuse 
glandular cytoplasmic staining (Figure 4.9A) or in its presence (Figure 4.9B). Many 
prostate carcinoma samples also share this pattern, displaying either rare ZSCAN4+ 
nuclei (Figure 4.9E) or none at all (Figure 4.9F). Glandular cytoplasmic staining of 
ZSCAN4 tended to be diffuse and weak to moderate intensity in tumour epithelium, and 
was not scored for further analysis. However, a subset of prostate carcinoma samples 
reacts more strongly positive for ZSCAN4 (Figure 4.9C and D, arrows), with 7 of 27 
evaluable tumours (25.9%) having an H-score>=15 (Figure 4.10A). On average, 
malignant prostate tissues displayed significantly higher nuclear H-Scores compared to 
benign samples, with mean H-Scores of 11.1 and 4.1 respectively (p=0.0342) (Figure 
4.10A). Although only a small proportion of the patients had an elevated burden of 
ZSCAN4-expressing tumour cells, this finding suggests that elevated ZSCAN4 
expression is a tumour-specific phenomenon but is restricted to a subset of cases. There 
was no significant difference in ZSCAN4 expression between low Gleason grade 
(≤3+4) and high Gleason grade (≥4+3) tumours (p=0.5354).  
Consistent with previous bioinformatics analyses at the mRNA level in Chapter 3, anti-
ZSCAN4 antibody signal was detected in the nuclei of enlarged cells of the decidual 
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layer of the placenta (Figure 4.9G, arrows). A weak to moderate, diffuse, cytoplasmic 
staining reaction was also observed in this area. Positive staining in the expected 
compartment in the placenta provided extra confidence in the prostate 
immunohistochemistry. Importantly, no primary antibody negative controls in the 
placenta suggest that the detection method does not produce any background staining 
reactions in this tissue (Figure 4.9H). 
4.2.3.11 ZSCAN4 is not significantly associated with 5-year biochemical recurrence 
status 
The rate of disease recurrence following primary therapy is approximately 15-30% 
(Pound et al., 1999; Stephenson et al., 2006) and the frequency of evaluable tumours 
with ZSCAN4-overexpressing phenotypes (H-score>=15) falls within this range, at 
25.9%. We used the clinical metadata to determine whether there was an association 
between ZSCAN4 staining and disease recurrence. As before, data were dichotomised 
based on a cut-off of 5 years from the date of diagnosis to biochemical recurrence. 
There was no significant difference between the scored levels of ZSCAN4 reactivity in 
recurrent patient tissues compared to non-recurrent (p=0.636) (Figure 4.10B). While 4 
of 17 patients (23.5%) in the recurrent group had a high burden of ZSCAN4-positive 
tumour cells (H-Score >= 15), this was also the case for 3 of 10 non-recurrent patients 
(30%). Taken together, the data do not suggest that there is an association between 
ZSCAN4 reactivity and patient outcome within the first five years of treatment. 
4.2.3.12 Assessment of ZSCAN4 nuclear staining is satisfactorily reproducible between 
two observers 
To further validate the reproducibility of the H-Scoring system, we compared the scores 
observed and calculated by the author, BS, to those of a certified pathologist, JRM, for a 
subset consisting of 16 samples: 2 benign adjacent tissues and 14 prostate tumours. 
Inter-observer reproducibility was assessed by comparing paired scores for each image 
from a total of 77 images, and calculating the Pearson’s product-moment correlation 
coefficient for the scores of both independent observers. Scoring between BS and JRM 
had a moderately strong correlation of 0.805 (95% CI: 0.709-0.872), which was 
statistically significant (two-tailed, p<2.2e-16). This correlation suggests that agreement 
between observers was good, as shown in Figure 4.10C, but scores became more 
variable as the H-Score increased, suggesting a higher inter-observer error rate in 
judging stronger intensities and/or higher proportions of stained cells (Figure 4.10D). 
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Overall, the good correlation suggests that the scoring procedure for assessing nuclear 
ZSCAN4 levels was suitably reproducible between observers. 
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Figure 4.9: Anti-ZSCAN4 IHC in benign and malignant prostate tissue. 
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ZSCAN4 nuclear staining is low or negative in benign prostate tissue (A), with uniform 
diffuse staining of epithelial cytoplasm occasionally observed (B). Conversely, 
proportions of ZSCAN4+ nuclei varied widely in malignant samples, with a subset of 
prostate carcinoma samples (PCa) displaying a high burden of ZSCAN4+ epithelial 
nuclei (C, arrows). Malignant samples with intermediate (D, arrows), low (E, arrows) or 
negative nuclear staining (F) were observed.  Placenta serves as a positive control for 
ZSCAN4 staining, showing ZSCAN4+ nuclei in the decidual layer (G, arrows). 
Negative controls are free of background staining, as shown by the no primary antibody 
control in placental tissue (H). Antibody binding is visualised with DAB (brown) and 
nuclei are counterstained with haematoxylin (blue). Representative fields of view are 
shown at 20x magnification, with representative epithelial cells shown inset and 
representative positive cells indicated with arrows. Scale bar – 100µm. 
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Figure 4.10: Quantification and Reproducibility assessment of ZSCAN4 nuclear 
staining. 
IHC staining of ZSCAN4 was quantified in the Bath cohort using the H-Score for 
nuclear stains. Boxplots of ZSCAN4 H-Scores were compared between benign (n=5) 
and malignant prostate tissue (n=27) (A), showing significantly higher ZSCAN4 H-
Scores in malignant tissue (p=0.0342). 5-year recurrence-free (n=8) and recurrent 
(n=17) patients were also compared for ZSCAN4 nuclear H-Scores (B), where there 
was no statistically significant difference. Data represent the mean of five random fields 
of view per sample. Two-sample t-tests were conducted to determine statistical 
significance for each set of conditions in A and B. A subset of 16 samples were scored 
by both the author (BS) and a certified pathologist (JRM) and the resulting paired scores 
were compared in (C); There was a statistically significant, moderately strong Pearson’s 
correlation between the paired scores of both observers (R=0.805, p<2.2e-16). The 
differences and means of paired H-Score values are visualised in a Bland-Altman plot 
(D), showing that most paired values lie ± two standard deviations from the mean 
(dashed lines).  
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4.2.3.13 RS1 is expressed in both benign and malignant prostate tissue 
We previously established RS1 as being a candidate differentially expressed gene 
between relapsing and non-relapsing prostate carcinoma using differential expression 
analysis of archival prostate tumour cDNA microarray data (Chapter 3.2.2). To test this 
hypothesis in a cohort of patients, we performed immunohistochemistry with an anti-
RS1 antibody. As RS1 is a secreted protein expressed in the retina and has not been 
studied in any other tissue type, a positive control tissue was not feasible and its 
expression was studied in benign and malignant prostate only. In benign tissue, anti-
RS1 antibody signal localised to the cytoplasm of glandular epithelial cells, with 
heterogeneous staining of epithelial nuclei, and considerable heterogeneity between 
cases. Nuclear staining was unexpected given the role of RS1 as a secreted protein. 
Within normal cases, 1/5 tumours strongly stained for nuclear RS1 and 2/5 showed 
moderate staining for cytoplasmic RS1 (Figure 4.11A). The remaining tumours had 
weak to negative RS1 staining in both the nucleus and cytoplasm (Figure 4.11B). 
Within the malignant prostate, nuclear staining ranged from intense and heterogeneous 
(Figure 4.11C and D), to weak and infrequent (Figure 4.11E) and negative (Figure 
4.11F). Cytoplasmic staining equally ranged from intermediate (Figure 4.11C) to weak 
(Figure 4.11D) and negative (Figure 4.9E and F). Negative controls confirmed that the 
detection protocol was background-free (Figure 4.11G).  
RS1 staining was scored using the nuclear H-score and cytoplasmic score for intensity 
only. Interestingly, paired benign and malignant tissue from the same patient had high 
levels of RS1 nuclear reactivity (Figure 4.11 A and C respectively), with a higher H-
Score of 126.6 in the benign tissue and 51.5 in malignant tissue respectively. However, 
overall there was no significant difference in RS1 nuclear (Figure 4.12A) or 
cytoplasmic reactivity scores (Figure 4.12B) between benign and malignant prostate 
tissue (p=0.5327 and 0.7006 respectively). There was also no significant difference 
between low Gleason grade (≤3+4) and high Gleason grade (≥4+3) tumours with 
respect to RS1 nuclear or cytoplasmic expression (p=0.8203 and 1 respectively) 
4.2.3.14 RS1 has higher mean expression in 5-year biochemical recurrent samples 
RS1 staining was assessed at both the nuclear and cytoplasmic levels, and compared 
between recurrent and recurrence-free patients after 5 years of retrospective follow-up 
as before. There was no significant difference between nuclear H-Scores in recurrent 
and non-recurrent patient groupings (Figure 4.12C) (p=0.4954). There appeared to be a 
trend towards increased RS1 cytoplasmic scores in recurrent prostate tissue (Figure 
Chapter 4: Assessment of Candidate Biomarkers in the Bath Cohort 
Benjamin Peter Sharpe - November 2016   187 
4.12D), although this was not significant (p=0.4506). This appears consistent with 
findings in Chapter 3, which identified increased RS1 mRNA expression in patients 
with subsequent recurrence. The trends of increasing RS1 cytoplasmic reactivity would 
benefit from further investigation in a larger cohort of patients, especially in light of 
other findings from Chapter 3 supporting the hypothesis, such as: increased mRNA 
expression in prostate tumours of recurrent patients on microarray analysis; and the 
finding of RS1 amplification in 20-30% of patients with metastatic and castration-
resistant prostate carcinoma. 
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Figure 4.11: Anti-RS1 IHC in benign and malignant prostate tissue. 
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RS1 localised to the nucleus and cytoplasm of benign prostate tissue, with variation in 
both staining patterns ranging from frequent but heterogeneous positive nuclei and 
intermediate cytoplasmic staining (A) to no nuclear staining and no cytoplasmic 
staining (B). Malignant prostate samples (PCa) display a similar expression pattern to 
benign samples, with large variation in both the cytoplasmic and nuclear stain of 
epithelial cells: intermediate intensity cytoplasmic staining and intermediate frequency 
nuclear staining (C); paired tumour sample from sample in A, with weak cytoplasmic 
staining and similarly high frequency nuclear staining (D); weak cytoplasmic staining 
and low frequency nuclear staining (E); negative staining for both compartments (F). 
Negative controls are free of background staining, as shown by the no primary antibody 
control in prostate carcinoma tissue (G). Antibody binding is visualised with DAB 
(brown) and nuclei are counterstained with haematoxylin (blue). Representative fields 
of view are shown at 20x magnification, with representative epithelial cells shown inset 
and representative positive cells indicated with arrows. Scale bar – 100µm. 
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Figure 4.12: Quantification of RS1 nuclear and cytoplasmic staining in benign and 
malignant prostate tissue.  
Staining was quantified using the H-Score and Cytoplasmic score. Boxplots of RS1 (A) 
nuclear H-Score and (B) Cytoplasmic score compared between benign (n=5) and 
malignant prostate tissue (n=23), showing no difference in RS1 levels between the two 
groupings. 5-year recurrence-free (n=6) and recurrent patients (n=15) were also 
compared for RS1 (C) nuclear H-Score and (D) Cytoplasmic score, where there was no 
significant difference, although a trend towards increased RS1 cytoplasmic staining was 
observed in recurrent patients. Data represent the mean of five random fields of view 
per sample. Two-sample t-tests were conducted to determine statistical significance for 
each pair of conditions. 
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4.2.4 Analysis of AR Expression in Prostate Tumours 
Expression of the AR has been shown to be more heterogeneous in prostate tumours 
than in benign prostate epithelium (Barboro et al., 2014), and studies suggest that AR 
expression (Donovan et al., 2008) and its downstream targets (Hendriksen et al., 2006) 
could be an important prognostic factor for patients with clinically localised prostate 
cancer. AR expression is positively correlated with other poor prognostic factors, such 
as tumour stage and Ki-67 labelling index for proliferating cells (Goltz et al., 2015). 
Therefore, a potential biomarker which displays a correlation with androgen receptor 
status may itself be subject to regulation by androgen signalling, and could also vary 
due to subsequent anti-androgen therapies. To assess whether selected candidate 
biomarkers co-varied with AR expression in the Bath cohort, immunohistochemistry 
was performed using a monoclonal anti-AR antibody. AR expression was analysed 
independently with respect to clinical data, before subsequent analysis with the 
candidate biomarkers. 
4.2.4.1 AR expression is heterogeneous, especially in prostate carcinoma 
AR expression data was obtainable 29 of 35 specimens (82.9%), including 5 adjacent 
benign prostate biopsies. Insufficient material was the only grounds for specimen 
exclusion. AR signal was predominantly localised to epithelial nuclei in both benign 
(Figure 4.13A and B, arrows) and malignant prostate tissue (Figure 4.13C-E). AR 
expression was heterogeneous even in benign tissue, with a salt-and-pepper pattern of 
nuclear AR staining in the luminal prostate epithelium (Figure 4.13A). Interestingly, 2 
of 5 benign samples had an H-Score of less than 10, indicating a very low proportion of 
cells expressing detectible AR protein (Figure 4.13B). Malignant prostate samples also 
tended to display this heterogeneous expression of AR, but appeared to have greater 
variation in the frequency and intensity levels, as represented by a greater range of H-
Score values (Figure 4.14A). Malignant expression patterns varied considerably, from 
widespread moderate intensity nuclear staining (Figure 4.13C) to heterogeneous 
moderate nuclear staining (Figure 4.13D); weak and heterogeneous nuclear staining 
(Figure 4.13E); and an absence of nuclear AR staining (Figure 4.13F). No primary 
antibody controls indicated that the detection system is background-free (Figure 4.13G). 
On average, benign tissues displayed a trend towards greater AR H-Scores than 
malignant tissues (29.0 and 23.4 respectively) (Figure 4.14A), but this was not 
statistically significant (p=0.6887) and would require more benign samples to test 
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conclusively. Additionally, there was no significant difference in AR expression 
between low Gleason grade (≤3+4) and high Gleason grade (≥4+3) tumours (p=0.1936). 
4.2.4.2 AR expression is not associated with 5-year biochemical relapse status 
Following comparisons between benign and malignant tissue, AR expression was 
compared between recurrent and non-recurrent patient groups. 22 patients with 
sufficient follow-up information were assessed for AR status, including 16 recurrent 
and 6 non-recurrent patients after 5 years of retrospective follow-up (Figure 4.14B). 
There was a trend towards reduced mean H-Score of AR in recurrent patient tissues 
(29.0 recurrent and 23.4 non-recurrent), but this was not statistically significant 
(p=0.6887). 
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Figure 4.13: Anti-AR IHC in benign and malignant prostate tissue. 
AR is expressed heterogeneously in the luminal epithelial nuclei in benign tissue (A, 
arrows), although 2/5 benign prostate samples have a very low frequency of AR 
staining (B). Prostate tumours (PCa) also show heterogeneous but predominantly 
nuclear staining, ranging in frequency from widespread (C) to mixed (D) to weak, low 
frequency staining (E) and complete absence of AR staining (F). Negative controls are 
free of background staining, as shown by the no primary antibody control in prostate 
carcinoma tissue (G). Antibody binding is visualised with DAB (brown) and nuclei are 
counterstained with haematoxylin (blue). Representative fields of view are shown at 
20x magnification, with representative epithelial cells shown inset and representative 
positive nuclei indicated with arrows. 
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Figure 4.14: Quantification of nuclear AR staining in benign and malignant 
prostate tissue by IHC. 
AR staining was quantified using the H-Score for nuclear staining. Boxplots comparing 
AR nuclear H-Scores in (A) benign (n=5) and malignant (n=24) tissue samples; and (B) 
5-year recurrence-free (n=6) and recurrent (n=16) samples. There was no significant 
difference between AR H-Scores in benign and malignant tissue, although a trend 
towards decreased AR cytoplasmic staining was observed in recurrent patients. Data 
represent the mean of five random fields of view per sample. Two-sample t-tests were 
conducted to determine statistical significance for each pair of conditions. 
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4.2.4.3 Assessment of correlation between AR and candidate biomarker expression 
Having established the expression patterns of AR in malignant prostate tissue, the 
nuclear H-Scores were tested for correlation with the scores from the candidate protein 
biomarkers and pre-existing clinical biomarkers such as age and PSA levels at diagnosis 
(Table 4.3). Due to the lack of patients in the N1 and M1 (N=2/27 each), and the wide 
dispersal of a small number of samples over a wide range of T categories, we were 
unable to assess any relationships between biomarker expression and TNM staging in 
this small cohort. 
Among the Bath cohort, nuclear AR expression was not associated with age or PSA 
levels at diagnosis. The only candidate biomarker that was significantly correlated with 
AR expression was RS1, and only the glandular cytoplasmic stain was significant with a 
moderately negative correlation of -0.454 (p=0.04459) (Figure 4.15A). Interestingly, 
nuclear expression of RS1 had no significant correlation with AR expression (Figure 
4.15B). A summary of the correlations between AR and potential biomarkers is 
provided in Table 4.4. 
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-0.454 -0.746 -0.014 0.045	
BMI1	H-Score	 0.339 -0.108 0.672 0.133	
Age	at	Diagnosis	 0.326 -0.111 0.657 0.139	
ALDH7A1	H-Score	 0.346 -0.144 0.700 0.159	
PCSP	Total	Area	 0.256 -0.198 0.619 0.263	
PCSP	Cell	Number	 -0.211 -0.589 0.243 0.359	
PSA	at	Diagnosis	 -0.190 -0.603 0.304 0.451	
RS1	H-Score	 0.162 -0.315 0.574 0.507	
SDC1	Glandular	
Cytoplasmic	Score	
0.149 -0.302 0.546 0.518	
ALDH7A1	Glandular	
Cytoplasmic	Score	
0.154 -0.338 0.579 0.543	
ZSCAN4	H-Score	 0.109 -0.351 0.526 0.648	
Nestin	Glandular	
Cytoplasmic	Score	
-0.077 -0.503 0.378 0.747	
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Figure 4.15: Plots of RS1 cytoplasmic and nuclear scores against paired AR 
nuclear H-Scores.  
AR nuclear H-Scores were plotted against RS1 Cytoplasmic Scores and nuclear H-
Scores. RS1 glandular Cytoplasmic Scores displayed a significant and moderately 
negative correlation with AR H-Scores (R=-0.454, p=0.04459) (A), whereas RS-1 
nuclear H-Scores showed no statistically significant correlation with AR expression (B). 
n=26 samples (21 malignant, 5 benign). 
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ALDH7A1:	    
Nuclear	 No trend No trend None 
Cytoplasmic	 No trend No trend None 
SLC31A1:	 Excluded from analysis due to strong ubiquitous staining 
MUC1-C:	 Excluded from analysis due to no detectable staining 
Nestin:	    
Cytoplasmic	 No trend No trend None 
BMI1:	    
Nuclear	 No trend Lower in recurrent 
(not significant) 
None 
ZSCAN4:	    
Nuclear	 Higher in subset of 
malignant 
(p=0.0342) 
No trend None 
RS1:	    
Nuclear	 No trend No trend None 
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4.3 Discussion 
In the current chapter, the expression of candidate biomarkers in benign and malignant 
prostate tissue has been addressed, and recurrent and non-recurrent prostate tumours 
have been compared for expression of these markers. A summary of the experimental 
findings of this chapter is presented in Table 4.4. BMI1 was found to be expressed in 
prostate tumours but was found to be reduced in recurrent tumours, although this was 
not significant and requires a larger sample size to verify. The stem cell marker 
ZSCAN4 was found to be expressed in a subset of prostate tumours. Additionally, RS1 
expression in the cytoplasm appears to be correlated with androgen receptor status in 
the primary tissue of patients with prostate carcinoma.  
4.3.1 ALDH7A1 is not associated with biochemical recurrence but is found 
in the nucleus of benign and malignant prostate tissue 
Studies on ALDH7A1 have focused on its role in invasiveness and metastasis, with 
functional assays being conducted in vitro and in xenograft models in vivo (van den 
Hoogen et al., 2011). It is expressed in both human prostate tumours and matched bone 
metastases (van den Hoogen et al., 2010). However, the results of this chapter suggest 
that ALDH7A1 expression is unable to distinguish between patients that will later 
relapse and those that will remain in remission. It is possible that it plays a role in later 
stages of tumour progression, such as invasion and metastasis, and therefore is not 
prognostically relevant in primary tissue at the time of therapy.  
Interestingly, van den Hoogen et al. (2010) only reported staining at the cytoplasmic 
level in their IHC studies. I report both cytoplasmic and nuclear staining in benign and 
malignant prostate tissue. Nuclear localisation of ALDH7A1 has been observed before 
in mouse and human tissues by immunohistochemistry, and both nuclear export and 
nuclear localisation signals have been found in the human protein (Brocker et al., 2010). 
The function of nuclear ALDH7A1 is currently unknown and could be a subject for 
future investigation. 
4.3.2 SLC31A1 shows strong ubiquitous IHC staining and was excluded 
SLC31A1 was identified as overexpressed in recurrent patients in a microarray analysis 
in chapter 3. During optimisation, SLC31A1 was excluded from the panel of potential 
biomarkers due to the presence of a strong background staining in the stroma and a 
ubiquitous and strong staining in the prostate epithelium, both of which would hinder 
Prostate Cancer Stem Cells: Potential New Biomarkers 
202  Benjamin Peter Sharpe - November 2016 
interpretation of the biomarker by IHC. This strong and ubiquitous staining pattern in 
both prostate epithelium and stroma could reflect a requirement for copper homeostasis 
in all cells of the prostate gland (Jong and McKeage, 2014). Conversely, one study 
conducted by Holzer et al. suggests that the protein is not expressed at the protein level 
in benign prostate tissue or in prostate carcinoma (Holzer et al., 2006), although this is 
unconfirmed due to reports of SLC31A1 expression in VCaP and LNCaP prostate 
cancer cell lines, and the dependence of benign prostate and prostate cancer cell lines on 
copper (Safi et al., 2014). Expression of SLC31A1 was identified at the mRNA level 
during this thesis, but this does not necessarily translate into upregulated protein levels 
and it is possible that the antibody staining results are a non-specific background 
staining effect. However, this biomarker may still be of use with further optimisation of 
IHC conditions and testing in more samples, and another antibody raised to this protein 
has the potential to provide more satisfactory staining with less background. Further 
investigation of SLC31A1 expression in prostate cancer would ideally require IHC 
staining with another antibody to confirm the reliability of these results. 
4.3.3 MUC1-C is not detected by IHC in prostate cancer samples 
Initial optimisation of the MUC1-C antibody for staining indicated that it produced no 
IHC signal on any of the four tissue samples studied. While this does not exclude the 
potential for its expression in a subset of carcinoma samples, this led to its exclusion 
from the panel of potential biomarkers, particularly due to the lack of defined positive 
control material to confirm staining specificity. There is also the possibility of MUC1-C 
expression being acquired only after therapy, rather than being expressed in a pre-
existing prostate cancer cell population. Androgen-independent prostate cancer cell 
lines that lack the androgen receptor, such as PC-3, appear to express MUC1-C, 
whereas androgen-sensitive cell lines which express AR do not (Joshi et al., 2009). 
MUC1-C expression in AR-expressing cell line LNCaP causes AR expression to be 
reduced and confers the ability to grow in the presence of the AR antagonist 
bicalutamide (Rajabi et al., 2012). However, prostate cancer cell lines are nearly all 
derived from metastatic lesions, and the expression of MUC1-C has yet to be confirmed 
in human prostate tumours. Staining a tissue microarray containing both primary 
tumour samples and metastatic and castration-resistant prostate carcinoma samples 
would help to confirm the relevance of previous in vitro studies to a patient setting. 
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4.3.4 Nestin is not associated with biochemical recurrence 
Nestin was expressed weakly in the glandular compartment of benign prostate epithelia, 
and expression was detected in the same compartment in malignant prostate epithelia 
with intensities ranging from intermediate to negative. Kleeberger et al. found that 
Nestin-positive endothelial cells were scattered in hormone-naïve prostate epithelia, but 
reported no Nestin staining in tumour cells of hormone-naïve tumours, whereas Nestin-
positive tumour cells were widespread in castration-resistant prostate tumours (2007b). 
We did not observe a staining pattern that would be consistent with endothelial cells as 
reported by Kleeberger, although we identified scattered stromal cells which 
infrequently stained weakly with anti-Nestin antibody and are of unconfirmed identity. 
Additionally, we found no association between staining levels and 5-year recurrence 
status. It might be that Nestin expression is induced as a result of hormone therapy, a 
finding that is supported by several groups (Kleeberger et al., 2007b; Pfeiffer et al., 
2011). Indeed, another study found that Nestin expression had no association with 
clinical variables on its own, but rather only when combined with proliferative marker 
Ki-67 (Gravdal et al., 2009). As the proliferation status of this cohort has not been 
determined, the findings of Gravdal et al. cannot be verified. Additionally, the Bath 
cohort did not include paired post-treatment biopsies, which would be required for 
verifying the hypothesis of post-treatment Nestin expression. Overall, the data in this 
chapter cannot support a role for Nestin in the prognostication of prostate carcinoma at 
point of primary therapy. 
4.3.5 BMI1 may be negatively associated with biochemical recurrence 
Others have reported the utility of BMI1 as a serum prognostic biomarker which 
positively correlates with tumour stage and PSA levels (Siddique et al., 2013c). This 
same group also demonstrated a stromal staining of BMI1 by IHC, which I do not 
observe in this study. Antibodies have individual specificities and sensitivities to their 
target antigens which also depend on the immunohistochemistry protocol employed, 
making the comparison of studies performed with different antibodies to the same 
protein difficult. Although the antibody used by Siddique et al. was from the same 
manufacturer, it was not possible to confirm whether the same antibody clone was used 
in the current work. However, consistent with a previous study (van Leenders et al., 
2007), BMI1 localised to epithelial nuclei in both benign and malignant prostate tissue, 
which helps to verify our observed staining patterns. 
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Van Leenders (2007) found that strong epithelial BMI1 staining was positively 
associated with biochemical recurrence. We have found that levels of nuclear BMI1 
staining have no significant association with biochemical recurrence (Figure 4.6B). 
Conversely, the findings show a trend towards decreased BMI1 nuclear staining in 
recurrent patients compared to non-recurrent controls. There is evidence that BMI1 
influences the progression and treatment response of prostate cancer. Reducing BMI1 
levels in prostate cancer cell lines sensitises them to Docetaxel treatment (Crea et al., 
2011a; Siddique et al., 2013a), possibly due to reduced antioxidant production (Crea et 
al., 2011a) and the suppression of TCF4-driven expression of the anti-apoptotic protein 
BCL2 (Siddique et al., 2013a). BMI1 is known to act as part of the PRC1 polycomb 
repressor complex to repress cyclin-dependent kinase inhibitors p21 and p16Ink4a in 
prostate cancer cell lines (Cao et al., 2011), which would promote cell cycle 
progression. The PRC2 polycomb repressor complex epigenetically silences 
microRNAs which are responsible for downregulation of PRC1 complex members, 
including BMI1, in the DU145 prostate cancer cell line (Cao et al., 2011). Expression of 
these microRNAs reduces cell proliferation, cell invasion and tumoursphere formation 
in DU145 cells in vitro, as well as reducing the expression of stem cell markers KLF4, 
SOX2 and c-Myc, suggesting that PRC1 activity is important for these phenotypes (Cao 
et al., 2011). Indeed, suppressing the activity of the PRC2 complex by inhibition of its 
histone methyltransferase EZH2 reduces tumorigenicity and invasiveness in vitro and in 
mouse xenograft models (Crea et al., 2011b). These lines of evidence suggest that the 
protein would contribute towards treatment resistance and tumour progression. 
Therefore, our results were surprising and a larger cohort of patients would be required 
to validate the observation of decreased BMI1 staining in the primary tissue of recurrent 
patients. 
4.3.6 ZSCAN4 is expressed in a subset of prostate carcinomas, but is not 
associated with biochemical recurrence 
ZSCAN4 was found to be expressed at very low levels in benign epithelium, with a 
subset of prostate carcinomas (25.9%) showing elevated expression which was 
predominantly nuclear (Figure 4.7 and 4.8A). Currently, there is very little known about 
the molecular function of ZSCAN4 and still less is known about it in tumour cells, with 
only two studies from Gollahon and Lee (2014, 2015) suggesting that it interacts 
indirectly with TRF1 to promote telomerase-independent elongation of telomeres in 
several cancer cell lines. This is the first study to demonstrate the expression of 
Chapter 4: Assessment of Candidate Biomarkers in the Bath Cohort 
Benjamin Peter Sharpe - November 2016   205 
ZSCAN4 in prostate cancer, and the fact that it is only present in a subset of prostate 
carcinomas suggests that it is fulfilling an unknown function in a subpopulation of 
patient tumours. 
Given its previously demonstrated roles in promoting telomere elongation and self-
renewal potential of embryonic stem cells (Storm et al., 2014), it is possible that it is 
fulfilling the same functions in tumour cells. Telomere elongation would be more highly 
required in proliferating cell populations, and it would be worth investigating whether 
the proliferative index of tumours correlates with ZSCAN4 status. Although we could 
not demonstrate a relationship between ZSCAN4 expression and recurrence (Figure 
4.8B), it is possible that ZSCAN4 is performing other interesting biological functions 
within tumour tissue that have yet to be investigated. For example, in mouse embryonic 
stem cells, ZSCAN4 expression is positively regulated by the p110α isoform of PI3K 
(Storm et al., 2014), and PI3K-Akt signalling is known to be deregulated by deletions of 
PTEN in prostate cancer. The PTEN deletion status of the Bath Cohort has not been 
identified, and is another possible avenue for further characterisation of ZSCAN4’s role 
in prostate cancer. However, this protein would need to be functionally characterised in 
primary prostate tumour cells or cancer cell lines to build on the data acquired here. 
4.3.7 Cytoplasmic RS1 is expressed in benign and malignant prostate tissue 
and may be positively associated with biochemical recurrence 
The secreted discoidin domain containing protein RS1 was found to be expressed in 
both benign prostate tissue and prostate carcinoma, with localisation to both the 
glandular cytoplasm and heterogeneously within nuclei (Figure 4.9 and 4.10A and B). 
This is unexpected given its extracellular localisation within the retina of mice (Ou et 
al., 2015), where its functional role is believed to lie in cell adhesion, possibly mediated 
through its discoidin domain (Wu et al., 2005). Interrogation of the protein sequence in 
the Uniprot database (Uniprot identifier: O15537) suggests that the RS1 protein has a 
signal sequence, meaning that it is destined for secretion. Therefore, it is unlikely that 
the nuclear staining reaction of the anti-RS1 antibody is a specific one. 
Mutations in the protein cause splitting of the retinal layers, a disease known as X-
linked retinoschisis after which the protein is named (Wu et al., 2005). Given the lack 
of normal human retina as a positive control tissue in this study, it is difficult to confirm 
the specific binding of this antibody to prostate tissue. If the staining pattern is specific, 
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this is the first time that RS1 expression has been demonstrated outside of the eye, in 
benign prostate tissue and in prostate tumour tissue.  
I observed a trend towards increased cytoplasmic staining intensity in patients that 
would go on to develop recurrent disease. I also observed a modest negative correlation 
between RS1 cytoplasmic staining and AR nuclear staining (Figure 4.13). It is possible 
that RS1 is upregulated as a result of reduced AR expression as the correlation suggests, 
or that AR represses RS1, as has been demonstrated for a number of genes in prostate 
cancer cell line C4-2B (Prescott et al., 2007). Alternatively, it is tempting to speculate 
that RS1 could be involved in the PI3K-Akt signalling pathway, which shows increased 
activity after inhibition of AR in mouse prostate cancer models and xenograft tumours 
(Carver et al., 2011), especially as Uniprot infers binding to phosphatidylinositol 
phosphates as one of the predicted molecular functions of RS1, though this has no 
experimental confirmation (Uniprot identifier: O15537).  
The finding that RS1 may be more highly expressed in recurrent patients would agree 
with the data analysed at the mRNA level (Chapter 3.2.2). No differences were detected 
between the nuclear staining of RS1 in benign and malignant prostate tissue, or between 
recurrent and non-recurrent prostate tumours, which would be consistent with the 
nuclear reaction being a non-specific staining reaction. However, the fact that RS1 
appears to be amplified in a subset of metastatic and castration resistant prostate 
carcinomas makes it an interesting target for further study. Ideally, such a study would 
include a larger cohort of patients with paired biopsies from diagnosis and after 
treatment, or perhaps paired castration-resistant or metastatic material, to investigate the 
prognostic relevance of RS1 expression and its amplification during prostate cancer 
progression. Given that this was the first time that RS1 expression has been reported 
outside of the eye, it would also be necessary to verify antibody specificity using 
positive control tissue on IHC or western blot. If RS1 is expressed in prostate cancer, 
further studies must also focus on determining its functional roles in prostate cancer cell 
lines. If RS1 is not the protein recognised by this antibody in prostate cancer tissue, then 
it may still have merit as a biomarker. For example, the proliferation marker Ki-67 was 
first identified as being an antigen associated with proliferation and marked by the 
monoclonal antibody Ki-67, even before it was characterised at the molecular level 
(Gerdes et al., 1984). However, in this situation, the antigen that anti-RS1 recognises in 
prostate tumours must also be identified. 
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4.3.8 Limitations of the Bath Cohort and conclusions 
The Bath Cohort data has limited statistical power due to the small sample size. The 
sample size of this study is insufficient to draw correlations or statistical inferences 
regarding survival time, node status, metastases and tumour stage, meaning that many 
important associations with prognostic indicators could have been missed. Indeed, a 
bias in sampling with higher proportions of recurrent patients to non-recurrent might 
have impaired the ability of the study to statistically resolve differences. Heterogeneity 
in patient treatments might also influence the study’s ability to resolve differences, as 
mechanisms of recurrence for each therapy modality will be different. Additionally, 
while there was no statistical association between any biomarker expression and 
Gleason grade, none of the patients in this study were assigned a primary Gleason 
pattern of 5 (Table 4.1), which is the poorest prognostic category in the Gleason grading 
system. Thus, following up any individual biomarker would require a larger cohort of 
patients, such as on a tissue microarray, where many patients can be analysed on the 
same slide for high throughput data acquisition. We have chosen a promising potential 
biomarker, Syndecan-1, to be analysed in this manner and the results of Bath Cohort 
and tissue microarray analysis for this potential biomarker are described in the 
following chapter. BMI1, RS1 and ZSCAN4 would also be suitable candidates for 
further analysis using this method. 
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5 SYNDECAN-1 POSITIVE 
STROMAL CELLS ARE 
FOUND IN PROSTATE 
TUMOURS 
5.1 Introduction 
One potential biomarker for prognostication in prostate cancer is the heparan sulphate 
proteoglycan Syndecan-1 (SDC1).  
5.1.1 Functional roles of SDC1 
Otherwise known as CD138, SDC1 is a heparan sulphate transmembrane proteoglycan 
and is a well-established marker of plasma cells that is expressed in myeloma and in 
plasma cell lines (Maiga et al., 2014). It is the principle syndecan expressed on 
epithelial cells (Gharbaran, 2015). As a co-receptor for integrins and growth factors, it 
plays diverse roles in cell adhesion, migration and cell signalling. In the context of 
epithelial cells, SDC1 has been shown to act as a co-receptor with α2β1 integrin to 
facilitate adhesion to type I collagen, and appears to be important for forming focal 
adhesions in a wide variety of cells including head and neck squamous cell carcinoma 
cell line HSC-3, Chinese hamster ovary cells and the breast cancer cell line MDA-MB-
231 (Ishikawa and Kramer, 2010; Vuoriluoto et al., 2008). The ectodomain of SDC1 is 
necessary for activation of α2β1 integrin (Altemeier et al., 2012). SDC1 expression 
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promotes adhesion and cell spreading to collagen substrates, and reduces invasion 
through them (Vuoriluoto et al., 2011; Ishikawa and Kramer, 2010). This is 
accompanied by regulation of Rho GTPases, with increased RhoA signalling and 
decreased Rac signalling occurring as a result of SDC1 binding (Ishikawa and Kramer, 
2010). Conversely, downregulation of SDC1 in HSC-3 cells results in decreased focal 
adhesions, increased lamellipodia formation and cell migration (Ishikawa and Kramer, 
2010). In B2b lung carcinoma cells, SDC1 silencing results in a similar increase in cell 
migration that is accompanied by a decreased focal adhesion lifespan, suggesting that 
the role of SDC1 in this process is to stabilise focal adhesions (Altemeier et al., 2012). 
In this cell line the transmembrane domain of SDC1 appears to be necessary for this 
function and the consequent negative regulation of cell migration (Altemeier et al., 
2012).   
SDC1 can also couple integrin activation to other receptor signalling events, such as 
those of the growth factor receptor IGF1R. SDC1 is required for the activation of αvβ3 
integrin at focal adhesions in HUVEC cells (Beauvais and Rapraeger, 2010), where 
ECM-bound SDC1 can cluster at focal adhesions and form a ternary complex together 
with αvβ3 integrin and IGF1R. This function requires the SDC1 ectodomain (Beauvais 
and Rapraeger, 2010), and the domain appears to be important for cell-ECM adhesion in 
mesenchymal cells as well, such as B6FS fibrosarcoma cells and STAV-AB 
mesothelioma cells (Zong et al., 2011). SDC1 overexpression in mesenchymal cells 
promotes adhesion and reduces migration and chemotaxis when examined at the 
functional (Zong et al., 2011) or gene expression levels (Szatmari et al., 2012). 
Another function of SDC1 is growth factor binding through the heparan sulphate chains 
on its ectodomain (Gharbaran, 2015). The inflammatory cytokine Macrophage 
Migration Inhibitory Factor (MIF) has been found to bind to SDC1 on the surface of 
lung carcinoma cell line A549 as well as MDA-MB-231 cells, where it stimulates cell 
migration in a SDC1-dependent fashion (Pasqualon et al., 2016). The ectodomain can 
also be shed through cleavage by matrix metalloproteinases, creating a soluble form 
which may have pro-angiogenic roles in tumours, for example in myeloma (Gharbaran, 
2015), and the shed ectodomain in itself may possess prognostic utility (Szarvas et al., 
2016b). Interestingly, shed SDC1 from myeloma cell lines has been shown to enter the 
nucleus of other cells, such as bone marrow-derived stromal cells (Stewart et al., 2015) 
– a process that depends upon binding of growth factors such as HGF to the shed 
protein, which it also shuttles to the nucleus. Similarly, in STAV-AB mesothelioma 
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cells, FGF2 and SDC1 colocalise with one another in the nuclear compartment, whereas 
its receptor FGFR1 does not (Zong et al., 2009). The roles of shed SDC1 in the nucleus 
are currently poorly understood, but in these stromal cells it binds to p300 and inhibits 
its histone acetyltransferase activity (Stewart et al., 2015), suggesting that it may be 
involved in the control of gene transcription. There is also evidence that SDC1 
signalling is involved in maintaining the tumour-initiating cell (TIC)/cancer stem cell 
(CSC) population in breast carcinoma (Alexander et al., 2000; Liu et al., 2004) and 
prostate carcinoma (Shimada et al., 2013) and can regulate the expression of several 
microRNAs that suppress expression of stem cell markers such as SOX-2, OCT4 and 
Nanog (Fujii et al., 2015). Suppression of SDC1 gene expression also reduces the 
amplification of the putative CSC population in PC-3 cells following treatment with 
docetaxel (Shimada et al., 2013), suggesting that it could exert effects of relevance to 
prostate cancer patients undergoing therapy. Overall, it appears that SDC1 primarily 
functions in growth factor binding, regulation of the actin cytoskeleton, cell adhesion 
and cell migration in both epithelial cells and mesenchymal cells. However, there may 
be additional functions of SDC1 that are not yet completely understood, such as 
regulation of the putative CSC population and stem cell factor expression. 
5.1.2 SDC1 expression in the human prostate and its association with 
cancer 
The expression of SDC1 has been linked to prognosis and treatment response in a large 
range of cancer types, including haematolymphoid malignancies and solid tumours 
(Gharbaran, 2015; Nguyen et al., 2013; Zellweger et al., 2003; Juuti et al., 2005; Lee et 
al., 2014; Ramani and Sanderson, 2014),  but in prostate cancer the role of SDC1 in 
prognosis is controversial. It is expressed in the basal epithelial layer of normal prostate 
glands, and this expression is often lost in prostate carcinoma cells (Chen et al., 2004a; 
Shimada et al., 2009; Brimo et al., 2010; Shariat et al., 2008; Fujii et al., 2015; Szarvas 
et al., 2016b).  
However, there are reports that hormone-refractory tumours (Brimo et al., 2010) and 
tumours treated with neo-adjuvant hormone therapy (Shimada et al., 2009) have 
increased SDC1 expression, suggesting a relationship between expression and androgen 
independence. There are also reports that expression of SDC1 is associated with high 
Gleason grade disease and/or early disease recurrence in prostate cancer patients (Chen 
et al., 2004a; Shimada et al., 2009; Brimo et al., 2010; Shariat et al., 2008; Fujii et al., 
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2015). Interestingly, an alteration in protein localization, from membranous to 
cytoplasmic, was found to be associated with a more rapid biochemical recurrence. This 
indicates that alterations in SDC1 expression and localization could be prognostically 
important and change throughout the course of the disease. Conversely, others have 
found that tissue SDC1 expression is not associated with recurrence-free survival 
(Purushothaman et al., 2010; Brimo et al., 2010) or Gleason grade in prostate carcinoma 
(Brimo et al., 2010), and even concluded that lower levels of SDC1 expression were 
associated with a high Gleason grade (Gharbaran, 2015). Therefore, the potential utility 
of SDC1 as a biomarker for prostate cancer is far from clear. 
Taken together, there is accumulating evidence that SDC1 is an important 
multifunctional molecule which shows altered expression in prostate cancer, but its 
potential role as a biomarker for prostate cancer remains controversial. Given the 
evidence concerning SDC1 expression in prostate tumours, I predict that SDC1 
expression will be predominantly localised to basal cells in benign prostate tissue, and 
that this expression will be lost in the majority of tumours. Additionally, I predict that 
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5.1.3 Aims 
Given the diverse functional roles played by SDC1 and the conflicting evidence 
surrounding its possible utility as a biomarker, we aimed to investigate SDC1 
expression further by IHC in three independent cohorts of prostate carcinoma samples. 
This chapter will: 
i. Assess epithelial expression patterns of SDC1 in benign and malignant prostate 
tissue, and the ability of this biomarker to distinguish between normal and 
disease states.  
ii. Identify any relationships between epithelial SDC1 expression patterns and 
biochemical recurrence status after 5 years of retrospective follow-up. 
iii. Further characterise the cell types marked by SDC1 expression in prostate 
tumours using IHC and IF techniques. 
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5.2 Methods 
5.2.1 Patient cohorts in this chapter 
Data obtained for this study came from three separate cohorts of patients with 
associated formalin-fixed, paraffin-embedded (FFPE) prostate material available. A 
subset of the Bath Cohort (detailed in Chapter 4) was used for preliminary staining and 
analysis of cell types by fluorescent co-staining, and consisted of six prostate cancer 
patients with confirmed SDC1+ stromal cells as assessed by anti-SDC1 IHC. In 
addition, one block of adjacent normal prostate tissue was used as a positive control for 
SDC1 staining. These samples were obtained retrospectively from patients treated for 
prostate cancer at the Royal United Hospital, Bath, United Kingdom, between 1997 and 
2008. The samples were obtained following ethical approval from the NHS Ethics 
Committee in 2013 (REC reference: 13/WS/0153; IRAS project ID: 112241). Informed 
written consent was obtained from all patients. NHS ethics approval also covered the 
other two patient cohorts. These were used for anti-SDC1 immunohistochemistry and 
were obtained from US Biomax (Rockville, MD, USA). The first cohort (PR1921) 
consisted of 80 cases of prostate adenocarcinoma with 8 cases of adjacent normal 
prostate tissue and 8 cases of histologically normal prostate tissue, with duplicate 1mm 
cores per cancer case for a total of 196 cores. The second cohort (PR803b) consisted of 
71 cases of prostate adenocarcinoma, 2 cases of prostate leiomyosarcoma, 1 case of 
benign prostate hyperplasia and 6 cores of histologically normal prostate, with a single 
1.5mm core per case. Each cohort was contained on a single tissue microarray slide. A 
summary of the patient characteristics of tissue microarray cohorts is given in Table 5.1. 
Immunohistochemistry was performed as described in Chapter 2.2.2. All anti-SDC1 




Table 5.1: Clinical characteristics of tissue microarray cohort 1 (PR1921) and 
cohort 2 (PR803B). 
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Number	of	Patients	 80	 	 71	 	
Age:	 	 	 	  
Range	 20-85	 	 20-87	 	
Mean	 67.85	 	 67.6	 	
Median	 69.5	 	 70	 	
<50	 2	 2.5	 3	 4.2	
50-59	 5	 6.3	 4	 5.6	
60-69	 33	 41.3	 27	 38.0	
>=70	 40	 50.0	 37	 52.1	
Clinical	Stage:	 	 	 	  
I	 6	 7.5	 2	 2.8	
II	 37	 46.3	 33	 46.5	
III	 14	 17.5	 10	 14.1	
IV	 22	 27.5	 26	 36.6	
ND	 1	 1.3	 0	 0.0	
Primary	Gleason	
Grade:	
	 	 	  
3	 8	 10.0	 19	 26.8	
4	 36	 45.0	 24	 33.8	
5	 30	 37.5	 24	 33.8	
ND	 6	 7.5	 4	 5.6	
Overall	Gleason	
Grade:	
	 	 	  
<=Gleason	3+4	 8	 10.0	 16	 22.5	
>=Gleason	4+3	 66	 82.5	 51	 71.8	
ND	 6	 7.5	 4	 5.6	
T	Category:	 	 	 	  
T1	 4	 5.0	 2	 2.8	
T2	 47	 58.8	 40	 56.3	
T3	 22	 27.5	 21	 29.6	
T4	 6	 7.5	 8	 11.3	
ND	 1	 1.3	 0	 0.0	
N	Category:	 	 	 	  
N0	 64	 80.0	 51	 71.8	
N1	 15	 18.8	 18	 25.4	
N2	 	 0.0	 2	 2.8	
ND	 1	 1.3	 0	 0.0	
M	Category:	 	 	 	  
M0	 64	 80.0	 49	 69.0	
M1	 15	 18.8	 22	 31.0	
ND	 1	 1.3	 0	 0.0	  
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5.2.2 Multiplex IF on FFPE Tissue 
FFPE tissue blocks were chilled to 4ºC and sections were cut at 5µm thickness, floated 
out onto silane-coated slides and air-dried as before. Prior to staining, sections were 
deparaffinised and rehydrated as described previously. Washing, permeablisation and 
antigen retrieval was all performed as described previously. Sections were ringed with 
an ImmEdge hydrophobic barrier pen (Vector Laboratories) and blocked for 30 minutes 
using IHC blocking buffer as in IHC, before incubation with primary antibodies (Table 
2.1) diluted in DAKO Antibody Diluent (DAKO) overnight at 4ºC in a humidified 
chamber. For double immunolabelling experiments, two antibodies recognising 
different antigens and raised in different host species were mixed together at their 
respective dilutions for simultaneous labelling. 
The next day, sections were washed three times in PBST and fluorescent labelling was 
performed in the dark for 30 minutes at room temperature with gentle agitation. Alexa 
Fluor 488-labelled goat anti-mouse IgG and Alexa Fluor 568-labelled goat anti-rabbit 
IgG antibodies were used, and both fluorescently labelled antibodies (Table 2.2) were 
mixed together at 1:200 dilutions in DAKO Antibody Diluent (DAKO) for 
simultaneous labelling. After incubation, sections were washed three times in PBST and 
then a modified protocol from Viegas et al. (2007) was used to quench endogenous 
tissue autofluorescence: samples were incubated with a filtered solution of 0.1% (w/v) 
Sudan Black B in 70% (v/v) ethanol for 10 minutes to quench endogenous tissue 
autofluorescence. Sections were rinsed briefly with PBST to remove any stain debris, 
then washed three times for 5 minutes each before mounting in Mowiol with 600nM 
DAPI (Sigma-Aldrich) for nuclear counterstaining. Samples were allowed to dry 
overnight in the dark at room temperature, or for at least two hours at 37ºC, before 
imaging on an LSM510 META laser scanning confocal microscope. Imaging was 
conducted using 405nm, 488nm and 543nm laser lines for excitation of fluorescent dyes 
and fields of view were collected under a 40x objective. Samples were stored at 4ºC in 
the dark and imaged within several days of staining for best results. 
5.2.3 SDC1 Antibodies 
Two SDC1 antibodies are used in this thesis chapter. The epitope for mouse monoclonal 
anti-SDC1 antibody clone B-A38 is unidentified, but the original immunogen was the 
SDC1-expressing plasmacytoma cell line U266, and it has been shown to robustly mark 
a CD45-expressing plasma cell population by flow cytometry (Maiga et al., 2014), a 
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cell population which has long been known to express SDC1 (Chilosi et al., 1999). The 
rabbit anti-SDC1 antibody clone H-174 was generated by immunization with amino 
acids 82-256 of human SDC1, corresponding to the human SDC1 ectodomain. Shed 
SDC1 ectodomain immunoprecipitated with this antibody has been successfully 
identified by western blot with another mouse monoclonal antibody to the protein 
(Schmidt et al., 2005), suggesting that the antibody is specific to SDC1 and can detect 
shed SDC1. 
5.2.4 Scoring 
5.2.4.1 Scoring of SDC1 IHC data 
For assessment of IHC staining on the Bath Cohort and the two tissue microarrays, 
whole cores were examined under a 10x objective to determine the extent and intensity 
of glandular cytoplasmic/membranous staining of SDC1. This was assessed on a scale 
of 0-3 for intensity: 0 – no staining; 1 – Weak staining; 2 – Moderate staining; 3 – 
Strong staining. Extent was scored on a scale based on the proportion of glandular cells 
stained: 0-4: 0 – no staining; 1 - <25% cells stained; 2 – 25-50% cells stained; 3 – 50-
75% cells stained; 4 – 75-100% cells stained. The score for SDC1 glandular staining 
was determined as the sum of extent and intensity scores, allowing for a maximum 
score of 7. 
For quantification of SDC1+ stromal cell burden, fields of view amounting to all 
SDC1+ stromal cells in every core were manually acquired under a 20x objective. 
Counting and measuring of the resulting images was performed using ImageJ v2.0.0. 
Each stromal cell was identified manually and the following size and shape descriptors 
were measured: area, circularity, aspect ratio, roundness and solidity. Mean values were 
taken for each measure within each cohort as a whole, and for each patient. 
5.2.4.2 Scoring of SDC1 IF co-staining data 
To score SDC1+ stromal cells for their colocalisation with test markers, images from 
each experimental run were pooled, and each SDC1+ cell was manually scored for 
positivity of the co-stained marker. The percentage of marker-positive cells was 
calculated as the percentage of SDC1+/Marker+ cells relative to the total number of 
SDC1+ cells in an experimental run. Data was plotted in R version 3.2.0. 
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5.2.5 Data Analysis 
To analyse the distribution of SDC1+ cell burden amongst different patient groups in 
both TMA cohorts, we classified patients into SDC1 stromal cell positive and negative 
categories based on whether SDC1+ stromal cells were present or absent in the core. In 
the case of PR1921, where duplicate cores were scored, patients were classified as 
positive if at least one core contained SDC1+ stromal cells. The distributions of SDC1+ 
and SDC1- patients amongst different levels of clinical variables were tested with the 
chi-squared test performed in R version 3.2.0 with default parameters. Clinical variables 
assessed were: age; stage; Gleason grade; T, N and M stages; Presence of SDC1 
staining in the glandular compartment was also scored as positive or negative, and 
tested for association as with clinical variables. A p-value of less than 0.05 was 
considered statistically significant. Graphs were also generated in R version 3.2.0. 
5.3 Results 
5.3.1 SDC1 expression patterns in benign and malignant prostate tissue 
To begin to investigate the expression of SDC1, I subjected the Bath Cohort, including 
benign and malignant prostate tissue, to anti-SDC1 IHC. Expression was found in the 
cell membrane and cytoplasm of the prostate epithelium basal cell layer in histologically 
normal tissue (Figure 5.1A). In prostate carcinoma tissues there was either a loss of 
epithelial staining or a widespread expression of the proteoglycan throughout the 
cytoplasm and/or cell membranes of prostate tumour epithelium (Figure 5.1A). Both 
normal and tumour staining patterns are consistent with previous studies (Zellweger et 
al., 2003; Chen et al., 2004a; Shariat et al., 2008; Ledezma et al., 2011; Contreras et al., 
2010; Szarvas et al., 2016b). Interestingly, in addition to these staining patterns, a 
population of scattered SDC1-positive cells were found in the stroma in a subset of 
cancer cases (Figure 5.1A, arrows). Since these SDC1-positive stromal cells had not 
been demonstrated before, subsequent experiments focused on validating and 
characterising them, as well as assessing their relevance as prognostic biomarkers.  
The prevalence of SDC1-positive stromal cells was further investigated in two 
additional cohorts of 80 and 71 prostate cancer patients, respectively. Each of the two 
additional cohorts was represented by a single tissue microarray, and tumour tissue was 
accompanied by histologically normal prostate tissue (in both cohorts) and 8 cases of 
matched adjacent normal tissue (in cohort 1). The scattered SDC1-positive stromal cells 
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were found in a subset of tumour samples from each of the two additional cohorts, 
either proximal or distal to an epithelial region. A range of examples from all three 
cohorts are shown in Figure 5.1A and B. SDC1 staining was found to be localized to the 
membranes and/or cytoplasmic regions of the SDC1-positive cells, and often appeared 
in close proximity to areas of inflammation which were characterised by the stromal 
infiltration of cells with compact, rounded and hyperchromatic nuclei that are thought to 
be lymphocytes (Figure 5.1B, arrowheads). 
To confirm that the staining was due to the presence of SDC1, and not cross reactivity 
from the mouse antibody, a second anti-SDC1 antibody raised in rabbit was used for 
IHC and IF staining on the Bath Cohort. IHC staining of sequential sections with the 
two different anti-SDC1 antibodies was performed. The rabbit anti-human SDC1 
antibody clone H-174 demonstrated a higher intensity of glandular cytoplasmic staining 
than the mouse anti-human SDC1 antibody B-A38, as shown by staining of consecutive 
sections in IHC (Figure 5.2A), but both antibodies stained PCSP cells (Figure 5.2A, 
arrows). It is possible that the increased glandular cytoplasmic staining of H-174 is due 
to its recognition of other domains of the protein, such as the soluble ectodomain in 
addition to the full length SDC1 protein (Schmidt et al., 2005). Double IF staining using 
both antibodies showed colocalisation in SDC1-positive stromal cells (Figure 5.2B, 
arrows), as well as demonstrating equivalent labelling of the basal cell layer in benign 
prostate tissue (Figure 5.2B).  
In summary, in addition to previously documented epithelial staining patterns of SDC1, 
a subset of prostate cancer samples contained a population of scattered SDC1 positive 
cells that can be detected using two different anti-SDC1 antibodies and in 3 patient 
cohorts. To our knowledge, this cell type has not been previously described. We call 
these cells Prostate Cancer SDC1 Positive (PCSP) cells. 
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Figure 5.1: SDC1 expression is altered in prostate carcinoma with the appearance 
of Prostate Cancer SDC1-Positive Stromal (PCSP) cells in a subset of cases. 
(A) In a subset of prostate cancer cases, PCSP cells are found scattered in the stroma 
(shown inset and by arrows). While not found in histologically normal tissue, PCSP 
cells can be found in the contexts of both epithelial SDC1 alterations in tumours, 
including expression across all epithelial cells, and where SDC1 expression is lost in the 
epithelium entirely. These cells are demonstrable by both IHC and IF staining 
techniques in FFPE prostate tissue. Representative images of samples from the Bath 
Cohort are shown. (B) Examples of PCSP cells detected by anti-SDC1 IHC with the 
mouse antibody clone B-A38. All PCSP cells are located in the stroma and tend to 
appear near regions containing putative lymphocytes with compact, round, 
hyperchromatic nuclei (arrowheads). Representative images of samples from TMA 
cohorts 1 and 2 are shown. Nuclei are counterstained with haematoxylin (blue) in IHC, 
or with DAPI (blue) in IF. IHC scale bars – 100um; IF scale bars – 50um. 
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Figure 5.2: The presence of PCSP cells is confirmed by staining with two distinct 
anti-SDC1 antibodies. 
(A) IHC staining of adjacent tissue sections of a representative prostate tumour (PCa) 
with a mouse (mo) anti-SDC1 antibody (left) and a rabbit (rb) anti-SDC1 antibody 
(right), showing increased cytoplasmic staining with the rabbit antibody, but detection 
of PCSP cells (arrows) by both antibodies. (B) The specificity of the mouse antibody 
(green) is further confirmed by IF co-staining with another SDC1-specific antibody 
raised in rabbit (red), showing colocalisation in both benign (basal cells, inset) and 
tumour tissues (PCSP cells, inset and arrows). Nuclei are counterstained with 
haematoxylin (blue) in IHC, or with DAPI (blue) in IF. IHC scale bars – 100um; IF 
scale bars – 50um. 
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5.3.2 Epithelial cytoplasmic SDC1 expression was reduced and PCSP cell 
burden was elevated in malignant prostate stroma of the Bath Cohort 
To quantify SDC1 expression patterns in both benign and malignant prostate tissue, the 
cytoplasmic scoring system was used to quantify epithelial staining, and the number and 
area of PCSP cells was quantified and expressed as the total number in five fields and 
the total area per field of view, expressed as an average of five fields respectively. There 
was a trend towards a reduced cytoplasmic score in malignant prostate when compared 
to benign prostate tissue (Figure 5.3A), but this difference was not significant 
(p=0.6689). A subset of malignant patient samples demonstrated a high burden of PCSP 
cells (Figure 5.3B), with 12/28 (42.9%) having a mean burden of greater than 3 PCSP 
cells per field compared with 1/5 (20%) of benign tissues. However, the sample size 
was insufficient to demonstrate a significant difference in PCSP cell burden between the 
benign and malignant prostate tissue (p=0.2726). Similarly, when measuring the total 
area of PCSP cells in patient tissues, there was no significant difference (p=0.6643) 
although a trend towards increased area in malignant tissues was apparent (Figure 
5.3C).  
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Figure 5.3: Quantification of cytoplasmic SDC1 staining and Prostate Cancer 
SDC1 Positive Stromal (PCSP) cells in benign and malignant prostate tissue. 
IHC staining of SDC1 was quantified in the Bath cohort using the cytoplasmic score for 
prostate epithelium, and the number and area of PCSP stromal cells was measured. 
SDC1 staining was compared between benign and malignant prostate epithelium: (A) 
glandular cytoplasmic score showing a slight trend towards reduced cytoplasmic 
staining of malignant prostate epithelium (p=0.6689); (B) mean frequency of PCSP 
cells per 20x field of view, which appeared to increase in malignant tissue, although not 
statistically significant (p=0.2726), and; (C) mean total area of PCSP cell occupancy per 
20x field of view, which showed a similar trend to cell burden, and was not statistically 
significant (p=0.6643). Two-sample t-tests were conducted to determine statistical 
significance for each set of conditions. n=5 benign samples, 28 malignant samples. 
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5.3.3 Associations between SDC1 staining and outcome in the Bath Cohort 
In order to determine the relevance of all forms of SDC1 staining patterns in a 
prognostic biomarker setting, we dichotomised all prostate cancer patients with 
available tissue for SDC1 staining in the Bath Cohort, based on 5-year biochemical 
recurrence-free survival status (n=26 patients, 9 non-recurrent and 17 recurrent). There 
was no significant difference between SDC1 glandular cytoplasmic staining scores in 5-
year recurrence-free and non-recurrent prostate tumour tissue (Figure 5.4A) (p=0.775). 
PCSP cell burden was similar between recurrent and non-recurrent patient samples, and 
there was no significant difference (Figure 5.4B) (p=0.952). However, when PCSP cells 
occupying the tissue were measured, there was a trend towards reduced total area of 
occupying cells in recurrent patient samples compared to non-recurrent samples (Figure 
5.4C), although it was not statistically significant (p=0.1597). Any conclusions on this 
relationship would require analysis of a larger cohort of patients with available 
recurrence data. 
 To summarise findings from the Bath Cohort, there were trends towards an increased 
PCSP cell burden in malignant tissue compared to benign tissue, and reduced burden in 
recurrent prostate tumours compared to non-recurrent tumours, but the small cohort was 
unable to demonstrate statistical significance in these findings. These trends in a 
previously uncharacterised cell type led us to verify our observations in larger datasets. 
To do this, we expanded our analysis of PCSP cell burden to look at the two tissue 
microarray cohorts stained for SDC1. 
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Figure 5.4: Quantification of epithelial cytoplasmic SDC1 staining and PCSP cell 
burden and total area in 5-year recurrence-free and recurrent prostate tumours 
from the Bath Cohort. 
IHC staining of SDC1 was quantified in the Bath cohort using the cytoplasmic score for 
prostate epithelium, and the number and area of PCSP stromal cells was measured. 
SDC1 staining was compared between recurrent and non-recurrent prostate tumour 
samples: (A) glandular cytoplasmic score showing similar levels of staining between 
recurrent and non-recurrent samples (p=0.775); (B) mean frequency of PCSP cell 
occurrence per 20x field of view over five fields per sample, which appeared to be 
similar between both groups (p=0.952), and; (C) mean total area of PCSP cell 
occupancy per 20x field of view, which showed a trend towards decreased occupancy in 
recurrent samples, although this did not reach significance (p=0.1597). Two-sample t-
tests were conducted to determine statistical significance for each set of conditions. N=9 
non-recurrent samples, 17 recurrent samples. 
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5.3.4 Analysis of PCSP cells in patient tissue microarrays reveals Gleason 
pattern 5 tumours with a particularly high burden 
Using the clinical metadata available for both prostate tissue microarray cohorts, we 
wished to determine if there was a relationship between SDC1+ stromal cell burden and 
clinicopathological features. These included age, Gleason grade and TNM stages of all 
patients in the study. In the first cohort, cores of histologically normal tissue adjacent to 
prostate cancer were included, as well as non-diseased normal prostate control cores. 
Patient characteristics for both cohorts are summarized in Table 5.1, and have similar 
patient distributions among the clinical variables. 
 PCSP cells were found in 28 of 80 cases (35%) of patients with prostate cancer in 
cohort 1, but they were not observed in any of the 8 control cases of non-diseased 
patient tissue (Figure 5.5A). 7 of 28 positive cancer cases (25%) were PCSP-positive in 
both cores. In cohort 2, PCSP cells were found in 15 of 71 prostate cancer cases 
(21.1%). In contrast with both TMA cohorts, the Bath cohort displayed some evidence 
of PCSP cell burden in all cases, even if the burden was very low (Figure 5.5B). 
Interestingly, in cohort 1, PCSP cells were also found in 4 of 8 cases of normal patient 
tissue that was adjacent to carcinoma (Figure 5.5A), but all of these cases only had a 
single PCSP-positive core. The presence of PCSP cells in normal adjacent tissue might 
be explained by being a migratory and/or ubiquitous cell type – a hypothesis that will be 
investigated further in Chapter 5.3.5.  
Chi-squared tests were conducted to determine the association between PCSP cell 
presence and available clinical parameters for the tissue microarray cases, and the full 
results are given for cohort 1 (Table 5.2) and cohort 2 (Table 5.3). With respect to 
Gleason grade, no patient in the Bath cohort presented with a primary Gleason pattern 5 
tumour, precluding analysis of all Gleason patterns. However, there was no significant 
difference in PCSP cell burden between primary Gleason pattern 3 and 4 tumours in the 
Bath Cohort (p=0.673). Interestingly, in both tissue microarray cohorts a subset of 
Gleason grade five tumours had a particularly high burden of PCSP cells (Figure 5.5C 
and D). Among cohort 2, there was also a statistically significant association between 
PCSP cell burden and higher primary Gleason grade (p=0.0167). However, in cohort 1 
it fell below significance (p=0.706).  
Similarly, there was a statistically significant association between PCSP cell presence 
and a lower clinical stage in cohort 1 (p=0.030), but this pattern did not hold true in 
cohort 2 (p=0.614). Given that there were only 6 stage I patients in cohort 1, 5 of which 
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had PCSP cells, it is likely that the under-sampling of the lowest grade tumours 
contributed to this result in cohort 1. Further studies are needed to confirm if there is a 
statistically significant and relevant relationship between PCSP burden and primary 
Gleason grade or clinical stage. In summary, analysis of PCSPs in the tissue 
microarrays showed that PCSP cells were not observed in the normal tissue analysed, 
but were found in adjacent normal and in roughly 1/3 of prostate carcinoma tissues, 
with a subset of high Gleason grade tumours having a particularly high burden.  The 
tissue microarray cohort data supports the findings of the Bath Cohort with respect to 
PCSP cell burden in benign and malignant prostate epithelium, and additionally 
indicates that PCSP cells may be found in adjacent normal tissue of prostate tumours. 
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Figure 5.5: PCSP cells are found in normal tissue adjacent to carcinoma in 
addition to carcinoma tissue, and a subset of Gleason 5 cases have a particularly 
high burden of PCSP cells.  
(A) Plots of PCSP cell burden in cohort 1. PCSP cells are detected in 4/8 normal 
adjacent (NAT) samples and in 28/80 malignant samples, but not in non-diseased 
normal samples (0/8). This distribution does not quite reach statistical significance by 
the chi squared test (p=0.0781). (B) Plots of PCSP cell burden in the Bath Cohort 
showing burden in both Gleason 3 and 4 cases with no significant difference between 
groupings (p=0.673). The Bath Cohort does not contain patients with a primary Gleason 
pattern 5. (C) Plots of PCSP cell burden in cohort 1 and (D) cohort 2 malignant tissues 
show primary Gleason pattern 5 patients with a particularly high burden in both cohorts, 
which was statistically significant in cohort 2 (p=0.0167) but not in cohort 1 (p=0.706). 
The entire core for each specimen was quantified. Tumour cases with available Gleason 
grading information:  Bath Cohort: N=24 tumours; TMA Cohort 1: N=74 tumours; 
TMA Cohort 2: N=67 tumours. 
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Table 5.2: Characteristics of patients from Cohort 1 (PR1921) and chi-squared 
tests between patients with (PCSP+) and without (PCSP-) a PCSP cell burden. 
	 All	
Patients	
%	 PCSP+	 %	 PCSP
-	
%	 P-Value	(	!"	test)	
#Patients	 80 100 28 35 52 65  
Age:	 Range: (20-85), Mean: (67.85), Median: (69.5)  
<50	 2 2.5 0 0.0 2 2.5  
50-59	 5 6.3 0 0.0 5 6.3  
60-69	 33 41.3 13 16.3 20 25.0  
>=70	 40 50.0 15 18.8 25 31.3 0.245 
Clinical	Stage:	        
I	 6 7.5 5 6.3 1 1.3  
II	 37 46.3 13 16.3 24 30.0  
III	 14 17.5 5 6.3 9 11.3  
IV	 22 27.5 4 5.0 18 22.5  
ND	 1 1.3 1 1.3 0 0.0 0.030 
Tumour	Grade:	        
2	 8 10.0 3 3.8 5 6.3  
2--3	 30 37.5 9 11.3 21 26.3  
3	 36 45.0 12 15.0 24 30.0  
NA	 6 7.5 4 5.0 2 2.5 0.910 
Primary	Gleason:	        
3	 8 10.0 3 3.8 5 6.3  
4	 36 45.0 10 12.5 26 32.5  
5	 30 37.5 11 13.8 19 23.8  
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NA	 6 7.5 4 5.0 2 2.5 0.706 
Overall	Gleason:	        
<=Gleason	3+4	 8 10.0 3 3.8 5 6.3  
>=Gleason	4+3	 66 82.5 21 26.3 45 56.3  
NA	 6 7.5 4 5.0 2 2.5 1.000 
T	Category:	        
pT1	 4 5.0 3 3.8 1 1.3  
pT2	 47 58.8 16 20.0 31 38.8  
pT3	 22 27.5 7 8.8 15 18.8  
pT4	 6 7.5 1 1.3 5 6.3  
NA	 1 1.3 1 1.3 0 0.0 0.280 
N	Category:	        
N0	 64 80.0 23 28.8 41 51.3  
N1	 15 18.8 4 5.0 11 13.8  
NA	 1 1.3 1 1.3 0 0.0 0.705 
M	Category:	        
M0	 64 80.0 25 31.3 39 48.8  
M1	 15 18.8 2 2.5 13 16.3  
NA	 1 1.3 1 1.3 0 0.0 0.112 
SDC1	Epithelial	
Reactivity:	
       
Absent	 66 82.5 17 21.3 49 61.3  
Present	 14 17.5 11 13.8 3 3.8 0.001 
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Table 5.3: Characteristics of patients from Cohort 2 (PR803b) and chi-squared 
tests between patients with (PCSP+) and without (PCSP-) a PCSP cell burden. 
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	 All	
Patients	
%	 PCSP+	 %	 PCSP-	 %	 P-Value	(!"	
test)	
#	Patients	 71	 100	 15	 21.1	 56	 78.9	 	
Age:	 Range:	(20-87),	Mean:	(67.6),	Median:	(70) 
<50	 3	 4.2	 2	 2.8	 1	 1.4	 	
50-59	 4	 5.6	 1	 1.4	 3	 4.2	 	
60-69	 27	 38.0	 5	 7.0	 22	 31.0	 	
>=70	 37	 52.1	 7	 9.9	 30	 42.3	 0.263	
Clinical	Stage:	 	       
I	 2	 2.8	 1	 1.4	 1	 1.4	 	
II	 33	 46.5	 7	 9.9	 26	 36.6	 	
III	 10	 14.1	 1	 1.4	 9	 12.7	 	
IV	 26	 36.6	 6	 8.5	 20	 28.2	 0.614	
Tumour	Grade:	 	       
2	 21	 29.6	 2	 2.8	 19	 26.8	 	
3	 47	 66.2	 11	 15.5	 36	 50.7	 	
NA	 3	 4.2	 2	 2.8	 1	 1.4	 1.000	
Primary	Gleason:	 	 	      
3	 19	 26.8	 1	 1.4	 18	 25.4	 	
4	 24	 33.8	 3	 4.2	 21	 29.6	 	
5	 24	 33.8	 9	 12.7	 15	 21.1	 	
NA	 4	 5.6	 2	 2.8	 2	 2.8	 0.017	
Overall	Gleason:	 	 	      
<=Gleason	3+4	 16	 22.5	 0	 0.0	 16	 22.5	 	
>=Gleason	4+3	 51	 71.8	 13	 18.3	 38	 53.5	 	
NA	 4	 5.6	 2	 2.8	 2	 2.8	 0.059	
T	Category:	 	       
T1	 2	 2.8	 1	 1.4	 1	 1.4	 	
T2	 40	 56.3	 9	 12.7	 31	 43.7	 	
T3	 21	 29.6	 3	 4.2	 18	 25.4	 	
T4	 8	 11.3	 2	 2.8	 6	 8.5	 0.635	
N	Category:	 	       
N0	 51	 71.8	 11	 15.5	 40	 56.3	 	
N1	 18	 25.4	 4	 5.6	 14	 19.7	 	
N2	 2	 2.8	 0	 0.0	 2	 2.8	 0.758	
M	Category:	 	       
M0	 49	 69.0	 10	 14.1	 39	 54.9	 	
M1	 22	 31.0	 5	 7.0	 17	 23.9	 1.000	
SDC1	Epithelial	
Reactivity:	
	 	      
Absent	 57	 80.3	 11	 15.5	 46	 64.8	 	
Present	 13	 18.3	 4	 5.6	 9	 12.7	 	
ND	 1	 1.4	 0	 0.0	 1	 1.4	 0.593	
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5.3.5 Characterisation of Prostate Cancer SDC1 Positive Stromal (PCSP) 
cells in the Bath Cohort 
To try and identify the PCSP cell population, we used double-IF labelling with SDC1 
and a range of markers commonly used to distinguish key cell types found in prostate 
tumour samples. Six tumour samples from the Bath Cohort which had confirmed PCSP 
cell burden were stained with markers for immune, epithelial and stromal cell lineages. 
5.3.5.1 PCSP cells do not express immune cell markers, but are found in proximity to 
inflammation 
Given that SDC1 is expressed in normal and neoplastic plasma cells (Chilosi et al., 
1999; Maiga et al., 2014), I began with the hypothesis that PCSP cells were a plasma 
cell population infiltrating prostate tumours. I began by assessing the expression of 
lymphoid lineage markers in PCSP cells. Fluorescent co-stains with SDC1 and a panel 
of antibodies raised against immune cell lineage markers: CD45, which is expressed in 
the majority of haematolymphoid lineages with the exception of erythrocytes and some 
macrophages, and known to be expressed in SDC1+ bone marrow plasma cells (Maiga 
et al., 2014); CD19, which is expressed on immature and memory B-cells (Mavropoulos 
et al., 2016); and CD27, which is expressed in plasma cells, memory B-cells 
(Mavropoulos et al., 2016) and T-cells (Hendriks et al., 2000). This showed that the 
majority of PCSP cells did not co-stain for any of the three immune cell markers (Figure 
5.6A and B). Interestingly, despite the lack of colocalisation, PCSP cells were often 
found in close proximity to CD45 positive immune cells (Figure 5.6A, arrows). This 
was consistent with IHC data from Chapter 5.3.1 showing that SDC1 positive cells were 
found in close proximity to cells whose nuclear morphology – round, compact and 
hyperchromatic - suggested an immune cell phenotype (Figure 5.1B, arrowheads). Due 
to lack of reactivity with immune cell markers, I proceeded to test the PCSP cell 
population for colocalisation with markers of other prostatic cell types. 
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Figure 5.6: PCSP cells are found in inflammatory areas of prostate tumours, but 
are not positive for common markers of immune cell lineages. 
5µm thick sections of FFPE prostate tumour tissue from the Bath Cohort were stained 
by IF for SDC1 (green) and immune cell markers (red). Nuclei were counterstained with 
DAPI (blue). (A) PCSP cells (inset) do not express the hematopoietic lineage marker 
CD45, the B-cell marker CD19 or the plasma cell marker CD27. (B) Quantification of 
the percentage overlap of SDC1+ cells with marker stains. Counts of PCSP cells were 
pooled from a minimum of 3 different patient samples, with a minimum of 200 cells 
counted in total per marker over at least 5 fields of view. Scale bars – 50µm. Insets: 
individual PCSP cells displayed at 3x zoom. 
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5.3.5.2 PCSP cells do not express epithelial cell markers 
Another possible origin for the PCSP population was epithelial cells, so co-staining was 
carried out for SDC1 and three markers of epithelial cell fate: pan-Cytokeratin, which 
stains multiple human cytokeratins expressed in epithelial tissues (Figure 5.7A); E-
Cadherin, which is normally present in the benign prostate epithelium and in most 
prostate tumours (Rubin et al., 2001); and Prostate-Specific Antigen (PSA), a secretory 
marker of luminal prostate epithelium, also expressed in prostate tumours. 
Quantification of the IF images showed none of these markers had significant co-
staining with SDC1 in PCSP cells (Figure 5.7B). There was also no apparent overlap in 
the IHC staining of the stromal cells in consecutive tissue sections for SDC1 and the 
basal cell markers p63 and Cytokeratin-5 (Figure 5.7C). Thus, PCSP cells did not have 
staining patterns consistent with them being a recognized prostate epithelial cell 
population, whether basal or luminal in origin.  
5.3.5.3 PCSP cells do not express stromal cell markers 
To examine if the PCSP cells were stromal in origin, or had undergone an epithelial-
mesenchymal transition and lost expression of epithelial markers, a panel of stains for 
mesenchymal and stromal cell types were examined. The mesenchymal cell markers 
Vimentin and N-Cadherin did not show significant co-staining with PCSP cells (Figure 
5.8A and B). Finally, the nerve marker S100 and the endothelial marker CD31 were 
examined, neither of which showed significant overlap (Figure 5.8A and B). Therefore, 
the marker analysis carried out did not allow the allocation of PCSP cells to an 
established cell population, and they remain an undefined cell type. 
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Figure 5.7: PCSP cells do not express markers of epithelial and secretory prostate 
cells. 
5µm thick sections of FFPE prostate tumour tissue from the Bath Cohort were stained 
by IF for SDC1 (green) and epithelial markers (red). Nuclei were counterstained with 
DAPI (blue). (A) PCSP cells (inset) do not express the epithelial cell markers Pan-
Cytokeratin or E-Cadherin. Similarly, the secretory epithelial marker PSA was also not 
expressed in PCSP cells. (B) Quantification of the percentage overlap of PCSP cells 
with marker stains. Counts of PCSP cells were pooled from a minimum of 3 different 
patient samples. A minimum of 200 cells were counted in total per marker over at least 
5 fields of view, with the exception of E-Cadherin where 176 cells were counted. (C) 
Adjacent sections of benign prostate and prostate tumours were stained for SDC1 and 
the basal cell markers p63 and CK5, showing no colocalisation in PCSP cells of tumour 
cases. Insets: individual PCSP cells displayed at 3x zoom. Scale bars – 50µm. 
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Figure 5.8: PCSP cells do not express common markers consistent with a 
mesenchymal/stromal, nerve or endothelial cell identity. 
5µm thick sections of FFPE prostate tumour tissue were stained by IF for SDC1 (green) 
and mesenchymal/stromal cell type markers (red), and nuclei were counterstained with 
DAPI (blue). (A) mesenchymal cell type markers Vimentin and N-Cadherin, nerve 
marker S100 and endothelial cell marker CD31. (B) Quantification of the percentage 
overlap of PCSP cells with marker stains. Counts of PCSP cells were pooled from a 
minimum of 3 different patient samples. A minimum of 200 cells per marker were 
counted in total per marker over at least 5 fields of view, with the exception of 
Vimentin, N-Cadherin and S100, where 69, 197 and 29 cells were counted respectively. 
Insets: individual PCSP stromal cells displayed at 3x zoom. Scale bars – 50µm. 
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5.3.5.4 PCSP cells are elongated and have prominent lamellipodia-like structures 
In order to characterize this unidentified cell type further, the cell shape of PCSP cells 
was analysed using anti-SDC1 IHC stained tissue microarrays from two independent 
cohorts of prostate cancer patients. The circularity and aspect ratios of the PCSP cells 
was quantified and on average PCSP cells were found to be elongated rather than 
rounded in shape (Table 5.4). When morphological data from individual cells of both 
TMA cohorts were pooled, a tail of elongated cells with high aspect ratio and low 
circularity became apparent (Figure 5.9A).  To further characterize this subpopulation 
of elongated cells, confocal laser scanning microscopy was used to carry out high 
resolution three-dimensional imaging of immunofluorescence-stained PCSP cells. They 
were found to have striking lamellipodia-like protrusions (Figure 5.9B, arrows) and 
polarized cell bodies and nuclei (Figure 5.9B, arrowheads). The elongated shape and 
prominent protrusions provide further evidence that PCSP cells may be a migratory cell 
type. This evidence is further compounded by the finding of PCSP cells in adjacent 
normal prostate tissue in Chapter 5.3.4. 
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Table 5.4: Summary of shape descriptors and statistics from PCSP cells in both 







Area	 72.14	 41.31	 66.42	 35.09	
Circularity	 0.70	 0.13	 0.69	 0.12	
Aspect	
Ratio	
1.83	 0.68	 1.88	 0.62	
Roundness	 0.60	 0.17	 0.58	 0.16	
Solidity	 0.88	 0.07	 0.88	 0.06	
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Figure 5.9: PCSP cells are elongated and have lamellipodia-like protrusions. 
(A) Pooled single cell measurement data of PCSP cells from both tissue microarray 
cohorts, showing a continuum between a more rounded cell morphology (circularity and 
aspect ratio close to 1) and a tail of cells assuming a more elongated cell shape with 
lower circularity and higher aspect ratio was observed. (B) Sequential slices are shown 
through a z-stack of IF-stained PCSP cells in a 5µm thick prostate tumour tissue section, 
showing elongated cell morphology, polarized nuclei and lamellipodia-like protrusions. 
Optical sections are 1µm apart. Blue: DAPI; Green: SDC1. Scale bar: 10µm. 
 
5.4 Discussion 
By examining SDC1 expression in normal prostate and prostate carcinoma specimens, I 
confirmed that SDC1 expression is lost in prostate carcinoma. Moreover, SDC1 
expression identifies a previously unreported cell population in the stroma of prostate 
adenocarcinoma with two different anti-SDC1 antibodies in three different patient 
cohorts and in adjacent normal tissue. These PCSP cells do not express lineage markers 
of common epithelial, stromal or immune cell lineages, including the plasma cell 
population which is marked by SDC1 expression (Maiga et al., 2014; Chilosi et al., 
1999).  PCSP cells display a continuum of rounded and elongated morphologies 
consistent with a migrating cell type, and appear in high burdens in a subset of primary 
Gleason grade 5 tumours. Gleason grade 5 morphology is a poor prognostic indicator, 
making this cell population an interesting but currently unidentified cell type.  
5.4.1 Epithelial SDC1 expression is lost in prostate carcinoma but SDC1-
expressing stromal cells are present 
Previous research on SDC1 expression has identified that the proteoglycan is expressed 
in basal cells of the benign prostate epithelium and epithelial expression is reduced 
overall in malignant tissue (Chen et al., 2004a; Shimada et al., 2009; Shariat et al., 
2008; Fujii et al., 2015), though some tumours continue to express SDC1 in their 
epithelial compartments in a cytoplasmic or membranous localization (Chen et al., 
2004a; Shariat et al., 2008; Fujii et al., 2015). However, this is controversial, with some 
studies reporting that there is no difference in epithelial SDC1 expression between 
benign and tumour tissue (Brimo et al., 2010). This study agrees with the former 
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findings, with the presence of basal cell staining of SDC1 in benign tissue providing a 
good positive control for antibody specificity.  
In addition to these previously demonstrated patterns, SDC1-expressing PCSP cells 
were found in the stroma of prostate carcinoma specimens. This is the first time that 
PCSP cells have been identified in prostate tumours, despite numerous attempts to 
characterise SDC1 expression patterns in prostate tumours. An in situ hybridisation 
study of multiple epithelial tissues found epithelial but not stromal mRNA localisation 
in both normal prostate and prostate carcinoma (Mennerich et al., 2004). It is possible 
that the focal and scattered nature of these cells, and their presence in only a third of 
surveyed tumour cores by TMA, has caused them to be missed in previous studies. The 
experimental evidence for the existence of an SDC1-expressing stromal cell population 
in this work is strong: PCSP cells were found in three independent patient cohorts and 
with two different anti-SDC1 antibodies, with staining specificity confirmed by double 
IF on benign and malignant prostate. This makes antibody-specific or fixation-induced 
staining artifacts an unlikely explanation for the staining pattern.  
There may be precedent for stromal expression of SDC1: T47D breast carcinoma cells 
co-cultured with mammary fibroblasts induce SDC1 expression and ectodomain 
shedding in the mammary fibroblast compartment, which is required by the carcinoma 
cells for a proliferative response to FGF2 (Su et al., 2007). This suggests that autocrine 
or paracrine signalling between carcinoma cells and their stroma can result in SDC1 
expression and shedding in the stromal compartment, at least in the breast. Evidence for 
an epithelial-stromal interaction that promotes SDC1 stromal expression is supported by 
the finding that breast, lung and colon tissues switch from an epithelial to a stromal 
pattern of SDC1 expression in carcinoma (Mennerich et al., 2004). However, this has 
yet to be demonstrated in prostate carcinoma. To more thoroughly demonstrate the 
existence of PCSP cells in prostate tumours, it would be necessary to isolate them from 
fresh tissue and characterise them in a tissue culture system in vitro, or produce patient-
derived xenografts from confirmed PCSP-bearing tumours to study the phenomenon 
further in mice. 
5.4.2 PCSP cell burden may indicate a non-recurrent tumour in the Bath 
cohort 
When the epithelial and stromal staining patterns of SDC1 staining in prostate tumours 
were quantified and associated with clinical data, I found that SDC1 epithelial staining 
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has no effect on recurrence status or Gleason grade. This is consistent with several 
previous reports on SDC1 expression by IHC which suggest it is not associated with 
recurrence (Purushothaman et al., 2010; Brimo et al., 2010) or with Gleason grade 
(Brimo et al., 2010). In contrast, PCSP cell burden showed a trend towards being 
positively associated with non-recurrent tumours, suggesting that the presence of these 
cells may be associated with favourable outcome. Other infiltrating cells in tumours, 
such as mast cells, have been previously associated with favourable outcome in prostate 
cancer patients (Fleischmann et al., 2009). However, given the small size of the Bath 
Cohort, further examination of a larger patient cohort would be required to verify this 
finding. 
5.4.3 Primary Gleason grade 5 tumours are enriched in PCSP cell burden 
Interestingly, we observed that there is a trend towards increased burden in the primary 
Gleason grade 5 tumours, suggesting that it might also be related to outcome given that 
assignment of a high Gleason grade is a predictor of metastasis and thus poor prognosis 
(Antonarakis et al., 2012). While cohort 2 showed a significant association between 
primary Gleason grade and the presence of a PCSP cell burden, cohort 1 did not reach 
significance. Meanwhile, the Bath Cohort did not contain any patients with primary 
Gleason grade 5 tumours, and yet all tumours showed some evidence of PCSP cell 
burden, even if small. These discrepancies could be due to differences in sampling 
strategy between the cohorts. In the case of tissue microarrays, the two studies had 
different core numbers and diameters, with cohort 1 having duplicate 1mm cores and 
cohort 2 having single 1.5mm cores. In the case of the Bath Cohort, core needle 
biopsies and prostatectomy specimens acquire far more tissue by area than could be 
represented in a single TMA core. This could lead to differences in successful detection 
of SDC1+ cells in tumours given their scattered nature. The utility of PCSP cells as a 
biomarker could be clarified by conducting a larger study focused on detecting PCSP 
cells in core needle biopsies, where many small cores can be taken for analysis to 
investigate the distribution and detection rate of cells and its impact on biomarker 
efficacy.  
5.4.4 PCSP cells are a cryptic cell type in prostate tumours 
By using multiplex immunofluorescence, we looked for co-staining of classical 
epithelial, mesenchymal, stromal and immune markers with the PCSP cell population. 
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We found no significant overlap between any classical lineage marker tested and PCSP 
cells, indicating a currently unidentified cell type. Several studies have specifically 
reported the absence of stromal SDC1 staining in prostate tumours (Chen et al., 2004a; 
Szarvas et al., 2016b; Shariat et al., 2008). We are also unable to detect a widespread 
stromal staining pattern in either benign prostate or prostate tumour tissue. PCSP cells 
do not show common markers of stromal cell types, and it is possible that the focal 
nature of this cell type – and their presence in a subset of tumours - has made this 
phenotype more difficult to detect. However, two separate antibodies recognizing SDC1 
have reliably detected this cell population - in both immunohistochemistry and 
immunofluorescence and using three different patient cohorts. 
I considered that the PCSP cell population could be immune cells, given their observed 
proximity to inflammation. SDC1 is a marker of plasma cell differentiation, being 
expressed at the later stages of the transition from plasmablast into a mature plasma cell 
(De Vos et al., 2006). Using three markers that would encompass a range of immune 
cell lineages including B- and T-cell repertoires, we were unable to identify an immune 
cell marker profile in PCSP cells. Given the enormous diversity in the immune cell 
repertoire, it is still possible that PCSP cells represent an immune cell population. 
Chronic inflammation is commonplace in the prostate (Nickel et al., 2008) and clusters 
of lymphocytes have been documented to surround prostate tumour tissue previously, 
such as the FOXP3+/PD-1+/PD-L1+ population of regulatory T-cells reported by Ebelt 
et al. (2009), and other studies have observed the infiltration of cytotoxic and regulatory 
T-cells following androgen deprivation therapy (Mercader et al., 2001; Sorrentino et al., 
2011). Additionally, mast cells have been shown to infiltrate into the stroma of prostate 
tumours (Fleischmann et al., 2009). However, the fact that immune cells tend to express 
both SDC1 and the pan-leukocyte marker CD45 (Maiga et al., 2014), whilst PCSP cells 
are CD45-, would suggest that this is an atypical immune cell or non-immune cell 
population. Tumour-associated macrophages - a component commonly associated with 
inflammation in tumours – also express CD45 being a leukocyte population, and that 
makes it unlikely that PCSP cells represent a subset of that population either.  
I next examined whether PCSP cells could be epithelial cells (basal, luminal or 
otherwise). Co-staining with epithelial markers again failed to mark a significant 
portion of the PCSP cell population. One study has shown a positive correlation 
between the expression of epithelial SDC1 and E-cadherin and β-catenin, with a trend 
towards decreased expression as Gleason grade increases (Contreras et al., 2010). There 
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remains the possibility that PCSP cells could have undergone dedifferentiation, as they 
do not possess an epithelial identity consistent with tumour cells. Epithelial-
Mesenchymal Transition (EMT) is an unlikely explanation for this observation, as 
PCSP cells also lacked mesenchymal markers such as Vimentin and N-Cadherin. 
Another possibility for the lack of differentiation markers is a stem-like status, either 
derived from a resident prostate cell population or from a mobilized stem cell niche 
such as Mesenchymal Stem Cells (Cheng et al., 2016) or cancer stem cells. There is 
evidence that SDC1 signalling is involved in maintaining the tumour-initiating cell 
(TIC)/cancer stem cell (CSC) population in the prostate carcinoma cell line PC-3, where 
its expression marks a population of CD133+/CD44+ stem-like holoclones (Shimada et 
al., 2013). Additionally, putative CSCs from the 22Rv1 and DU145 prostate cancer cell 
lines lack expression of basal or luminal differentiation markers, suggesting that a 
dedifferentiated CSC-like cell population might not express differentiated cell type 
markers and thus evade our method of cell type characterisation. Testing this hypothesis 
in PCSP cells would require extensive co-staining with stem cell markers and/or 
functional assays with PCSP cells isolated in vitro.  
Another possibility is that SDC1 is being shed from other cell types in the prostate and 
bound or taken up by PCSP cells, which cannot yet be excluded because the anti-SDC1 
antibody clone H-174 also recognises the soluble ectodomain, and the binding epitope 
for the B-A38 antibody is unknown. Additionally, while SDC1 expression is lost in the 
epithelial compartment, some residual heterogeneous SDC1 staining is often observed 
which could potentially correspond to the shed form of the protein being produced in 
tumour cells. Shed SDC1 from tumour cells has been shown to enter stromal cells in a 
non-cell autonomous manner previously (Stewart et al., 2015). Future attempts to 
distinguish whether the recognised protein on the surface of PCSP cells is shed or full-
length would require staining with antibodies specific to the soluble ectodomain and the 
core protein. 
5.4.5 The PCSP cell population is also present in adjacent normal tissue 
and may contain migratory cells 
Our data suggest that, while PCSP cells are predominantly present in a subset of 
prostate tumours, histologically normal tissue adjacent to a carcinoma can also harbour 
PCSP cells. This would be consistent with the hypothesis of a migratory cell population 
either recruited from other tissues, or migrating out from the prostate tumour. Detection 
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of PCSP cells in adjacent normal tissue could expand the diagnostic and prognostic 
utility of the biomarker in a biopsy setting, where many small cores are taken and 
histologically normal tissue is a common finding. It is possible that, if the PCSP cell 
type is only present in benign tissue that is adjacent to a carcinoma, it may be possible 
to both confirm diagnosis and glean prognostic information from even a normal tissue 
core. Additionally, a recent study has demonstrated a prognostically relevant field effect 
at the gene expression level that can be detected in adjacent normal tissue to prostate 
tumours (Magi-Galluzzi et al., 2016), suggesting that using such tissue for 
prognostication could be feasible if suitable biomarkers were identified. A larger study 
with a larger proportion of matched normal adjacent tissue would be required to further 
assess the diagnostic and prognostic importance of PCSP cell presence in both benign 
and malignant tissue settings. 
The hypothesis of PCSP cells being migratory is further supported by morphological 
data, suggesting a continuum of rounded and elongated cells. SDC1 can be shed and it 
is possible that the protein being detected is the shed version acting in a non-cell-
autonomous manner, rather than expressed by PCSP cells. To characterize the 
behaviour of these cells in more detail, migration and chemotaxis assays would need to 
be performed on live cells from fresh patient tissue. Alternatively, more information 
about PCSP cell morphology could be obtained in situ by co-staining for components of 
the actin cytoskeleton and focal adhesions in prostate tumours. 
5.4.6 Conclusions 
Although the prognostic importance of tissue (Zellweger et al., 2003; Chen et al., 
2004a; Shariat et al., 2008; Shimada et al., 2009; Brimo et al., 2010; Contreras et al., 
2010; Ledezma et al., 2011; Poblete et al., 2014) and serum SDC1 (Szarvas et al., 
2016b) has been assessed by multiple studies and remains controversial, the prognostic 
significance of PCSP cells had not been elucidated. The current study is the first to 
identify stromally-located SDC1+ cells, an unknown cell type, found in prostate 
carcinoma and its adjacent normal tissue, and their heightened burden in Gleason 
pattern 5 tumours. This provides the foundation for a detailed investigation into the 
identity - and diagnostic and prognostic utility - of PCSP cells in prostate carcinoma. 
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6 FINAL DISCUSSION 
Prostate cancer is a challenging disease to diagnose and prognosticate, as many patients 
present with disease that may not be a significant risk to health, whereas a subset of 
approximately 20-25% of patients will experience recurrence following primary 
therapy. Gleason grade and tumour stage are currently the best prognostic biomarkers 
available, and biomarkers that better predict patient outcome are urgently needed. The 
current project aimed to identify new biomarkers to predict disease recurrence in 
primary tumour samples from patients with prostate cancer, in attempt to risk-stratify 
patients and produce more tailored therapies. 
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6.1 Main conclusions 
This thesis presents the following key findings: 
• Potential biomarkers related to stem cells and cancer stem cells could be 
identified using a literature searching approach, with SDC1, BMI1, MUC1-C, 
ALDH7A1, Nestin and ZSCAN4 being selected for evaluation by IHC. Out of 
these, heparan sulphate proteoglycan SDC1 and pluripotency factor ZSCAN4 
show novel staining patterns in prostate tumours that warrant further 
investigation. 
• A bioinformatic approach identified secreted matrix protein RS1 and SLC31A1 
as potential biomarkers. As well as being overexpressed at the mRNA level in 
relapsing tumours, the RS1 gene is amplified in up to 32% of metastatic and 
castration-resistant prostate tumours. Bath cohort evidence suggests that RS1 
protein expression may be elevated in recurrent primary prostate tumours at the 
protein level, and negatively correlated with AR protein expression. 
• The extremes of expression analysis method was developed to study the 
potential functional consequences arising from elevated expression of genes of 
interest at the transcriptional level. The method confirms already known 
functions of SDC1 in prostate cancer transcriptome datasets as well as 
identifying hypothetical new functions for ZSCAN4 in metabolism. 
• SDC1 is expressed in a novel cell type, referred to as Prostate Cancer SDC1-
Positive Stromal (PCSP) cells, in the stroma of approximately a third of primary 
tumours and in adjacent normal tissue. These cells do not express markers of 
immune cell, epithelial or mesenchymal differentiation, making them an 
unidentified cell type. Additionally, PCSP cells show evidence of lamellipodia-
like structures and an elongated cell shape suggestive of a migratory cell type, 
although this requires further investigation. 
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6.2 Biomarker identification methods were effective but could be 
improved 
This project utilised both a manually-curated literature searching approach and a 
bioinformatic approach to identify biomarkers related to recurrence and cancer stem 
cells (Chapter 3). Interestingly, although every potential biomarker identified by 
literature searching had been reported to be expressed in putative CSCs with the 
exception of ZSCAN4, SDC1 and ZSCAN4 were the only biomarkers to show 
restricted patterns of protein expression to a subset of epithelial or stromal cells 
(Chapter 4). The rest of the markers showed widespread staining in glandular 
epithelium, suggesting that they alone do not identify a stem-like fraction within 
prostate tumours. Stem-like cell populations would be expected to constitute only a 
small fraction of epithelial tissues, and the CSC population of prostate cancer cell lines 
and primary tumours is similarly restricted to a subpopulation of cells characterised by 
the expression of multiple markers or properties (see Chapter 1.3). For example, when 
the pluripotency marker ZSCAN4 was originally identified, whole mount in situ 
hybridisation found that it had a heterogeneous and restricted expression pattern in 
mouse embryonic stem cell colonies (Falco et al., 2007; Carter et al., 2008). Therefore, 
while the literature searching approach has identified several potential biomarkers of 
interest in prostate cancer, it does not appear to identify CSCs in this tissue. 
One disadvantage of the approaches taken in this project, where candidates are filtered 
and tested by IHC, is that only a small number of proteins can be examined. To identify 
CSC markers related to prostate cancer, I speculate that an experimental screening 
approach could be invaluable when combined with the initial candidate biomarker 
approach. However, antibody staining by IHC often requires optimisation of reaction 
conditions, which was often difficult to achieve for many of our antibodies in the mouse 
TMA constructed (Chapter 3), and prostate biopsies are too small and precious to use 
for optimisation purposes. A high-throughput screen of many proteins by IHC in 
prostate tissue is therefore unfeasible. In contrast, high-throughput expression screening 
by in situ hybridisation is readily used for heterogeneous mRNA expression pattern 
detection in embryonic stem cells (Carter et al., 2008) and even in model organisms 
such as Medaka embryos (Quiring et al., 2004). In situ hybridisation screening could be 
conducted on explanted prostate tumour tissue or prostate cancer cell lines in a high-
throughput setting, using a panel of probes recognising previously identified stem cell 
markers, candidate genes such as those identified by literature searching, or even probes 
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generated from a human embryonic stem cell cDNA library. Heterogeneous or restricted 
expression patterns could then be further characterised in vitro and in human prostate 
tumour tissue to identify candidate markers for putative CSCs. Such an approach would 
provide additional experimental validation before potential biomarkers are investigated 
in depth.  
It is important to note that, despite only 7 candidates being tested by IHC in total, both 
approaches yielded potential biomarkers of interest in prostate cancer, suggesting that 
the literature searching and bioinformatics methods are effective in identifying potential 
candidates. Examples include: a heightened burden of SDC1-expressing PCSP cells 
being related to high-grade tumours, ZSCAN4 being heterogeneously expressed in a 
subpopulation of prostate cancer patients, and RS1 being associated with recurrence. 
The main limitation of this approach was in sample size, as the Bath Cohort was not 
large enough to fully test the relationships between potential biomarkers and the clinical 
data. Future work for characterisation of these markers should therefore include larger 
patient cohorts, likely using tissue microarray technology, and should also include 
important clinical data such as recurrence-free survival and overall survival. 
While many markers of putative CSCs in the human prostate are related to 
tumorigenicity and metastasis in mouse xenograft models, it remains to be seen if a 
population of CSCs exist in the human prostate tumour in situ (see Chapter 1.3). This 
project found biomarkers with relationships to clinical variables but did not find any 
biomarker expression patterns that were consistent with a CSC niche in prostate 
tumours. Therefore, the question of whether CSCs are related to recurrence of prostate 
carcinoma still remains to be addressed. Regardless of the existence of prostate CSCs, 
the phenotypes associated with putative prostate CSC populations such as CD44-
expressing cells, including an increased propensity for proliferation and metastasis 
(Patrawala et al., 2006), and the ability of these markers to regulate these phenotypes 
(Liu et al., 2011a), both suggest a relationship with prostate cancer cell behaviour that 
may be prognostically relevant. 
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6.3 Integration of data from the DNA, RNA and protein levels is 
essential for characterising potential biomarkers in prostate 
tumours 
The landscape of prostate cancer is marked by many different mutational events, from 
its potential beginnings in PIA or PIN through to carcinoma and castration-resistant 
disease (Chapter 1.2.3). These mutations, which can be due to point mutations, 
rearrangements, losses and gains of individual loci or even whole chromosomes and 
chromosomal arms, are thought to be key for driving disease progression and may even 
be predictive of recurrence (Hieronymus et al., 2014). There have been several attempts 
to profile the genomes and transcriptomes of both primary prostate tumours (Tomlins et 
al., 2007; Abeshouse et al., 2015; Ellwood-Yen et al., 2003; Grasso et al., 2012; Taylor 
et al., 2010) and castration-resistant disease (Tomlins et al., 2007; Grasso et al., 2012; 
Robinson et al., 2015) in order to identify key drivers and signalling pathways involved 
in prostate cancer progression and therapeutic resistance. Harnessing this wealth of data 
at the DNA and RNA level has merit for both identifying potentially novel biomarkers 
and for filtering and further characterising biomarkers identified by other means.  
A good example of this is RS1, which was identified as being upregulated at the mRNA 
level in recurrent prostate tumours in a cDNA microarray dataset (Chapter 3). This trend 
was also apparent at the protein level by IHC as well as a negative correlation between 
RS1 protein levels and AR protein levels, although a larger patient cohort is required to 
verify these findings (Chapter 4). When combined with data from a meta-analysis of 
large-scale prostate cancer genomics studies, which found that RS1 is amplified in 
castration-resistant prostate carcinomas, the integrative approach creates a stronger case 
for continued study of RS1 in prostate cancer as a potential prognostic biomarker.  
Another example that supports the use of an integrative approach comes from the study 
of SDC1, where the extremes of expression method adds additional weight to the 
hypotheses generated as a result of the data generated (Chapter 5). I found a novel cell 
type expressing SDC1, PCSP cells, in prostate tumour tissue and its adjacent normal 
tissue, but these cells still remain unidentified despite attempts to identify their 
differentiation markers. Morphological examination of PCSP cells suggested that they 
may be a migratory cell type, but this has yet to be confirmed. Extremes of expression 
analysis on SDC1 in two prostate cancer cDNA microarray datasets (Chapter 3) 
provided additional information on potential roles of SDC1 expression in prostate 
tumours: GO terms associated with cell motility and cell adhesion and the acute 
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immune response were enriched in patients with high expression of SDC1 in their 
tumours. Given that SDC1 expression is often lost in prostate carcinoma, and that these 
transcriptomics datasets measure the transcriptome from all components of the tumour 
tissue, it is tempting to speculate that this expression pattern and its GO terms are 
reflecting PCSP cells. Moreover, the proximity of PCSP cells to inflammation and their 
elongated cell shapes with observed lamellipodia-like structures in vivo (Chapter 5) are 
further evidence to back up the observations from the extremes of expression analysis in 
silico. These combined findings also inform the direction of future experiments, which 
should aim to identify the cell type marked by PCSP cells, and additionally characterise 
their biological properties – including cell migration - in vitro and in vivo. 
6.4 Final conclusion 
In summary, the current project attempted to identify new prognostic biomarkers for 
prostate cancer. The work presented in this thesis suggests that, while a CSC-related 
candidate biomarker approach is insufficient to identify CSCs in prostate tumours, both 
candidate biomarker and bioinformatics approaches are suitable for identifying potential 
biomarkers for prostate cancer. 7 potential biomarkers were identified using literature 
searching and bioinformatics techniques, further characterised using bioinformatics 
analysis of microarray and genomics data, and subjected to evaluation by IHC. SDC1 
marked an unidentified cell type found in the stroma of Gleason pattern 5 tumours; RS1 
was potentially upregulated in recurrent prostate tumours and amplified in castration-
resistant disease; and ZSCAN4 had a heterogeneous expression pattern that was present 
in a subset of prostate tumours with as yet undefined clinical and biological 
characteristics. Therefore, at least 3 of 7 potential biomarkers warrant more extensive 
investigation in prostate tumours. 
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APPENDIX 1: CODE FOR EXTREMES OF EXPRESSION 
ANALYSIS AND SUBSEQUENT GO ENRICHMENT ANALYSIS 
 
# Extremes of Expression Analysis R Code Functions 
# Segregates data on 10th/90th percentiles of expression 
# Conducts a differential expression analysis on these groups 
# Attempts to determine functions co-regulated with genes 
# of interest in microarray expression data. 
# Author: Benjamin Peter Sharpe 
################################################################ 
#Internal functions for dichotomising the data on 10th/90th percentiles 
#IDs for a gene must be looked up manually using the platform information or by 
calling fData() on the ExpressionSet to extract feature info. 
#Eset is expression data that can be generated by calling exprs() on an object of class 
ExpressionSet, producing a 2d array of intensities labelled by sample ID and probe ID. 
 
Extreme_lower<-function(Eset, Probe){lowertruncated<-




Eset[,Eset[Probe,]>quantile(Eset[Probe,], 9/10)] #Identifies samples in the upper 90th 
percentile 
 return(colnames(uppertruncated))} 
Function.LowTruthsAsOne<-function(q){if(q==TRUE) 1 else 0} 
Function.HighTruthsAsTwo<-function(y){if(y==TRUE) 2 else 0} 
Function.RecogniseNumbersAsFactors<-function(z){if(z==0) "MID" else( #Function 
for recognising samples as low, medium or high categories based on above functions. 
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     if(z==1) "LOW" else "HIGH")} 
Factors.Extreme<-function(Eset, Probe){ #Returns a list of samples labelled with 
"LOW", "MID", or "HIGH" based on intensity values of probe. 
 Lower.Matrix<-colnames(Eset) %in% Extreme_lower(Eset, Probe) 











#Internal functions for colour assignment of heatmaps in R based on factors passed 
from Factors.Extreme 
#Assigns blue colour label to 'low' samples, yellow colour label to 'high' samples and 
optional grey colour to 'mid' samples (if boolUseMidSamples is set to true it will 
heatmap intermediate samples also) 
Color.assignment<-function(x, boolUseMidSamples=c(FALSE, 
TRUE)){if(boolUseMidSamples==FALSE){if(x=="LOW") "BLUE" 
else(if(x=="HIGH") "YELLOW")} else {if(x=="LOW") "BLUE" else(if(x=="HIGH") 
"YELLOW" else "GRAY")}} 
Color.labels<-function(Factor, boolUseMidSamples){ 
 unlist(lapply(Factor, Color.assignment, 
boolUseMidSamples=boolUseMidSamples))} 
 
#User-run function.  
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#Eset must be extracted by exprs() on ExpressionSet, Probe manually identified as 
above. Intermediate samples (10%<x<90%) are plotted if boolPlotMidSamples is set to 
true, default false. 
##Function plots a heatmap contrasting top and bottom 10 percentiles with one another, 
conducts differential gene expression analysis on these two groups and writes a csv file 
with the results. 
#boolPlotSubset will plot only the top 50 differentially expressed genes (where they are 
many) - default true. Otherwise, all are plotted. ResultsFileName writes a csv file to the 
specified name. 
#This function will work with Agilent Whole Genome Microarray platforms such as 
GSE35988. The structure of fData is platform-dependent and will need code adjustment 
for different platforms. 
ExtremesOfExpression.Agilent<-function(ExpressionSet, Eset, Probe, 





 AnnotationLookup<-fData(ExpressionSet)[,c("ID", "GENE_SYMBOL", 
"ENSEMBL_ID")] 
 AnnotationLookup<-
AnnotationLookup[!(AnnotationLookup$GENE_SYMBOL==""),] #Removing all 
unannotated probes 
 AnnotationLookup<-AnnotationLookup[AnnotationLookup[,"ID"] %in% 
rownames(Eset),] #Ensuring a match between Annotations and probes on the Eset 
 f<-Factors.Extreme(Eset, Probe) 
 phenoData(ExpressionSet)$CATEGORY<-f #Make a new phenotypic 
data annotation to store Low/mid/high expression categorisation. 
 Eset<-Eset[,!(ExpressionSet@phenoData$CATEGORY=="MID")]
 #Filter out samples labelled with "MID" from the DGE analysis. 
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 f<-factor(f[f %in% c("LOW", "HIGH")]) 
 Eset<-Eset[rownames(Eset) %in% AnnotationLookup[,"ID"],] 
 design<-model.matrix(~f) 
 fit<-eBayes(lmFit(Eset, design)) #Fit linear model to the data 
 TopTable<-topTable(fit, coef=2, number=1000) #Reports top 1000 ranked 
genes from the linear model fit 
 TopTable<-merge(TopTable, AnnotationLookup, by="row.names")
 #Merge ranked genes with feature data including gene symbols. 
 TopTable<-TopTable[,c("Row.names", "logFC", "AveExpr", "t", "P.Value", 
"adj.P.Val", "B", "GENE_SYMBOL", "ENSEMBL_ID")] 
 TopTable<-TopTable[(TopTable$adj.P.Val<0.05),] #Only write results 
significant at the level of p<0.05, P-value adjusted for multiple testing. 
 if(boolPlotMidSamples==FALSE){ 
  Eset_Extremes<-Eset[,f %in% c("LOW", "HIGH")]} 
 else{Eset_Extremes<-Eset} 
 rownames(Eset_Extremes)<-AnnotationLookup[,"GENE_SYMBOL"] 
 selected<-p.adjust(fit$p.value[,2], method="holm") < 0.05 #Use Holm-
Bonferonni method to correct p-value for multiple comparisons testing. 
 Eset_Extremes_Selected<-Eset_Extremes[selected,] 
 if(boolPlotSubset==TRUE){ 
  Eset_Extremes_Selected<-Eset_Extremes_Selected[1:50,]} #Plot only 
top 50 ranked genes if boolPlotSubset=TRUE 
 heatmap.2(Eset_Extremes_Selected, col=redgreen(75), scale="row", 
ColSideColors = Color.labels(f, boolPlotMidSamples), key=TRUE, symkey=FALSE, 
density.info="none", trace="none", cexRow=0.8, cexCol= 0.8) 
 write.csv(TopTable, file=ResultsFileName) 
} 
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#Identical function to ExtremesOfExpression.Agilent, but with fData structure adapted 
to Illumina expression beadchip platforms such as those used by GSE70768. 
ExtremesOfExpression.Illumina<-function(ExpressionSet, Eset, Probe, 





 AnnotationLookup<-fData(ExpressionSet)[,c("ID", "Gene symbol")] 
 AnnotationLookup<-AnnotationLookup[!(AnnotationLookup$"Gene 
symbol"==""),] #Removing all unannotated probes 
 AnnotationLookup<-AnnotationLookup[AnnotationLookup[,"ID"] %in% 
rownames(Eset),] #Ensuring a match between Annotations and probes on the Eset 
 f<-Factors.Extreme(Eset, Probe) 
 phenoData(ExpressionSet)$CATEGORY<-f 
 Eset<-Eset[,!(ExpressionSet@phenoData$CATEGORY=="MID")] 
 f<-factor(f[f %in% c("LOW", "HIGH")]) 
 Eset<-Eset[rownames(Eset) %in% AnnotationLookup[,"ID"],] 
 design<-model.matrix(~f) 
 fit<-eBayes(lmFit(Eset, design)) 
 TopTable<-topTable(fit, coef=2, number=1000) 
 TopTable<-merge(TopTable, AnnotationLookup, by="row.names") 
 TopTable<-TopTable[,c("Row.names", "logFC", "AveExpr", "t", "P.Value", 
"adj.P.Val", "B", "Gene symbol")] 
 TopTable<-TopTable[(TopTable$adj.P.Val<0.05),] #Only write results 
significant at the level of p<0.05, P-value adjusted for multiple testing. 
 if(boolPlotMidSamples==FALSE){ 
  Eset_Extremes<-Eset[,f %in% c("LOW", "HIGH")]} 
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 else{Eset_Extremes<-Eset} 
 rownames(Eset_Extremes)<-AnnotationLookup[,"Gene symbol"] 
 selected<-p.adjust(fit$p.value[,2], method="holm") < 0.05 
 Eset_Extremes_Selected<-Eset_Extremes[selected,] 
 if(boolPlotSubset==TRUE){ 
  Eset_Extremes_Selected<-Eset_Extremes_Selected[1:50,]} 
 heatmap.2(Eset_Extremes_Selected, col=redgreen(75), scale="row", 
ColSideColors = Color.labels(f, boolPlotMidSamples), key=TRUE, symkey=FALSE, 
density.info="none", trace="none", cexRow=0.8, cexCol= 0.8) 
 write.csv(TopTable, file=ResultsFileName) 
} 
 
#User function designed to generate list of GO annotations for each feature on the 
platform used. i.e. generates "Gene Universe". Used for Agilent platforms. 
makeGOAnnotations.Agilent<-function(ExpressionSet){ 
 require(biomaRt) 
 GeneUniverse<-fData(ExpressionSet)[,c("ID", "GENE_SYMBOL")] 
 GeneUniverse<-GeneUniverse[!(GeneUniverse$GENE_SYMBOL == ""),] 
 GeneUniverse<-unique(GeneUniverse$GENE_SYMBOL) 
 mart<-useMart(biomart="ensembl", dataset="hsapiens_gene_ensembl") 
 GOAnnotations<-getBM(attributes=c("hgnc_symbol", "go_id"), 
filter="hgnc_symbol", values=GeneUniverse, mart=mart) #Use BiomaRt to get a list of 
gene symbols and GO IDs which correspond to the gene symbols in our gene universe. 
 GOAnnotations<-aggregate(GOAnnotations$go_id, 
by=list(GOAnnotations$hgnc_symbol), paste) #Process the data so that it is in the 
correct format to be an annotation file for topGO. 
 row.names(GOAnnotations)<-GOAnnotations[,1]  
 GOAnnotations<-cbind(row.names(GOAnnotations), GOAnnotations$x) 
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 row.names(GOAnnotations)<-GOAnnotations[,1]  




#Illumina beadchip platforms have a different fData structure. Adjusted function of 
makeGOAnnotations to suit. 
makeGOAnnotationsIllumina<-function(ExpressionSet){ 
 require(biomaRt) 
 GeneUniverse<-fData(ExpressionSet)[,c("ID", "Gene symbol")] 
 GeneUniverse<-GeneUniverse[!(GeneUniverse$"Gene symbol" == ""),] 
 GeneUniverse<-unique(GeneUniverse$"Gene symbol") 
 mart<-useMart(biomart="ensembl", dataset="hsapiens_gene_ensembl") 
 GOAnnotations<-getBM(attributes=c("hgnc_symbol", "go_id"), 
filter="hgnc_symbol", values=GeneUniverse, mart=mart) #Use BiomaRt to get a list of 
gene symbols and GO IDs which correspond to the gene symbols in our gene universe. 
 GOAnnotations<-aggregate(GOAnnotations$go_id, 
by=list(GOAnnotations$hgnc_symbol), paste) #Process the data so that it is in the 
correct format to be an annotation file for topGO. 
 GOAnnotations<-cbind(GOAnnotations$Group.1, GOAnnotations$x) 
 row.names(GOAnnotations)<-GOAnnotations[,1] 




#User function for conducting GO enrichment analysis of significantly upregulated and 
downregulated genes based on probe expression, using the csv file generated from 
ExtremesOfExpression.  
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#Can specify GO analysis of Biological Process "BP", Molecular Function "MF or 
Cellular Component "CC", can specify how many GO terms to list using ResultsToList 
parameter. 
#Generates two CSV files of results, one for 'upregulated in high' and one for 
'downregulated in high'. 
DoGOAnalysis<-function(GOAnnotations, TopTableFile, GO_category=c("BP", 
"MF", "CC"), ResultsToList){ 
 require(topGO) 
 options(width=600) 
 interestingGenes<-read.csv(TopTableFile, header=TRUE) #Load the csv file 
of the top 1000 (or those which adj.p.val<0.05, whichever is smaller) differentially 
expressed genes produced by ExtremesOfExpression. 
 i <- sapply(interestingGenes, is.factor) 
 interestingGenes[i] <- lapply(interestingGenes[i], as.character) 
 DOWN.in.HIGH<-unique(interestingGenes[interestingGenes$logFC>0, 9]) 
#Choose only those genes which are downregulated in high expressers (positive logFC), 
get a list of their gene symbols. 
 in.Genes.DOWN<-factor(as.integer(names(GOAnnotations) %in% 
DOWN.in.HIGH)) #Make a list of factors denoting which of genes in our universe are 
part of our interesting set of genes. 
 names(in.Genes.DOWN)<-names(GOAnnotations) #These factors must be 
labelled by gene name, in this case. 
  
 UP.in.HIGH<-unique(interestingGenes[interestingGenes$logFC<0, 9]) #Do 
the same for those genes upregulated in high expressers. 
 in.Genes.UP<-factor(as.integer(names(GOAnnotations) %in% UP.in.HIGH)) 
 names(in.Genes.UP)<-names(GOAnnotations) 
  
 #Instantiate objects of class topGOdata to put our own data into. 
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 GOdata_down<-new("topGOdata", ontology=GO_category, 
allGenes=in.Genes.DOWN, annot=annFUN.gene2GO, gene2GO=GOAnnotations, 
nodeSize=5) 
 GOdata_up<-new("topGOdata", ontology=GO_category, 
allGenes=in.Genes.UP, annot=annFUN.gene2GO, gene2GO=GOAnnotations, 
nodeSize=5) 
  
 #Conduct Fisher's Exact Tests to determine significantly enriched GO nodes, 
and store two objects containing the results 
 results.fisher.down<-runTest(GOdata_down, algorithm="classic", 
statistic="fisher") 
 results.fisher.up<-runTest(GOdata_up, algorithm="classic", statistic="fisher") 
  
 #Summarise the results in a table using the GenTable function. 
 top.x.results.down<-GenTable(GOdata_down, 
classicFisher=results.fisher.down, orderBy="classicFisher", topNodes=ResultsToList, 
numChar=300) 
 top.x.results.up<-GenTable(GOdata_up, classicFisher=results.fisher.up, 
orderBy="classicFisher", topNodes=ResultsToList, numChar=300) 
  





 names(Results$Up)<-c("GO ID", "Term", "Annotated", "Significant", 
"Expected", "p-Value") #Rename our table columns for presentation's sake. 
 names(Results$Down)<-c("GO ID", "Term", "Annotated", "Significant", 
"Expected", "p-Value") #Do the same with Down in High. 
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 write.csv(Results$Down, file=paste("DownInHigh.", ResultsToList, ".", 
GO_category, ".", TopTableFile, sep="")) 
 write.csv(Results$Up, file=paste("UpInHigh.", ResultsToList, ".", 
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APPENDIX 2: NEGATIVE CONTROL STAINING WITHOUT 
PRIMARY ANTIBODIES ON MOUSE TMA SECTIONS 
  
Mouse No Primary (Negative Control) 
  
Run 1 Run 2 Run 3 Run 4 Run 5 Run 6 
Lung 1 X C C C C C 
  2 C X - C C C 
  3 C C C   C C 
  4 X X X C C X 
  5 C X X C   C 
  6 X C C C C C 
Kidney 1 X C C C C C 
  2 X C C - - C 
  3 - - X C C X 
  4 - C C - - C 
  5 X X X     X 
Liver 4 - X X C   X 
  5 - - - - - - 
  6 X - X - - - 
  7 - - - - - X 
  8 - - - - - 
Junctiona
l 









  10 
Junction
al X -     X 
Brain 1 - - - - - - 
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  2 - X - - - - 
  3 - - C   - - 
Pancreas 1 - C C - - - 
  2 - - C - - - 
  3 - - X - - X 
Intestine 1 - - - - - C 
  2 - - - - - C 
  3 X X X - - X 
Skin 1 - X X - - - 
  2 - X X - - C 
  3 X - -     X 
Spleen 1 C - X     X 
  2 X C C C C C 
Skeletal 
Muscle 1 X - C - - - 
  2 - - X C   X 
Heart 1 C - C - C C 
  2 C C C C C C 
Ovary 1 - X X     X 
  2 X X X     X 
Testis 1 - - - - - - 
  2 - - - - - - 
Prostate 1 X - - - - - 
  2 X - - - - - 
  3 X X X - - - 
  4 - - - - - - 
Prostate Cancer Stem Cells: Potential New Biomarkers 
310  Benjamin Peter Sharpe - November 2016 
  5 X - - - - - 
  6 X X X -   X 
  7 - - - - - - 
  8 - - - - - - 
% Core 











        
 
  
= absent core 
material 
    
  
N = nuclear staining 
    
  
C = cytoplasmic 
staining 
    
  
M = membranous 
staining 
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Rabbit No Primary Negative Control 
  
Run 1 Run 2 Run 3 Run 4 Run 5 
Lung 1 C C C X C 
  2 X X C C X 
  3 - C C C X 
  4 X X   X X 
  5 X X - C - 
  6 C C C C - 
Kidney 1 - - C X - 
  2 - X C C - 
  3 - - C C X 
  4 - - - - - 
  5 X X   X X 
Liver 4 X X   X X 
  5 - - - - - 
  6 - - - - - 
  7 - - - - - 
  8 - - - X - 
  9 - X - - - 
  10 X X   X X 
Brain 1 - - - - - 
  2 - - - - - 
  3 - - - - - 
Pancreas 1 - - - - - 
  2 - X - - - 
  3 X X - - X 
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Intestine 1 - X - - - 
  2 - - - X - 
  3 X - - - X 
Skin 1 - -   X X 
  2 - -   X X 
  3 - X   X X 
Spleen 1 X X   X X 
  2 - - C C - 
Skeletal 
Muscle 1 - - - C X 
  2 - X   X X 
Heart 1 - X C C C 
  2 C C C X C 
Ovary 1.1 X X   X X 
  1.2 X X   X X 
Testis 1.1 - - - - - 
  1.2 - - - - - 
Prostate 1 - - - - - 
  2 - - - - - 
  3 - X - X - 
  4 - - - X - 
  5 - - - - - 
  6 X X   X X 
  7 X X - C - 
  8 - - - - - 
% Core Loss   27.08333333 41.66666667 25 39.58333333 37.5 
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   = absent core material 
   
  
N = nuclear staining 
   
  
C = cytoplasmic staining 
   
  
M = membranous staining 
   
  
Moderate blood vessel and extracellular staining is ignored. 
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APPENDIX 3: SUMMARY OF ANTI-ALDH7A1 IHC 
EXPERIMENTS ON MOUSE TMA SECTIONS 
  
ALDH7A1 1:200, Tris/EDTA Antigen Retrieval 
  
Run 1 Run 2 Run 3 
Lung 1 C N C 
  2 X X C 
  3 C N/C C 
  4 X X C 
  5 X X C 
  6 C N C 
Kidney 1 N N N 
  2 N X N 
  3 N N N 
  4 N N N 
  5 X N X 
Liver 4 X X X 
  5 N N N 
  6 N N X 
  7 N N N 
  8 N N X 
  9 X X N 
  10 X X N 
Brain 1 N N  N 
  2 N N N 
  3 N N N 
Pancreas 1 N N N 
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  2 N N N 
  3 X X N 
Intestine 1 - X C/N 
  2 C/N C/N C/N 
  3 X C/N C/N 
Skin 1 C C - 
  2 C N - 
  3 C X C 
Spleen 1 X X X 
  2 C C C 
Skeletal Muscle 1 C C C 
  2 C C C 
Heart 1 C/N X C/N 
  2 C C N 
Ovary 1.1 X X X 
  1.2 X X X 
Testis 1.1 C/N C/N C/N 
  1.2 C/N C/N C/N 
Prostate 1 - C C 
  2 C C C 
  3 X X C 
  4 C C C 
  5 C C C 
  6 X X X 
  7 X X C 
  8 C C C 
Prostate Cancer Stem Cells: Potential New Biomarkers 
316  Benjamin Peter Sharpe - November 2016 
% Core Loss 31.25 35.4166667 16.6666667 
     
 
X = absent core material 
N = nuclear staining 
C = cytoplasmic staining 
M = membranous staining 
- = no staining 
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APPENDIX 4: SUMMARY OF ANTI-ZSCAN4 IHC 
EXPERIMENTS ON MOUSE TMA SECTIONS 
  
ZSCAN4 1:200, Citrate Antigen Retrieval 
  
Run 1 Run 2 Run 3 
Lung 1 X C C 
  2 C X C 
  3 C C C 
  4 X X C 
  5 C X C 
  6 X C C 
Kidney 1 X C C 
  2 X X C 
  3 - C C 
  4 - C C 
  5 X C C 
Liver 4 C X X 
  5 - C C 
  6 X C C 
  7 C C C 
  8 C C X 
  9 X X C 
  10 Junctional X X 
Brain 1 - - C 
  2 - C C 
  3 - C C 
Pancreas 1 C - - 
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  2 - - C 
  3 - X - 
Intestine 1 - X C 
  2 - C C 
  3 X C C 
Skin 1 X C C 
  2 C C C 
  3 X X C 
Spleen 1 C X X 
  2 X C C 
Skeletal Muscle 1 X X C 
  2 C C C 
Heart 1 C X C 
  2 C C C 
Ovary 1.1 C X X 
  1.2 X X X 
Testis 1.1 C N/C C 
  1.2 C C C 
Prostate 1 X - C 
  2 X C C 
  3 X X - 
  4 - C C/M 
  5 X X C 
  6 X X X 
  7 - - - 
  8 - C C 
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% Core Loss 39.5833333 37.5 12.5 
     
 
X = absent core material 
N = nuclear staining 
C = cytoplasmic staining 
M = membranous staining 
- = no staining 
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APPENDIX 5: BATH COHORT STUDY PROTOCOL AS 
APPROVED BY NHS R&D 
Introduction 
Prostate cancer is the most common male cancer in the UK and represents 25% of all 
new cancer diagnoses in males (Cancer Research UK). However, prostate cancer is a 
very heterogeneous disease with a large variation in clinical outcome. There is a 
pressing need to identify biological features (termed biomarkers) that can distinguish 
between aggressive tumours requiring radical intervention and those that have a good 
prognosis, where patients may be spared the potential side effects of treatment. The 
discovery of cancer stem cells is one of the most exciting recent advances in cancer 
research. Cancer stem cells are thought to have the ability to develop into all cancer cell 
types found in a tumour and may persist in tumours as a distinct cell population, 
offering an explanation for the post-treatment recurrence of cancers. It is hoped that 
understanding their behaviour will lead to the more effective diagnosis and treatment of 
cancer. 
To this end, efforts are underway to find biomarkers that are suitable for identifying 
prostate cancer stem cells. We have collated published evidence from multiple 
publications using many experimental approaches - including cell line studies in vitro, 
xenograft transplantation studies in vivo and immunohistochemical examination of 
human tissue samples – in order to identify candidate biomarkers that may be associated 
with cancer stem cells in prostate cancer. Expression of candidate biomarkers will be 
examined in surplus prostate cancer specimens taken prior to primary treatment, in 
order to retrospectively identify potential predictive biomarkers of relapse. Such 
biomarkers would be useful for making initial treatment decisions in prostate cancer 
patients, and identify individuals at greater risk of relapse where more monitoring 
following treatment may be required. Additionally, if a group at low risk of relapse 
could be identified then it could help spare some patients the side effects of unnecessary 
treatment. 
Background on Immunohistochemistry 
Immunohistochemistry (IHC) is a method for detecting antigen (often protein) 
localisation (Ramos-Vara, 2005). Formalin-fixed and paraffin embedded tissue sections 
must be de-waxed and rehydrated in graded alcohols. To restore some of the 
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antigenicity that is masked during formalin fixation, antigen retrieval methods may then 
be used prior to staining, which consist of either heat or enzyme-mediated cleavage of 
methylene cross-links. The staining procedure involves primary antibodies specific to 
an antigen being adsorbed onto tissue sections 4-5um thick. Secondary antibodies which 
are conjugated to an enzyme are then applied to the section, causing a signal when 
substrates for this enzyme are added. In this way, coloured products are deposited at the 
sites of antigen localisation, allowing for semi-quantitative assessment of antigen 
abundance under a light microscope. The protocol for immunohistochemistry must be 
optimised separately for each antibody to be used. This requires that different 
combinations of antibody concentration and antigen retrieval techniques are trialled to 
establish the protocol which provides optimum signal strength and minimum non-
specific staining. IHC is already well established in pathology laboratories and many 
antibodies are now used to assist in the diagnosis and staging of cancer. 
Background on Tissue Microarrays 
A tissue microarray (TMA) consists of an array of multiple paraffin-embedded tissue 
cores taken from formalin-fixed, paraffin-embedded tissue blocks (Camp et al., 2008), 
such as those archived by hospital pathology departments. TMAs can be routinely 
sectioned, allowing many different tissues to be stained simultaneously on the same 
microscope slide. This conserves staining reagents and archived patient tissue while 
allowing for high-throughput analysis of many cases simultaneously. These properties 
make tissue microarrays ideal for biomarker studies.  
Due to the small core sizes used in TMAs, there are concerns that staining a single core 
may be insufficient to obtain a representative sample in highly heterogeneous tumours 
such as breast and prostate cancers (Rubin et al., 2002). There is some controversy over 
the size and number of cores that would be required to obtain a representative sample.  
According to Rubin et al., accurate estimates of the abundance of prostate cancer 
biomarkers - such as Ki-67 - may be better achieved when 3 or more 0.6mm cores are 
used. However, a recent study of prostate TMAs indicates that using multiple cores per 
tumour may introduce a bias towards marker positivity, suggesting that a single 0.6mm 
core is sufficient (Tennstedt et al., 2012). In cases where the expression of markers is 
rare or focal, even large numbers of cores may be insufficient to assess protein 
abundance and result in false negative errors (Eckel-Passow et al., 2010). To gather as 
much data as possible, two 1mm cores per tumour will be used for identifying candidate 
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biomarkers in this preliminary study. These have a total surface area equivalent to over 
five 0.6mm cores (Pinder et al., 2013) and should provide a better representation of 
tumour heterogeneity. This sampling strategy has previously been employed in a large 
expression study of a candidate marker, BMI1(Sanchez-Beato et al., 2006). This will be 
sufficient to evaluate if the candidate markers can be assessed using tissue microarrays. 
In subsequent studies the number and size of tissue cores may be reconsidered, and will 
depend on the abundance and heterogeneity of the markers to be studied. 
Study Aims 
This is a scientific research project to determine if markers for prostate cancer stem cells 
can be used to predict relapse in retrospective prostate cancer cases. Archived formalin 
fixed paraffin-embedded primary prostate cancer tissue from patients who have been 
treated with either hormone therapy or radical prostatectomy will be used in this study. 
Patients who have had neo-adjuvant hormone therapy followed by radiotherapy will be 
pooled with the hormone therapy patients. The aim is to identify markers whose 
expression is associated with relapse for each treatment group. Any markers identified 
in this initial study will be followed up in a subsequent study with a larger sample size 
to establish if they are useful biomarkers.  
Study Design and Methods 
Tissue microarrays will be constructed from archived formalin fixed paraffin-embedded 
prostate cancer tissue. Two cores of tumour tissue measuring 1mm in diameter will be 
taken from each tissue block, and a tissue microarray block will be prepared in order to 
immunohistochemically stain all sampled tissues simultaneously. This leaves the 
remainder of the tissue block intact if required clinically. Placement of cores will be 
guided by haematoxylin and eosin (H&E) stained whole sections that had previously 
been used for diagnosis. Cell lines with known expression of candidate markers will be 
fixed in formalin, embedded in agarose, processed and embedded in paraffin to form 
“cell blocks”. These cell blocks will be cored simultaneously with the tissues. These 
will serve as positive and negative controls in the tissue microarray, provided that these 
blocks are shown to be reliable. Alternatively, surplus archived human control tissue 
(for which informed consent will be obtained) can be used, where tissues with known 
expression of candidate markers will be cored simultaneously with the prostate samples 
and will serve as positive and negative controls in the tissue microarray. These tissues 
may be obtained by biopsy or autopsy. Control tissue may also be obtained from 
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recognised commercial suppliers which have obtained suitable informed consent. 
Control tissues that may be analysed (in addition to prostate cancer) include liver, 
breast, stomach, melanoma, pancreas, bone marrow or tonsil. Tissue microarray 
sections will be stained for the presence of putative cancer stem cell markers, such as 
BMI1 and Nestin. To confirm that the stained regions consistently represent cancer 
tissue, a single TMA section will be stained with routine H&E staining for every 25 
tissue microarray sections examined – a greater level of quality control than the 
minimum suggested by Kumar et al.(2004). IHC stained sections will be examined 
microscopically using a semi-quantitative scoring system to assess the intensity and 
number of cells stained. Examples of scoring methods include the Allred scoring system 
(Allred et al., 1998) – which adds scores for staining intensity and proportion of total 
cells stained to obtain a final score; the H-score system (Ishibashi et al., 2003), where 
the percentage of cells staining in each of three intensity levels is multiplied by its 
intensity score and then totalled to give a range of values from 0-300; and automated 
scoring systems that make use of image analysis software (Hatanaka et al., 2003). 
Scoring will be performed blinded, by multiple assessors if possible. For each treatment 
group, scores will be compared between those patients that have relapsed and those that 
remain in remission.  
Primary Endpoint: 
1. A difference between expression of candidate biomarkers in patients who have 
relapsed and patients who remain in remission after 5 years of retrospective 
follow-up. In both treatment groups, relapse is defined as serum PSA levels 
which persist at or rise above nadir and must be confirmed by a subsequent 
clinical evaluation. 
There are no secondary endpoints for this study. 
Study Monitoring and Data Handling 
The research will be monitored internally by the University of Bath as part of the 
assessment of Ben Sharpe’s PhD progress. He will submit a report after 11 months and 
have a formal viva to establish that sufficient progress is being made. He will be 
assessed at 24 months and finally by writing a thesis and defending it at a viva at the 
end of his studies (36-42 months). 
Non-identifiable patient data will be provided in linked anonymised form. Individual 
patients will be referred to by randomly generated code numbers. Only authorised 
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personnel at RUH will have access to the personal data. No identifiable data will be 
provided to researchers. Data will be collected and retained in accordance with the Data 
Protection Act 1998. Data will be retained in a secure location during and after the trial 
has finished (for 10 years after the end date of the study). Any tissue samples remaining 
at the end of the study will be returned to the Department of Pathology, RUH. 
Inclusion Criteria 
Inclusion criteria must be met at the time of entry into the study. 
• Age ≥ 18 years 
• Diagnosis of prostate adenocarcinoma at time of sampling. This must be 
histologically confirmed and the original haematoxylin & eosin stained slides 
must be available for the case.  
• Patients treated with radical prostatectomy must be stages T1-3 N0 M0. Patients 
treated with hormone therapy must be stages T1-3 N0-1 M0-1. 
• Signed informed consent must be obtained prior to any archived tissue samples 
being taken.  
• Patient must have undergone radical prostatectomy. Alternatively, patients must 
have undergone core needle biopsy prior to hormone therapy.  
• All patients must have archived primary tumour tissue in formalin-fixed and 
paraffin-embedded form. This tissue must be surplus to clinical requirements. 
• For patients treated with Radical Prostatectomy, patients must have no evidence 
of metastatic disease at the time of sample acquisition. 
• Minimum 5 years of retrospective follow-up time for patients in the non-relapse 
category. 
• Patients with stored non-identifiable clinical data. 
Exclusion Criteria 
Patients who meet the following criteria during the study duration will be excluded: 
• Previous or concurrent cancer (at time of treatment) that is distinct in primary 
site or histology from the cancer being evaluated in this study EXCEPT treated 
basal cell carcinoma, and superficial bladder tumours [Stage Ta, Tis & T1]. 
• Patients that have undergone radical prostatectomy with positive lymph node 
involvement [Stage N1] or metastases [Stage M1]. 
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• All patients that have not been assessed for lymph node involvement [Stage NX] 
or metastases [Stage MX].  
• Patients treated with neoadjuvant hormone therapy or chemotherapy prior to 
radical prostatectomy. 
• Insufficient amounts of archived tumour tissue available from the patient. Tissue 
blocks must be at least 1mm thick in order to provide an adequate core depth for 
microarray construction. 
• Withdrawal of consent for the use of archived patient tissue. 
Statistical Considerations 
The aim of this study is to identify potential predictive biomarkers of relapse in prostate 
cancer. The study will look at markers in patients following two treatment types. The 
first treatment type will be radical prostatectomy, and 20 samples from patients who 
relapsed and 20 samples from patients who remain in remission will be analysed for 
each marker. The second treatment type will be hormone therapy (either as a primary 
therapy or as neoadjuvant therapy prior to radiotherapy) and 20 samples from patients 
who relapsed and 20 samples from patients who remain in remission will be analysed 
for each marker. The two groups will be non-overlapping so there will be a total of 80 
samples analysed. 
Power calculations carried out by Dr Taylor (Reader in Medical Statistics, Department 
for Health, University of Bath) indicated that 13 patients per group would be sufficient 
to identify a difference. The calculation assumed that a marker showing a difference 
would be scored positive in 80% of cases with relapse and 20% of cases without 
relapse. Our aim of 20 samples per group exceeds this minimum value.  
Commonly used scoring systems, such as the Allred system (Allred et al., 1998), will be 
used to analyse the IHC staining. The Allred system gives one score for intensity of 
stain and one for the proportion of cells stained (%) and these are combined to create a 
score out of eight for each marker. If a tumour receives a score of 3 or more it is 
considered positive for that marker. For each primary tumour, each marker will be 
classified as positive or negative and the data will be collated and statistically analysed 
as appropriate. Confidence intervals will be calculated to estimate the sensitivity and 
specificity of the marker. Any marker which shows a correlation with tumour relapse 
may have the potential to be used as a biomarker and would warrant further analysis in 
subsequent studies. 
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Ethical Considerations 
This study involves immunohistochemical analysis of archived patient prostate 
specimens. Written informed consent will be obtained from each patient before the 
study begins. Tissue used will be archived formalin fixed paraffin-embedded tissue 
which is surplus to clinical requirement. Archived patient tissue and non-identifiable 
data will be in “linked anonymised form” and referred to by a randomly generated code 
number. This tissue will be securely stored in the Department of Pathology at the RUH 
and in the Department of Biology and Biochemistry at the University of Bath. On 
completion of the study all tissue will be returned to the site of origin – the Department 
of Pathology, RUH. Signed informed consent can be withdrawn at any time during the 
study, at which point the withdrawn tissue and corresponding anonymised data will no 
longer be used. No identifiable data will be released to researchers. 
Ethics and R&D approval 
This study is subject to Research Ethics Committee (REC) and local Research and 
Development (R&D) approval.  
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Chairman, Brian Stables 
Chief Executive, James Scott 
 










Tel: 01225 825096 
 




Dear   
 
We would like to invite you to take part in our research study which is looking at 
new laboratory tests for prostate cancer. You are being invited as you have been 
treated for prostate cancer at the RUH.  
 
If you decide to take part you will need to discuss the project with us and give us 
written consent to study some of your existing tissue samples. You would not 
require any new procedures or tests and it would not affect your future treatment or 
follow-up. 
 
If you would be interested in learning more about this study and possibly 
participating, please let us know by returning this letter in the envelope provided 
and we will be in touch. 
 
Thank you for your time in reading this letter. 
 
With kind regards, 
 
Dr Mark Beresford and Dr Rebecca Bowen 
Consultant Oncologists 
 
I would be happy for you to contact me with regard to 
participating in the study  
 
 
Preferred contact telephone number: 
  
Preferred day and time for us to contact you: 
Cancer Clinical Trials Unit 
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APPENDIX 7: BATH COHORT PATIENT INFORMATION SHEETS
 
Patient Information: Prostate Cancer Biomarker Study Version 2 (25/6/2013) 
 
Chairman, Brian Stables 







Tel: 01225 825096 
 
 
Patient Information Sheet 
Prostate Cancer Biomarker Study 
 
 
We would like to invite you to take part in our research study. Before you decide 
we would like you to understand why the research is being done and what it would 
involve for you. One of our team will go through the information sheet with 
you and answer any questions you have. You may find it helpful to talk to others 
about this study.  Before you decide whether or not to take part it is important you 
understand why this research is being done and exactly what is involved. Please 
read the following leaflet carefully and ask the nurse or doctor if there is anything 
that is unclear or if you require any further information. 
 
Part 1 tells you the purpose of this study and what will happen to you if you take 
part. 
 
Part 2 gives you more detailed information about the conduct of the study. 
 
Part 1 
What is the purpose of this study? 
Prostate cancer is the most common male cancer in the UK. Many men with 
prostate cancer have a very good prognosis and could potentially be spared the 
side effects of treatment. There is, however, a pressing need to identify biological 
features (termed biomarkers) that can distinguish the more aggressive prostate 
cancers requiring more radical treatment. 
Cancer stem cells are thought to have the ability to develop into any cancer cell 
type and offer an explanation for the recurrence of cancer after the completion of 
treatment. It is hoped that understanding their behaviour will lead to more effective 
and individualised treatment of cancer. 
 
What does the study aim to do? 
This project will examine if expression of stem cell markers might be used to 
identify the aggressive variants of prostate cancer. To do this we will use 
immunohistochemistry tests, a well-established approach, in prostate cancer 
samples. In order to have been told you have a diagnosis of prostate cancer you 
will have had either a prostate biopsy or a prostatectomy (removal of the prostate 
gland). After initial diagnostic tests are complete, these tumour samples are stored 
Cancer Clinical Trials Unit 
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as blocks in the Pathology department of the hospital. It is these stored blocks, 
now surplus to clinical requirement that we would like to use to examine the 
expression of stem cell markers. These markers, or subset of them, may enable us 
to identify the aggressive relapsing prostate cancers. 
 
Why have I been invited? 
You have been invited because you are currently being treated or were previously 
treated or for prostate cancer at the RUH. The study aims to recruit 80 participants. 
Do I have to take part? 
No.  It is entirely your choice. We will describe the study and go through this 
information sheet. If you agree to take part, we will then ask you to sign a consent 
form. You are free to withdraw at any time, without giving a reason, without 
affecting your care in any way. 
 
What will happen to me if I take part? 
If you agree to join the study then some of your prostate tissue which is currently 
stored at the RUH will be used. The stored tissue was originally taken and used to 
help with your diagnosis. A small part of this stored tissue, which is not needed for 
your treatment, will be used. No new tissue samples will be taken.  You will not 
be asked to undergo any extra tests or procedures in order to participate in this 
study. 
 
Expenses and payments 
We are unable to offer payment for participation in this research but you should not 
incur any extra expenses as a result of participation. 
 
What will I have to do? 
Should you agree to participate we will ask you to sign a consent form.  You will 
not be required to do anything else. 
 
What are the possible advantages and disadvantages of taking part? 
As this study does not involve any new procedures or treatments there should no 
risk or disadvantage in taking part.  This study may not benefit you directly but the 
information we get from this study may impact on the future treatment of prostate 
cancer. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study will be 
addressed. The detailed information on this is given in Part 2.  
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before you 
make any decision. 
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What will happen if I don’t want to carry on with the study? 
If you decide to withdraw from the study then information collected using your 
tissue samples will be removed from the study and destroyed. No further 
information will be collected.  You are free to withdraw consent at any time and this 
will not adversely affect your treatment.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, the researchers will do their 
best to answer your question (see phone number above). If you remain unhappy 
and wish to complain formally, you can do this through the Patient Advice and 
Liaison Service (PALS).   
Email:  ruh-tr.PatientAdviceandLiaisonService@nhs.net 
Tel:   01225 825656   
Address: Head of PALS, RUH Bath NHS Trust 
Combe Park 
Bath 
BA1 3NG  
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential, and any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised. 
 
What will happen to any samples I give? 
A small part of your existing sample which was used to assist in your diagnosis, 
currently stored at the RUH, will be used.  Samples used will be stored securely at 
the RUH or at the University of Bath, where some of the analysis will take place. 
Only members of the study team will have access to the samples and it will not be 
possible to identify you from these samples.  At the end of the study the samples 
will be returned to the RUH or destroyed. 
 
Will any genetic tests be done? 
No genetic tests will be carried out. 
 
What will happen to the results of the research? 
The nature of the research is such that it is very unlikely to have any direct impact 
on you or your management.  Results will not be relayed directly back to you, your 
hospital doctor or GP. The results of the project, which may not be available for 
several years, may be published in scientific journals or conferences in 
anonymised form so you cannot be identified. 
 
Who is organising and funding the research? 
The research is being organised by clinicians from the RUH (Dr Mark Beresford, Dr 
Rebecca Bowen and Dr John Mitchard) and researchers from the University of 
Bath (Dr Andrew Chalmers and Mr Ben Sharpe).  The project is being funded by 
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the University of Bath and the Annet Trust, which is a local charity which funds 
medical research projects. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been 
reviewed and given favourable opinion by The Proportionate Review Sub-
Committee of the West of Scotland Research Ethics Committee 5.  
 
What if I have further questions? 
 
If you have any further queries about tissue donation or about research projects is 
general please contact the Clinical Trials Unit at the Royal United Hospital, Bath.  
Tel: 01225 825096.  For advice on whether to participate please ask a member of 
the study team, who can be contacted via the clinical trials unit (Tel: 01225 




Many thanks for taking the time to read this information sheet and 
for considering being involved in our research. 
 
 
Dr Mark Beresford and Dr Rebecca Bowen 
Consultant Oncologists 
Royal United Hospital Bath 
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Centre Number:  
Study Number:  
Patient Identification Number for this trial:  
	
	
Consent form date of issue:    Consent form version number: 1 (10/513) 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in medical notes. 
Chairman, Brian Stables 






Title of Project: Identifying new biomarkers for prostate cancer 
 
Name of Researcher: Dr Mark Beresford and Dr Rebecca Bowen 
           
          Please initial box  
 
1. I confirm that I have read and understand the information sheet dated.................... 
(version............) for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily. 
 
2. I understand that the donation of this tissue is voluntary and that I am free to withdraw 
consent at any time without giving any reason, without my medical care or legal rights 
being affected. 
 
3. My donated tissue and medical details will be anonymised.  Relevant information from 
my medical records will be recorded and held on a computer database and supplied 
anonymously to the researcher. 
 




5. Any tissue which remains unused after 30 years will be disposed of in a lawful manner 
 
 
6. I understand the tissue used in this research is surplus to clinical requirements and 
would otherwise be discarded. 
 
 
7. I agree to my GP being informed of my participation in the study. 
 
 












Name of Person taking consent ........................................................................................  
    
 
 
Signature .......................................................................... Date............................. 
